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Abstract 
 
Successful haemodialysis depends on the availability of safe, efficient, and durable 
access to the vascular tree.  This can be provided by creation of an arteriovenous 
fistula, insertion of a synthetic vascular graft or insertion of a central venous catheter. 
Established haemodialysis vascular access is associated with a number of important 
complications which can impact significantly on both the quality of life and survival 
of haemodialysis patients. 
 
The primary aim of this thesis was to perform a detailed evaluation of the risks to 
health conferred by haemodialysis vascular access and its maintenance in patients 
with advanced renal failure.   
 
The work described in this thesis describes the relative strength and independence of 
association between haemodialysis vascular access type and risk of mortality, 
bacteraemia and catheter thrombosis.  Greater clarity is demonstrated on the relative 
effect of heparin-based haemodialysis catheter lock solutions on markers of systemic 
coagulation in vivo, whilst the in-vitro variability of antimicrobial activity against 
planktonic and biofilm-embedded staphylococci achieved with catheter lock solutions 
containing heparin and vancomycin, alone and in combination, is clearly shown. 
 
New insights are gained into the benefits of contrast magnetic resonance venography 
as a tool for demonstrating thrombosis and stenosis of the central veins in the 
assessment of vascular access in haemodialysis patients.  Similarly, the emergence of 
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a new disease, nephrogenic systemic fibrosis was found and its association with 
gadolinium-enhanced magnetic resonance imaging was explored in detail.   
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Summary 
 
The aim of this thesis was to perform a detailed evaluation of the risks to health 
conferred by haemodialysis vascular access and its maintenance. 
  
The first part of this thesis examines the relationship between haemodialysis vascular 
access, bacteraemia and mortality.  A retrospective analysis of vascular access type 
and subsequent outcome in all 265 prevalent haemodialysis patients attending 
Glasgow Royal Infirmary Renal Unit on a given date was conducted.  Multivariate 
analyses of clinical and laboratory variables demonstrated an especially strong, 
independent relationship between the type of haemodialysis vascular access in use 
and risk of bacteraemia and death.  When considering bacteraemia tunnelled catheters 
and non-tunnelled catheters were each independently associated with adverse 
outcome compared to arteriovenous fistulae (tunnelled HR 5.43 (p<0.001); non-
tunnelled HR 3.14 (p=0.01)).  When considering mortality tunnelled catheters and 
non-tunnelled catheters were each independently associated with adverse outcome 
compared to arteriovenous fistulae (tunnelled HR 2.75 (p=0.012); non-tunnelled HR 
3.39 (p=0.001)). 
 
The role of the central venous catheter in determining outcome was then explored in 
greater detail by a two-year prospective analysis of all patients undergoing 
haemodialysis catheter insertion in Glasgow Royal Infirmary.  This study evaluated 
independent risk association between clinical and laboratory variables and instances 
of catheter-related bacteraemia and catheter thrombosis for each catheter type by 
univariate and multivariate analysis.  Over the period of observation 823 central 
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venous catheter insertion procedures were conducted.  Tunnelled central venous 
catheters (TCVCs) were associated with lower rates of bacteraemia and thrombosis 
than non-tunnelled central venous catheters (NTCVCs), independent of whether 
patients have acute or chronic renal failure, high levels of comorbidity and levels of 
routinely recorded biochemical and haematological parameters.  Using TCVCs as a 
comparator, a hierarchy of risk association within the NTCVC insertion procedures 
was found with catheterisation of the internal jugular veins to be the best NTCVC 
insertion procedure (bacteraemia HR = 2.93, p<0.001 / thrombosis HR = 4.65, 
p<0.001), followed by insertion of a femoral venous catheter (bacteraemia HR 5.97, 
p<0.001 / thrombosis HR = 9.23, p<0.001).  Catheter-exchange over a guidewire was 
associated with especially high risks of bacteraemia and thrombosis (femoral 
exchanges, bacteraemia HR = 9.84, p=0.002 / thrombosis HR = 11.73, p<0.001; 
internal jugular exchanges, bacteraemia HR = 6.42, p<0.001 / thrombosis HR = 5.26, 
p<0.001). 
  
The second part of this thesis evaluates the performance of catheter lock solutions. 
This was explored by a prospective, randomised, controlled comparison of 
heparinised catheter lock solutions in 28 consecutive patients undergoing NTCVC 
insertion.  Heparin 1000iu/mL incurred less disruption of systemic coagulation than 
heparin 5000iu/mL, without an obvious loss in clinical utility.  When expressed as the 
percentage rise in activated partial thromboplastin time (APTT) at 10 minutes post 
catheter locking, the difference between groups amounted to a rise in APTT of 22.2% 
(range 0, 210) in the heparin 1000iu/mL group compared with 373.7% (range 133, 
800) in the heparin 5000iu/mL group (p<0.001).  
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An in-vitro assessment of combined anti-microbial/anticoagulant catheter lock 
solutions was then conducted.  This studied six isolates of staphylococcus aureus in 
planktonic and biofilm models with regard to their response when exposed to heparin 
and vancomycin solutions alone and in combination.  Heparin had the capacity to 
enhance and suppress staphylococcal growth, depending upon the strain studied.  
When combined with vancomycin heparin appeared to increase its potency although 
not in a dose-dependent way.  The relative resilience of biofilm-embedded 
staphylococci to vancomycin compared with planktonic staphylococci was 
demonstrated. 
 
The third part of the thesis begins with a retrospective evaluation of 78 consecutive 
magnetic resonance venograms conducted in haemodialysis patients with poorly 
functioning vascular access.  A significant association was found between the 
frequency of vascular access procedures and the frequency of acquired structural 
abnormalities of the central venous system seen on magnetic resonance venography 
(central venous stenosis on imaging; arteriovenous fistulae or grafts p=0.04, central 
venous catheters p=0.034).  It was noted that within this cohort a significant 
proportion of patients were found to have developed the relatively new disease 
nephrogenic systemic fibrosis (NSF).   
 
The next chapter describes a case-control analysis of NSF cases in all 1826 patients 
who underwent renal replacement therapy over a six and a half year period in North 
Glasgow.  This demonstrated a significant association between gadolinium-enhanced 
magnetic resonance imaging (MRI) and development of NSF (proportion of patients 
exposed to MRI, non-NSF 408/1812, 22.5% v NSF 13/14, 92.9%, p<0.001).  Patients 
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with NSF were exposed to a significantly higher total dose of gadodiamide than their 
non-NSF counterparts (median 45ml v 30ml, p<0.001), indicating dose-dependency.  
This was further supported by weight-adjusted data (median 0.39mmol/kg v 
0.23mmol/kg, p=0.008). 
 
In conclusion, the work described in this thesis demonstrates the relative strength and 
independence of association between haemodialysis vascular access type and risk of 
mortality, bacteraemia and catheter thrombosis.  Greater clarity has been 
demonstrated on the relative effect of heparin-based haemodialysis catheter lock 
solutions on markers of systemic coagulation in vivo, whilst the in-vitro variability of 
antimicrobial activity against planktonic and biofilm-embedded staphylococci with 
heparin and vancomycin, alone and in combination, has demonstrated the need for 
more rigorous evaluation and selection of potential haemodialysis catheter lock 
solutions.  New insights were gained into the risks and benefits of contrast magnetic 
resonance venography in the assessment of vascular access in haemodialysis patients.   
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Chapter 1 
 
Introduction 
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1.1 Chronic Kidney Disease 
 
Chronic kidney disease (CKD) is an important condition with considerable public 
health implications.  It affects a significant proportion of the general population and, 
when progressive, has an increasing impact on morbidity and mortality.  CKD is an 
independent risk factor for cardiovascular disease and the development of established 
renal failure (ERF).  Once a patient reaches ERF, quality of life has become 
invariably poor and life expectancy considerably shortened.  Through the provision of 
renal replacement therapy (RRT) survival and quality of life of ERF patients can be 
markedly improved.   
 
CKD places a considerable demand on medical resources around the world.  The 
United States Renal Data System (USRDS) report of 2008 describes expenditures 
associated with CKD as having more than doubled over the past 10 years, from 11.3% 
of the total Medicare budget in 1996 to 24.5% in 2006.  Costs for Medicare patients 
with CKD exceeded $49 billion in 2006.  The increasing cost of CKD to the US 
population is demonstrated in figure 1.1. 
 
When considering the cost of providing RRT to the ERF population, the cost per 
patient rises significantly.  In 2006 the prevalence of ERF patients maintained on RRT 
in the United States was 506,256.  In that year total Medicare spending on patients 
with ERF rose to $23 billion which accounted for 6.4% of the entire Medicare budget 
(1).   
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Figure 1.1 - Expenditure in the Medicare (1993-2006) and Medstat (2000-2006) populations of the 
United States.  (Adapted, with permission, from the USRDS Annual Report, 2008). 
 
In order to understand the resource implications of CKD and ERF, there is a pressing 
need to develop our understanding of their epidemiology.  Historically, many 
estimates of CKD incidence were drawn from population studies using varied, 
arbitrary definitions of renal impairment.  In one such study in 2003, by defining 
CKD as a serum creatinine level of ≥150µmol/L for 6 months, the annual incidence of 
detected CKD was determined as 1,701 per million population (2).  An earlier study 
of advanced renal failure used a cut off of >500µmol/L and reported an incidence of 
148 patients per million population (3).  Whilst these data were of significant interest, 
their clinical applicability was undermined by the use of serum creatinine as opposed 
to glomerular filtration rate when wishing to consider the absolute level of renal 
function. 
 
The publication of the NKF/DOQI clinical guidelines in 2002 greatly improved our 
ability to study the epidemiology of CKD.  These guidelines gave a universally 
applicable definition of CKD as either kidney damage for >3months accompanied by 
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pathological or functional abnormalities of the kidney or a glomerular filtration rate of 
<60mL/min/1.73m2 for >3 months.  This definition was further refined by sub-
division into a 5-stage CKD classification.  Stage 1 was defined as an estimated 
glomerular filtration rate (eGFR) of >90 mL/min and either >20 mg/dL of albumin in 
the urine, an albumin/creatinine ratio ≥30 mg/g, or other evidence of structural kidney 
damage.  A similar definition was applied to stage 2 although with an eGFR range of 
60–89.  Stages 3, 4, and 5 were defined solely by eGFR ranges of 30–59, 15–29, and 
less than 15, respectively (4).  By applying this structure to US data from the National 
Health and Nutrition Examination Survey (NHANES), the prevalence of CKD stages 
1, 2, 3 and 4/5 was determined as 3.2%, 4.1%, 7.8% and 0.5% respectively.  Recent 
USRDS data from 1999-2004 suggest an overall CKD prevalence of 16.8% in the 
U.S. population aged 20 years (5).  This relatively high prevalence translates into a 
significant lifetime risk of developing ERF.  In the US in 2002, Kiberd and Clase 
determined cumulative lifetime risk of ERF for a 20-yr-old black female, black male, 
white male and white female as 7.8%, 7.3%, 2.5%, and 1.8% respectively.  These 
risks equated to the lifetime risks of breast, prostate and colorectal malignancies in the 
same population (6). 
 
There is a relative wealth of data on the epidemiology of ERF compared with that of 
CKD.  This is due to many countries with established RRT services engaging in 
comprehensive data collection programs overseen by national registries.  These data 
have proven an invaluable resource in assessing service provision, establishing 
clinical standards and providing reproducible audit measures.  Such data, collected 
year on year, have provided an insight into recent and expected trends within the RRT 
population.   
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1.2 Current Trends in Renal Replacement Therapy  
 
The provision of renal replacement therapy (RRT) prolongs survival in patients with 
established renal failure (ERF) and in most cases improves quality of life.  RRT may 
be provided by renal transplantation, haemodialysis or peritoneal dialysis.  Over 
recent years the prevalent number of patients on RRT in the UK and around the world 
has been rising (figure 1.2) (7). 
 
 
 
 
 
 
 
 
Figure 1.2 – Growth in prevalent UK patients by treatment modality at the end of each year 1982-2006 
(Adapted, with permission, from the UK Renal Registry Tenth Annual Report, 2007).  
 
At the end of 2006, the UK Renal Registry reported the prevalence of adult patients 
receiving renal replacement therapy in the UK as 43,901.  This amounts to a UK 
prevalence of 725 per million population (7).  Over recent decades the UK population 
prevalence of RRT has risen steadily in line with other developed countries within 
Europe, Australasia and the Americas (1, 8, 9).  This is predominately due to a trend 
of rising incidence of starting RRT over recent decades (figure 1.3) and slowly 
increasing survival (figure 1.4) (10). 
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Figure 1.3 - Incident rates of RRT uptake in the countries of the UK: 1990-2006.  (Adapted, with 
permission, from the UK Renal Registry Tenth Annual Report, 2007). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 - Change in one-year, after 90 day, adjusted (age 60) survival, 1999-2005 within the UK 
Renal Registry participating centres from 1999 only (left) and all centres over time within the UK 
(right).  (Adapted, with permission, from the UK Renal Registry Tenth Annual Report, 2007). 
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In 2006 the incidence of starting RRT in the UK was 113 per million population, a 
rise from 110 per million population in 2005.  The age adjusted (60 years) one-year 
survival for the prevalent RRT population was 87.7% in 2006 compared with 84.9% 
in 2000 (7).  The rise in RRT incidence over recent decades is predominately due to 
an increase in the availability of renal replacement therapy programs around the 
world.  This has led to more inclusive RRT acceptance policies with a resultant 
expansion in the numbers of elderly patients and those with comorbidity such as 
diabetes and vascular disease.  This phenomenon is demonstrated in figure 1.5 below. 
 
 
Figure 1.5 – Primary renal diagnosis of patients aged 75 years and older starting RRT in Scotland 
1980-2004. (Adapted, with permission, from the Scottish Renal Registry Report 2002-2004). 
  
The elderly now represent the fastest growing group of prevalent patients on RRT.  
An analysis of age ranges within the Scottish RRT population over the past 50 years 
is demonstrated in figure 1.6.  This shows a steady expansion in the proportion of 
patients aged between 65 and 74 years of age, and those greater than 75 years of age.  
In 2004 the median age of patients starting RRT in Scotland was 65.3 years compared 
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with a median age of 60.9 years in 1995 (11).  These findings are similarly reflected 
in data recently reported by the UK Renal Registry, European Renal Registry and 
USRDS (1, 7, 9). 
 
 
Figure 1.6 – Age distribution of patients when starting RRT 1960-2004. (Adapted, with permission, 
from the Scottish Renal Registry Report 2002-2004). 
 
It also appears that as the RRT population ages, the burden of comorbidity within the 
population increases.  The UK Renal Registry publishes a standardised list of 
accepted comorbid conditions.  This contains a range of diagnoses covering 
cardiovascular diseases, diabetes, chronic obstructive pulmonary disease, liver 
disease, malignancy and smoking.  From this list, the degree of comorbidity expressed 
within the UK RRT population has been found to vary between ethnic groups, with 
white patients tending to exhibit a higher prevalence of comorbid illness than those 
patients from Black, Asian, Chinese or other ethnic populations.  Throughout all 
ethnicities, however, the burden of comorbidity has been shown to steadily increase 
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with age.  This is demonstrated in figure 1.7 which displays the proportion of patients 
with a comorbid illness within differing age ranges.  These data suggest that over two-
thirds of the RRT population over 65 years of age will have at least one comorbid 
illness compared with one-third of the RRT population less than 44 years of age.   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 - Presence or absence of co-morbid conditions at the start of RRT amongst patients of White 
origin starting RRT (2001-2006).  (Adapted, with permission, from the UK Renal Registry Tenth 
Annual Report, 2007). 
  
The implications of an aging, more comorbid RRT population are significant.  Data 
from the Scottish Renal Registry supports the association between age and 
comorbidity with adverse clinical outcome (12, 13).  Whilst overall survival on RRT 
has increased, considerable variability in survival rates may be seen within the RRT 
population when considering the different age groups and the different primary renal 
diagnosis groups contained within.  Data from the Scottish Renal Registry describe a 
median survival of 27.5 yrs in those patients under 20 years of age, falling to a median 
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survival of 1.3 years in those over 75 years of age.  When considering primary renal 
diagnosis, patients with interstitial renal disease or glomerulonephritis may be 
expected to have a median survival of 9.3 years compared with 2.2 years in those with 
a multisystem disease (11).  Consequently, as the age and proportions of constituent 
primary renal disease within the RRT population evolve, it can be anticipated that 
expected survival will change accordingly.   
 
The dramatic difference in survival between the RRT population and the general 
population is illustrated below in figure 1.8.  This figure demonstrates the 
considerable burden of cardiovascular disease within the ERF population and how it 
translates into heightened rates of mortality (14).   
 
 
 
Figure 1.8 - Cardiovascular mortality in the US general population (GP) and in ERF treated by dialysis.  
(Recreated with permission). 
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This pattern has been elicited in several other studies of RRT populations in the 
developed world (8, 15).  These findings not only reflect the high prevalence of 
traditional cardiovascular risk factors within the ERF population such as 
hypertension, left ventricular hypertrophy (16, 17) diabetes and proteinuria, but also 
the presence of risk factors generally specific to ERF such as vascular endothelial 
dysfunction (18-20), the development of atherogenic lipid profiles (21, 22) and 
vascular calcification (23).  Many of these acquired risk factors have been found to 
develop early in the development in chronic kidney disease, and are associated with 
escalating cardiovascular risk as ERF approaches. 
 
As the demographics of the RRT population change, dependence on the different 
modes of RRT provision also appears to be changing.  When considering the 
prevalent UK RRT population, on the 31st December 2006, 44.9% were maintained 
on a functioning transplant, 44.3% maintained on haemodialysis and 10.6% 
maintained on peritoneal dialysis.  Whilst the proportion of patients maintained on a 
functioning renal transplant appears to have been stable over recent years, the 
proportion of patients on haemodialysis appears to be increasing with a concurrent 
decrease in the proportion maintained on peritoneal dialysis.  This trend may be partly 
explained by the increasing age and comorbidity of the RRT population limiting 
patients’ ability to meet the physical demands that peritoneal dialysis incur.   
 
Registry data have demonstrated an increasing trend in the overall frequency of 
haemodialysis as the first modality of RRT.  In the UK in 2006, haemodialysis was 
the first modality of RRT in 76.6% of ERF patients compared with 58% in 1998.  Of 
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the remainder 20.0% started RRT on peritoneal dialysis and 3.4% with a pre-emptive 
renal transplant.  Increasing age is also associated with a greater likelihood of starting 
RRT on haemodialysis.  When considering incident dialysis patients 90 days after 
starting RRT, 83% of patients over 65 years of age were started on haemodialysis 
compared with 70% of those less than 65 years of age (7).   
 
In summary, the registry data accrued for the UK and other developed countries are 
suggestive of an RRT population that is increasing in size, age, comorbidity and its 
reliance on haemodialysis as the predominant means of delivering RRT. 
 
 
1.3 Renal Replacement Therapy with Haemodialysis 
 
RRT with haemodialysis does not provide true replacement of renal function.  
However by removing waste solutes, excess body water and restoring biochemical 
and acid-base balance, haemodialysis has considerably improved the morbidity and 
mortality of ERF patients.   
 
The first description of dialysis was made by Thomas Graham of Glasgow in 1854.  
In his pursuit of the study of colloids, Graham was able to demonstrate a method of 
separating a mixture of colloids and crystalloids using a “dialyser”, a wooden hoop 
covered on one end by a selectively permeable membrane which floated on the 
surface of a mixed solution of crystalloid and colloid (24).   
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By applying Graham’s principles Abel, Rountree and Turner developed the first 
artificial kidney in 1913 when they published on the removal of diffusible substances 
from circulating blood in living animals by dialysis.  This was conducted in dogs and 
rabbits, and described the first successful in-vivo haemodialysis (25).  The first 
occasion haemodialysis was performed in a human was by Haas in 1924, however it 
was another 20 years before Willem Kolff overcame the difficulties of providing 
adequate vascular access, establishing safe and effective anticoagulation and 
producing reliable equipment for widespread use when he created the rotating drum 
kidney in 1943 (26). 
  
Kolff’s original design was further refined in the early 1950s with the emergence of 
the stainless steel Kolff-Brigham dialysis machine.  This was used for the treatment of 
acute renal failure as sustainable vascular access for repeated dialysis treatments was 
still difficult to obtain and effectively prevented its use as a long-term treatment for 
ERF.  Further refinement of the Kolff dialysis machine and improvement in methods 
of establishing vascular access were led by Nils Alwall in Sweden and Belding 
Scribner in the US.  Their work led to increasing numbers of patients with acute renal 
failure being treated by haemodialysis from the mid 1940s to the 1960s.  By then 
many other centres were improving both the design of the haemodialysis machine and 
methods of establishing sustainable vascular access.  In 1962 the world’s first 
outpatient dialysis facility was opened in Seattle by Scribner and from then on 
demand for provision of RRT by haemodialysis facilities spread around the world. 
  
The current haemodialysis machine bears little resemblance to that devised by Kolff 
in 1943 although the design adheres to similar principles.  These centre on removing 
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blood from the intravascular compartment, passing it through an extracorporeal circuit 
into a dialyser and removing waste solutes and excess water by exposure to conditions 
that promote diffusion, convection and movement in response to hydrostatic pressure 
gradients.  Dialysed blood is then returned to the patient via the venous system. 
 
The volume of plasma cleared of solute per unit time by dialysis is expressed as the 
solute clearance.  Diffusion is the predominant method by which solute clearance 
from plasma is achieved by haemodialysis.  The process of diffusion is dependent 
upon blood from the extracorporeal circuit flowing through the dialyser, a collection 
of microfilament fibres bathed in dialysate fluid which circulates in the opposing 
direction to blood flow.  These conditions are favourable to the rapid diffusion of 
solutes through pores within the microfilament fibres, down a concentration gradient 
from blood to dialysate or vice-versa.  The rate of diffusion varies with the degree of 
concentration gradient between compartments, the surface area of the microfilament 
membrane, the number and size of pores within the membrane, the molecular size of 
the solute and the relative flow rates of both extracorporeal blood and dialysate.  
These factors determine the capacity of a dialyser and are collectively described as the 
mass transfer coefficient (KoA) of the dialyser, a quantitative measure of the 
dialyser's efficiency of clearance.   
 
Convection describes the movement of fluid between blood and dialysate 
compartments where, with increasing volumes of fluid movement from extracorporeal 
to dialysate circuits some solute may be concurrently dragged across the membrane 
and thus may contribute to the overall solute clearance achieved.  Such movement is a 
key contributor in expressing the degree of flux exhibited by the microfilament 
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membrane in the dialyser.  The concept of flux has arisen from a greater 
understanding of the clearance of small, medium and large molecular weight 
molecules.  High-flux membranes have characteristically high permeability for water, 
low and middle molecular weight solutes and most are made from materials of high 
biocompatibility.  While transport of solutes through low-flux membranes is mainly 
achieved by diffusion, convection plays an especially important role in the 
performance of high-flux membranes. 
 
Fluid is predominately removed by the production of a transmembrane pressure 
gradient across the microfilament membrane.  This causes fluid to cross from the 
relatively high pressure within the extracorporeal circuit to the relatively low pressure 
created on the dialysate side of the membrane.  This process of fluid removal from the 
extracorporeal circuit is termed ultrafiltration.  The degree of ultrafiltration achieved 
across a membrane is a function of its permeability, surface area and the size of the 
transmembrane pressure gradient and may be expressed as the ultrafiltration 
coefficient. 
 
It can be seen that a key determinant in the success of haemodialysis are the 
characteristics of the selectively permeable membranes used to form the 
microfilament tubes within dialyser units.  Membranes may now be classified by the 
type of material used in their manufacture (synthetic, cellulose, substituted cellulose), 
their capacity, surface area, ultrafiltration coefficient, flux and, in some cases, their 
ability to be reused.   
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The prescription of haemodialysis therefore requires consideration of its constituent 
components.  Alteration of the KoA, ultrafiltration coefficient and flux all have the 
ability to affect the amount of dialysis delivered and the relative clearances of small, 
medium and large molecular solutes.  Despite greater understanding of haemodialysis 
method and significant advances in haemodialysis technology, the morbidity and 
mortality of dialysis patients has remained disproportionately high.  Whilst it has been 
demonstrated that low doses of delivered haemodialysis are associated with adverse 
outcome (27) the precise components of the optimal haemodialysis prescription 
remain controversial and have yet to be fully determined by randomised controlled 
trials (28-30). 
 
One component, however, has consistently been shown to be fundamental to the 
effective delivery of haemodialysis – the successful provision of functioning vascular 
access.  Without effective and sustainable methods of establishing and maintaining 
vascular access, haemodialysis, irrespective of modality, cannot be provided. 
 
 
1.4 Methods of Haemodialysis Vascular Access  
 
Successful haemodialysis depends on the provision of safe, efficient and durable 
vascular access.  Establishing and maintaining effective vascular access is a 
demanding process for both patients and renal services.  These demands are set to 
increase in response to an RRT population that is becoming increasingly reliant on 
haemodialysis whilst also increasing in size, age and comorbidity. 
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Initially, vascular access methods relied on repeated peripheral cannulation to deliver 
arterial blood to the dialysis machine and return it to an accompanying vein.  In 1949, 
Alwall from Lund, Sweden, made the first attempt to make a direct connection 
between an artery and a vein, using glass cannulae and rubber tubing (26).  This 
device would allow blood to be diverted onto an extracorporeal circuit for dialysis 
when required.  His attempt was unsuccessful although it provided the template for 
the arteriovenous Teflon Shunt developed by Quinton, Dillard and Scribner in the US 
in 1960 (31).  Their device consisted of two Teflon cannulae inserted into the wrist, 
one in the radial artery and one in accompanying cephalic vein.  The external ends of 
the cannulae were connected by flexible tubing from which connection to an 
extracorporeal circuit could be made.  This provided nephrologists with the first 
permanent vascular access device and was a decisive breakthrough in the provision of 
haemodialysis to the ERF population.  The ‘Scribner’ shunt, as it became known, 
underwent many refinements before being ultimately superseded by the successful 
development of arteriovenous fistulae, arteriovenous grafts and central venous 
catheters.  Nonetheless, the Scribner shunt played a key role in the development of 
permanent vascular access devices. 
 
The Arteriovenous Fistula 
 
In 1962, Cimino and Brescia described a technique where haemodialysis was 
conducted through a simple puncture of the most accessible forearm vein.  Patency of 
the vein was assured by the use of an inflatable tourniquet.  This allowed needles of 
varying sizes to be used with resultant haemodialysis flows of 150-400mL/min.  
Whilst successful, this technique was limited by the poor longevity of peripheral veins 
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in comparison with that of Scribner’s external arteriovenous shunt.  Logical 
development of this technique, however, led to the creation of the first internal 
arteriovenous fistula (AVF).  The successful use of the new technique was reported in 
a landmark paper published by Brescia et al in 1966.  They reported 12 cases in which 
successful primary function of an AVF had been achieved by creating a side-to-side 
anastamosis between the radial artery and the cephalic vein at the wrist.  Exposure to 
high-pressure arterial flow was found to promote enlargement and thickening of the 
venous wall.  After approximately six weeks maturation a robust vessel wall had 
developed that could sustain repeated cannulation and allow regular haemodialysis to 
take place (32).   
 
A year later the technique had been amended to allow successful creation of an end-
to-end anastamosis between radial artery and cephalic antebrachial vein in the 
forearm (33).  This technique restricted arterial inflow into the AVF to that delivered 
by the feeding radial artery and thus led to a high risk of developing steal syndrome.  
Consequently the technique latterly became regarded as a secondary option available 
to surgeons when considering surgical revision of a failed AVF.   
 
The technique was further refined in 1968 by Rohl, who devised the radial artery-
side-to-vein-end anastamosis, with or without ligation of the radial artery distal to the 
anastamosis.  This allowed a more suitable positioning of the AVF with excellent 
subsequent flows.  It is this technique that has become the standard AVF creation 
procedure of choice and has allowed AVF creation surgery to evolve and successfully 
provide a range of potential sites for AVF creation, predominately within the upper 
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limbs (26).  A diagrammatic representation of an upper limb AVF is demonstrated in 
figure 1.9. 
 
 
    
Figure 1.9 – A typical radiocephalic arteriovenous fistula with cannulation points for attachment to the 
extracorporeal haemodialysis circuit. 
 
For practical purposes AVF creation is best conducted on the non-dominant arm with 
use of distal sites where possible; preserving the proximal vascular tree should 
vascular access surgery be required in the future.  The longevity, durability and 
favourable complication rate of the AVF have established it as the leading method of 
establishing permanent haemodialysis vascular access.  Approximately 68% of 
haemodialysis patients in the UK dialyse via an AVF at present (34). 
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Synthetic Arteriovenous Grafts 
 
An alternative to the AVF is the synthetic arteriovenous graft (AVG).  This was 
devised following the introduction of the Scribner shunt, which was noted to employ a 
length of flexible tubing to connect the arterial and venous cannulae.  In 1969 George 
Thomas developed this principle by replacing the cannulae with Dacron patches 
sutured into the vessel wall and bringing out a loop of connecting silastic material to 
the skin surface.  By avoiding the use of intraluminal cannulae, this device was less 
prone to thrombosis (35).   Meanwhile Buselmeier et al had adapted the Scribner 
shunt by using a silastic material which could be tunnelled subcutaneously to connect 
the two cannulae.  During the same period the first vein graft had been performed 
using a length of excised saphenous vein to connect the brachial arterial to its 
accompanying vein.  By combining each of these three principles – direct anastamosis 
of vessels to tubing, looping a section of tubing to connect artery to vein and 
subcutaneous tunnelling of the connecting loop, the modern AVG was created (26). 
  
Whilst initially Dacron was the most commonly used graft material, the emergence of 
the synthetic material polytetrafluoroethylene (PTFE) as a pliable, biocompatible 
material that may be repeatedly cannulated yet maintain its structural integrity, led to 
significant improvement in the durability of the AVG.  First described by Soyer in 
1972 PTFE has since become the most commonly used graft material for 
haemodialysis vascular access worldwide (36).    A diagrammatic representation of an 
upper limb AVG is demonstrated in figure 1.10 
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Figure 1.10 - A typical looped brachiocephalic arteriovenous graft used for attachment to the 
extracorporeal haemodialysis circuit. 
 
Commonly an AVG is used to connect the brachial artery to the basilic vein, although 
grafts between the radial artery and basilic vein and the brachial artery and axillary 
vein are also regularly used.  When vascular access in the upper limbs is exhausted, 
synthetic grafts can be used to establish vascular access using the subclavian or 
axillary vessels, femoral vessels, or even may be anastamosed between the arterial 
system and the right atrium.  Approximately 3% of haemodialysis patients in the UK 
dialyse via an AVG at present (34). 
 
Central Venous Catheters 
 
In the early years of haemodialysis the demand for experienced surgeons to create 
arteriovenous shunts, fistulae and grafts outstripped supply.  The paucity of vascular 
surgeons prepared to perform these procedures provoked one UK nephrologist, 
Stanley Shaldon, to develop hand-made cannulae that could undergo insertion into the 
femoral artery and accompanying vein to permit immediate haemodialysis access.  He 
made use of the Seldinger insertion technique - a method that enables safe catheter 
 47 
placement into the vascular tree introduced by Sven-Ivar Seldinger in 1953 (37).  
Arterial cannulation was soon abandoned after it was found to be associated with an 
unacceptably high risk of bleeding compared to veno-venous cannulation.  Gradually 
different insertion sites were used including the jugular and subclavian veins.  These 
had the advantage of allowing central venous pressures to be estimated in patients 
with extracellular fluid depletion (38), a common occurrence in many patients with 
acute renal failure requiring dialysis.  Cannulation of the subclavian vein became the 
favoured approach for central venous catheter (CVC) insertion until the early 1990s 
when angiographic data demonstrated a significantly increased risk of central venous 
stenosis at the site of cannulation.  This predisposed patients to a high risk of limb 
oedema which could impair the ability to create and maintain a functioning AVF (39).  
Insertion into the internal jugular veins is now regarded as standard practice although 
femoral venous cannulation is also performed. 
 
CVCs are frequently used temporarily to provide vascular access for haemodialysis 
whilst the patient awaits creation or maturation of an AVF or AVG or because they 
have run out of suitable options for permanent vascular access.  Some CVCs may be 
tunnelled subcutaneously en-route to entering the vein with a securing cuff to stabilise 
the position of the catheter and reduce periluminal infection.  Direct transcutaneous 
cannulation of the vein is often performed acutely and tends not to involve 
subcutaneous tunnelling or use of a securing cuff.  Polyurethane and silicone are the 
two materials most commonly used in the manufacture of haemodialysis catheters 
although polymers such as carbothane are increasingly common.  These materials 
provide sufficient flexibility, durability and biocompatibility for intravascular use.  
Approximately 29% of haemodialysis patients in the UK dialyse via a CVC (34).   
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These different methods of obtaining vascular access allow haemodialysis to be a 
viable treatment for the majority of patients with ERF.  The diversity of vascular 
access options available can help nephrologists address a range of clinical scenarios 
more effectively.  Late presentation of ERF is one frequently experienced scenario 
that may have a significant impact on vascular access provision.  In this setting the 
time in which RRT is required to start may arrive before the patient can undergo 
vascular assessment, surgery and successful maturation of their fistula or graft.  This 
phenomenon is often used to explain the relatively high prevalence of ERF patients 
using CVCs as their first haemodialysis access modality.   In the UKRR vascular 
access survey of 2006, 66% of patients started haemodialysis on a CVC compared 
with 34% using an AVF or AVG.  By 12 months 28% of prevalent patients were 
using a CVC compared with 71% using an AVF or AVG (34).  Similarly when an 
AVF or AVG fails, CVCs are a rapid means of establishing vascular access and thus 
have an important role in the emergency provision of vascular access.  
 
Whilst each access type has its relative attributes, it is vitally important to consider the 
differing degrees of reliability, durability and complications associated with each 
approach.  Whether considering an individual patient’s circumstances or planning 
vascular access provision at a population level, understanding the range of 
complications expressed by each access type and which factors predispose to these 
complications is of fundamental importance in deriving maximum benefit with 
minimal risk. 
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1.5 The Complications of Haemodialysis Vascular Access 
 
Each vascular access method has associated complications that may arise immediately 
following creation or later during regular use.  Failure of vascular access is most 
frequently due to thrombosis occurring within or around the AVF, AVG or catheter 
however other significant problems such as infection, aneurysm formation, heart 
failure and ischaemia distal to the site of access creation may occur. 
 
Establishing and maintaining vascular access in the face of these complications is 
costly.  USRDS data suggest that the total annual cost of establishing and maintaining 
haemodialysis vascular access is approximately one billion dollars.  The recent trend 
of increasing expenditure on dialysis access reported to the USRDS is demonstrated 
in figure 1.11 below. 
 
 
 
Figure 1.11 - Per person per year access costs, by type of access, in the USRDS ERF population (1999-
2005).  (Adapted, with permission, from the USRDS Annual Report, 2008). 
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Within these figures there has been a notable rise in the amount spent on 
interventional radiology services and a relative fall in the amount spent on vascular 
surgery and thus access creation costs have remained relatively static.  The main rise 
in expenditure relates to vascular access maintenance with access-related 
complications accounting for nearly a quarter of hospitalisations in the RRT 
population (1).   
 
Thrombosis 
 
Over 80% of vascular access loss is due to local vascular thrombosis.  In the case of 
arteriovenous fistulae or grafts, this is mostly due to intravascular stenosis from 
anatomical defects arising within venous drainage from the access site although rarely 
from the arterial inflow.  The rate of AVF thrombosis is estimated as 0.2-0.4 episodes 
per patient year compared with 0.8-1.2 episodes per patient year for AVGs (40).   
 
The main substrate for venous stenosis is endothelial cell injury, most commonly at 
the site of the anastamosis.  This results in the up regulation of a pro-inflamatory 
cascade which promotes smooth muscle cell accumulation at the site of injury (41).  
This process may be escalated in response to shear stress arising from turbulent flow 
(42), repeated cannulation and the relative difference in vascular elasticity either side 
of the anastamosis (43).  Other contributing factors include compression of the fistula 
or graft between dialysis sessions, hypotension, hypovolaemia and hypercoagulable 
states (44).   
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Primary prevention of AVF or AVG stenosis has focussed on selecting an appropriate 
site for vascular access creation, as determined by vascular imaging, and monitoring 
fistula or graft performance.  Monitoring relies on assessment of access structure, 
assessment of access blood flow, measurement of delivered dialysis dose and 
assessment of the resistance to blood flow on return to the venous tree.  These features 
may all contribute towards determining whether an AVF or AVG is at risk of failure.    
Where venous stenosis of >50% is discovered, percutaneous angioplasty or surgical 
revision may improve AVF or AVG longevity.  Intervention on a thrombosed AVF, 
however, is not likely to lead to restoration of long-term patency unless an acute, 
unexpected deterioration in AVF performance occurs and patency is restored 
promptly.  Monitoring may occur routinely as part of a regulated screening program 
or be undertaken in response to clinical deterioration in a previously functioning AVF 
or AVG.  Best practice remains uncertain.  Whilst many of the methods used in 
detecting venous stenosis and thrombosis are effective, routine screening with 
subsequent intervention has not yet been proven to reproducibly increase the long-
term survival of AVFs and AVGs.  Prospective monitoring thus remains controversial 
(45, 46).  Some guideline groups are recommending some form of prospective 
monitoring for all AVFs and AVGs (47) whilst others recommend restricting detailed 
AVF and AVG assessment to those with clinical signs of deterioration such as a 
decrease in intradialytic blood flows (48).   
 
The issue of antiplatelet agent use in preventing AVF or AVG thrombosis is 
unresolved.  Several antiplatelet agents including aspirin, dipyridamole, clopidogrel, 
sulfinpyrazone and ticlopidine have been studied in the past.  Many of the studies 
were conducted in the 1970s and 1980s where dialysis populations and treatments 
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were very different to those seen today (49).  Recent studies have focussed primarily 
on primary patency in arteriovenous grafts.  One more recent trial compared 
dipyridamole and/or aspirin in PTFE AVGs.  Neither treatment approach appeared to 
be effective as a secondary preventative measure although primary prevention of 
thrombosis was demonstrated with dipyridamole (50).  A randomised controlled trial 
evaluated use of aspirin and clopidogrel although was stopped early because of a 
significantly elevated risk of bleeding among those receiving antiplatelets (51).  More 
recently a randomised controlled trial of 649 patients with a new AVG assessed 
dipyridamole (200 mg twice daily) plus aspirin (25 mg twice daily) or placebo.  The 
intervention group demonstrated greater rates of primary patency with a similar rate 
of adverse events, including bleeding, albeit in a population designed to be of low 
bleeding risk and with relatively short exposure to the antiplatelets on trial (52).  Use 
of anticoagulants such as warfarin has not been proven to reduce thrombosis and has 
been associated with an increased risk of bleeding (53). 
 
When considering CVCs, thrombosis is a common problem that frequently results in 
catheter loss.  Two types of thrombosis may occur with central venous catheterisation 
– extrinsic venous thrombosis and intrinsic catheter thrombosis.  Extrinsic venous 
thrombus arises in lumen of the vein in which the catheter has been inserted, 
invariably around the outside of the catheter and thus impairing blood flow past the 
device.  Whilst not necessarily attached to the catheter surface, the catheter or its tip 
may be embedded within the thrombus, further exacerbating abnormal venous flow 
patterns.  Intrinsic thrombus arises from within the catheter lumen and may extend 
from the catheter tip outwards, reflecting back over the catheter as a surrounding 
sheath.  Up to 70% of CVCs may develop a fibrin sheath soon after insertion.   
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Both extrinsic and intrinsic catheter thrombosis may arise from (i) abnormalities of 
blood flow such as turbulence and low venous flow rates; (ii) abnormalities of the 
vessel wall such as local vascular endothelial damage following catheter insertion and 
the presence of a foreign body within the venous lumen; and (iii) a local or systemic 
pro-coagulant state such as that mediated by the release of pro-inflammatory 
cytokines from the damaged venous endothelium or the presence of a systemic 
coagulopathy.  Once local thrombosis occurs, venous flow is disturbed and an 
escalating cascade of thrombus formation may perpetuate. 
 
Primary prevention of catheter thrombosis focuses on selection of an appropriate site 
for CVC insertion and adequate heparinisation of the catheter in between dialysis 
sessions.  The internal jugular vein is favoured over the sub-clavian vein due to its 
lower risk of subsequent venous stenosis that could impair the function of future 
AVFs or AVGs.  Many patients who have undergone previous vascular access 
procedures may benefit from imaging of target sites – a practice increasing in 
frequency with the development of interventional radiology services.  Controversy 
exists as to the best means of assessing the central veins in complex patients, with 
ultrasound, radiocontrast venography and magnetic resonance venography all being 
available methods.  Use of contrast enhanced magnetic resonance venography (CE-
MRV) had increased over recent years due to its proven speed, accuracy and 
reproducibility in the detection and evaluation of central venous thrombus and 
stenosis (54).  Recently, however, use of CE-MRV has come under close scrutiny 
following reports indicating an association between the administration of gadolinium-
based contrast agents and the development of the rare condition nephrogenic systemic 
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fibrosis (NSF) (55).  This has limited the use of CE-MRV in these patients and placed 
renewed focus on imaging practices in ERF patients. 
   
The routine practice of filling the internal lumen of CVCs with heparin solution is 
almost universal in haemodialysis catheter use due to the clear benefit in preventing 
intraluminal thrombosis.  The concentration and volume of heparin solution instilled 
into catheters may vary greatly between renal units. The benefits of maintaining 
catheter patency with heparin-locking are balanced against the risk of systemic 
heparinisation and subsequent bleeding.  In a Canadian longitudinal study of 6940 
haemodialysis sessions the use of a 1000iU/mL heparin lock solution in central 
venous haemodialysis catheters was not associated with higher rates of catheter 
malfunction compared with the use of 10,000iU/mL heparin solution but the 
1000iu/ml group did require greater anti-thrombotic intervention with thrombolytic 
drugs (56).   Concentrations of heparin up to 5,000iU/mL are regularly used yet no 
prospective studies have been performed to examine the effects of higher 
concentrations of heparin solution. 
  
Several measures may be used to treat established catheter thrombosis.  Catheter 
salvage may be attempted by infusion of saline flushes which are easily performed, 
economical, safe and frequently effective (57).  Intraluminal thrombolytic or a 
systemic infusion of thrombolytic may also restore catheter patency.  Historically this 
was conducted with urokinase however tissue plasminogen activator (tPA) has been 
demonstrated as providing better long-term patency without any additional risk of 
bleeding or other adverse events (58).  Despite this, one prospective study found tPA 
infusion to allow for a median of only five to seven additional haemodialysis sessions 
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before needing repeated or the catheter needing exchanged.  The overall clinical 
benefit and cost-effectiveness of tPA treatment thus remains doubtful (59).   
 
Anticoagulation with warfarin as a means of preventing catheter thrombosis remains 
controversial.  Sub-therapeutic warfarinisation has been found to be of no benefit to 
catheter patency in patients on haemodialysis (60).  Warfarinisation to an INR range 
of 1.5 to 2.5 has been found to be of some benefit in patients deemed at high risk of 
thrombosis (61, 62).  Recent USRDS data, however, have found the rate of 
development of subdural haematomas in long-term dialysis patients is 10 times higher 
than that of the general population and cite a concurrent increase in warfarin usage as 
being a possible contributant (63).  Further data has also demonstrated an association 
between warfarin use and heightened risk of stroke in haemodialysis patients (64).  
Consensus opinion is therefore that anticoagulation with warfarin only be used in 
long-term haemodialysis patients when deemed absolutely necessary and when 
justified by published evidence. 
 
Another option is catheter replacement over a guidewire with or without stripping of 
the fibrin sheath (65, 66).  This approach allows optimal preservation of the venous 
anatomy with a significant rate of success.  Doubts exist, however, when considering 
the likelihood of recurrent thrombosis and the prospect of introducing infection 
through the subcutaneous tunnel during catheter exchange.  One small study of 42 
catheter exchange procedures found comparable rates of subsequent infection and 
failure to de novo catheter insertions (67) however others have suggested an increase 
in complication rates (68).  How the complication rate of catheter exchange 
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procedures compares with other catheter insertion procedures is unclear and remains 
an area of controversy. 
 
Infection 
 
Infection is a common problem in haemodialysis patients and accounts for increasing 
rates of hospitalisation, comorbidity and mortality.  Figure 1.12 demonstrates recent 
trends in admissions for principle diagnoses of infection and bacteraemia/septicaemia 
in the USRDS ERF population.   It has been found that approximately 20% of 
vascular access loss is due to the development of infection.   
 
          
 
Figure 1.12 – USRDS 2008 report, adjusted admissions for principle diagnoses, by modality from 1993 
to 2005.  (Adapted, with permission, from the USRDS Annual Report, 2008). 
 
Vascular access is the source of the majority of infections within haemodialysis units.  
The predominance of skin commensals as pathogenic organisms in bacteraemic 
patients suggests that inoculation during vascular cannulation is the main mechanism 
by which infection arises (69).  Once inoculated, synthetic materials such as those 
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used in AVGs and CVCs have a tendency towards chronic infection due to their lack 
of innate immune defence mechanisms and their propensity to develop biofilm 
compared with autologous AVFs.  Biofilm is a complex community of sessile cells 
that attach to a substratum and to each other.  Bacteria may form biofilm through the 
production of a matrix of glycoprotein polymers that act as both a physical and 
chemical barrier to the immune response.  These properties allow biofilms to develop 
resistance to biocides, phagocytes and antimicrobials with the degree of resistance 
correlating with the maturity of the biofilm (70).  Biofilm formation is a key substrate 
in the development of chronic infection in vascular access devices.  A scanning 
electron microscopic image of a staphylococcal biofilm is demonstrated below in 
figure 1.13. 
 
     
Figure 1.13 – A scanning electron microscopic image of a staphylococcal biofilm formed on a 96-peg 
lid plate. 
 
Prevention and treatment of vascular access infection is a major component in the safe 
delivery of haemodialysis.  When considering arteriovenous fistulae and grafts, sterile 
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cannulation is fundamentally important.  Poor cannulation technique, often due to 
relative inexperience of dialysis personnel, may lead to pseudoaneurysm formation or 
the development of perifistular haematomas and is significantly associated with 
subsequent infection (71).   
 
Routine antibiotic prophylaxis is controversial.  Topical antibiotic use has not been 
found to be effective with benefits in reducing nasal staphylococcus aureus carriage 
by topical mupirocin treatment being found to be associated with the development of 
resistant pathogens (72).  Consequently most primary prevention strategies focus on 
the ability to ensure aseptic technique when inserting or handling vascular access 
devices. 
 
Practices such as sterile barrier nursing, hand hygiene, use of antiseptic solutions such 
as chlorhexidine and removal of the catheter at the earliest point possible are widely 
established and reflected in national guidelines (48).  
 
When considering CVCs the location and type of catheter used have an important 
association with subsequent rates of infection.  Infection is more commonly seen in 
patients who have undergone catheterisation of the femoral veins compared with 
those in whom catheterisation is undertaken in the internal jugular veins.  Catheters 
tunnelled subcutaneously prior to entry into the vein are associated with lower rates of 
infection.  Whether these associations arise due to the location and method of 
catheterisation in distinct sites or as a function of the characteristics of the types of 
patients who undergo different catheterisation procedures remains unclear.   
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New methods for the primary and secondary prevention of CVC infection have been 
devised over recent years with a growing evidence base detailing their applicability. 
Catheter materials coated or impregnated with anticoagulants, antibiotics, and silver 
ions have been studied with conflicting results.  One meta-analysis of 11 randomised 
trials demonstrated significant reductions in catheter colonisation and catheter-related 
bacteraemia with antiseptic-impregnated catheters compared to standard non-
impregnated catheters.  These conclusions were disputed in a second meta-analysis 
which highlighted inconsistencies in key definitions, failures in determining clinically 
important end points and the neglect of potential confounding variables in many of 
the study populations examined (73).  Despite these uncertainties such catheters are 
often found in routine use within dialysis centres. 
 
Another area of increasing interest is the development of combined anticoagulant-
antimicrobial catheter lock solutions.  Known as the antibiotic lock technique, this 
method is targeted at preventing and eradicating biofilm on the endoluminal surface 
of haemodialysis catheters.  An antibiotic-anticoagulant solution is instilled into the 
catheter lumen and left to dwell between haemodialysis sessions.  This method 
delivers a small absolute amount of antibiotic to the patient but achieves a high local 
concentration in the catheter lumen that is 100 to 5,000 times higher than the 
minimum inhibitory concentration (MIC) for the infecting bacterium.  Use of 
antibiotic lock solutions as a primary prevention strategy has raised concerns 
regarding the risks of developing antimicrobial resistance with leakage of the 
antibiotic-lock solution into the circulation.  Using antibiotic-lock solution as a 
secondary adjunctive measure to systemic antibiotics in treating CRB is, however, 
less contentious.   
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A recent meta-analysis of the antibiotic lock technique was reported by Jaffer et al in 
2008.  This reported the relative success of antibiotic lock solutions in haemodialysis 
cohorts with a significant reduction in the frequency of catheter-related infection (74).  
A further meta-analysis using different inclusion criteria arrived at the same 
conclusions with the techniques appearing to offer significant improvements in 
bacteraemia rates (75).  In both studies the authors, however, cited major limitations 
incurred due to the relatively short duration of follow-up and thus an inability to 
assess the risk of antibiotic resistance.   
 
Other reported barriers to the use of these solutions are concerns of systemic leakage 
of the lock solutions, a finding demonstrated by one of the randomised controlled 
trials which used gentamicin 40mg/ml in combination with citrate where basal levels 
of gentamicin were detected in the systemic circulation (76).  This may result in a 
cumulative increase in risk of toxicity/adverse effects.  The potential economic costs 
of these solutions are also yet to be fully evaluated.  Whilst this area continues to 
evolve, our understanding of how combinations of anticoagulant and antimicrobial 
interact is limited and remains an area of considerable interest.   
 
 
1.6 Summary 
 
It can be seen that when considering the complications of haemodialysis vascular 
access, many areas of controversy and uncertainty persist.  This thesis consists of 
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several studies which aim to bring clarity and certainty to specific areas of vascular 
access practice and thus enhance clinical judgement and decision making. 
 
The first part of this thesis scrutinises the hierarchy of complications seen across the 
range of haemodialysis access types.  In particular the complication rates associated 
with different types of vascular access catheter insertion procedure are examined.  
The prevalence of maintenance procedures, thrombotic complications and infectious 
complications reported by each vascular access population in the USRDS 2008 survey 
are demonstrated in table 1.1 below. 
 
Complication AVF (%) AVG (%) CVC (%) 
Removal 0.7 1.1 13.3 
Replacement 0.7 1.3 25.4 
Declotting 3.3 14.4 1.5 
Mechanical Complication 0.5 0.8 1.6 
Infection 1.1 2.6 10.2 
Sepsis 4.2 4.8 15.7 
 
Table 1.1 – A comparison of prevalent maintenance procedures, thrombotic complications and 
infectious complications reported by each vascular access population reported in the USRDS 2008 
Data Report.   
 
AVFs have the lowest complication rates followed by AVGs and then CVCs.  
Consensus opinion thus suggests that AVF creation should be sought where possible 
(47).  Clearly there are logistical hurdles to this – late presentation to renal services, 
fitness for surgery, suitable peripheral vascular anatomy, delays due to primary or 
secondary access failure and slow rates of AVF maturation.  Consequently there 
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remain situations, especially when starting RRT, where use of an AVG or CVC may 
be required.  This is demonstrated by the relative preponderance of CVC use in 
patients starting RRT around the world.  Similarly CVC insertion is the mainstay of 
vascular access provision to the acute renal failure population who require 
haemodialysis.  CVCs therefore have an important role in haemodialysis vascular 
access provision although do so at a cost.   
 
USRDS data from 2007 suggest that expenditure on catheter placement is 
approximately 2.5 to 2.8 times higher than on AVF and AVG surgery.  It is suggested 
that these figures reflect the excess costs the catheter group incur by being a 
predominately in-patient comorbid population compared to the population who 
undergo elective AVF and AVG surgery (1).   
 
The association between catheter use, comorbidity and in-patient care is strong.  The 
question of whether the adverse features related to catheter use, such as catheter 
thrombosis and bacteraemia, are specifically related to use of a catheter or are simply 
related to the greater level of comorbidity expressed by the population who require 
catheter insertion has been subject to controversy.  This question is addressed in 
chapters 2 and 3 of this thesis where prevalent and incident RRT populations are 
studied by detailed univariate and multivariate analyses in an effort to determine the 
relative strength of independent association between clinical, laboratory and vascular 
access variables and the outcomes of catheter-related bacteraemia and thrombosis. 
 
Methods of preventing and treating CVC related bacteraemia and thrombosis have 
come under close scrutiny.  Numerous strategies targeting these problems have been 
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examined however the introduction of anticoagulant-antimicrobial catheter lock 
solutions into clinical practice appears to have been successful despite many 
uncertainties remaining.  In this thesis the contentious issue of heparin and also 
antibiotic-lock solution leakage into the circulation is addressed by the work detailed 
in Chapter 4.  This work describes a randomised controlled study of heparinised 
catheter lock solutions and their relative effects on systemic markers of coagulation.  
Secondly, the uncertain issue of how the combination of an antimicrobial with an 
anticoagulant may affect the antimicrobial performance of the antibiotic lock solution 
is addressed in the studies detailed in Chapter 5.  This work describes an in-vitro 
assessment of the properties exhibited by heparin and vancomycin against planktonic 
and biofilm embedded staphylococci. 
 
Many of the complications of vascular access, however, can only be definitively 
addressed by removal or replacement of the vascular access device.  As noted earlier, 
significant controversy exists as to the best means of assessing the central veins in 
complex patients.  In recent years the development of contrast-enhanced MRV 
imaging had become a favoured approach.  The work detailed in Chapter 6 describes 
a retrospective assessment of all CE-MRV examinations undertaken in haemodialysis 
patients within the renal unit of Glasgow Royal Infirmary.  This work describes the 
abnormalities found on CE-MRV and the subsequent clinical course followed by the 
patients in whom CE-MRV imaging was undertaken.  It was during this study that a 
relatively high prevalence of the serious condition nephrogenic systemic fibrosis was 
noted.  During this period the first published association between NSF and 
gadolinium-enhanced MRV was made (77).  Consequently a large retrospective 
analysis of all RRT patients in the West of Scotland was made to assess whether an 
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association between gadolinium contrast agents and NSF existed in our population.  
This work is presented in Chapter 7. 
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Chapter 2  
 
A Retrospective Study of Vascular Access in Haemodialysis 
Patients and Risk of Bacteraemia and Death 
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2.1 Background 
 
Haemodialysis patients have high rates of morbidity and mortality of which infection 
makes a significant contribution (7, 78).  The immunosuppressive effects of advanced 
renal failure, concurrent co-morbid disease and associated malnourishment combine 
with the repeated intravascular intervention required for haemodialysis to provide an 
environment conducive to the development of bacteraemia and sepsis syndrome (79).   
 
The effect of sepsis can be profound.  The financial cost of treating dialysis patients 
with septicaemia is high with estimates of up to $32,000 per patient hospitalised with 
bacteraemia in the United States (80-84).  Septicaemia in a haemodialysis patient 
confers a relative risk for mortality of 2.8 with relative risks of subsequent myocardial 
infarction, cardiac failure and stroke of 4.1, 5.5 and 4.1 respectively.  The 
development of sepsis syndrome is now classed as second only to cardiovascular 
disease as the leading cause of death in patients on renal replacement therapy (RRT) 
(78).  These implications have become increasingly recognised and recent reports 
have suggested methods such as cohort surveillance and bacteraemia monitoring to 
help define at risk groups before targeting resources to prevent and treat bacteraemia 
(85, 86).  
 
Vascular access is an established risk factor for sepsis in patients on RRT.  Different 
types of haemodialysis vascular access are associated with differing rates of 
bacteraemia (87-91).  Patients using different types of vascular access, however, tend 
to have different clinical characteristics.  Indeed, the true independence of the 
association between vascular access and bacteraemia in comparison with other 
 67 
clinical and laboratory risk factors has yet to be clearly established.  This study was 
designed to determine which routinely recorded clinical variables, laboratory 
variables and vascular access types are independently associated with bacteraemia and 
death in haemodialysis patients.  
 
 
2.2 Methods 
 
A retrospective analysis of all patients in our renal unit who were on haemodialysis on 
the 1st of January 2004 was performed.  Clinical, demographic and laboratory 
variables for each patient were retrieved from the unitary electronic patient record.  
Where multiple measurements of a single variable had been recorded, the first value 
after 1st January 2004 was used.   
 
Clinical variables collected were age, gender, primary renal diagnosis, the presence or 
absence of diabetes, length of time on renal replacement therapy, vascular access flow 
rate on haemodialysis and urea reduction ratio (a standard measure of haemodialysis 
adequacy).  The dialysis access in use at the time of study initiation was recorded as 
one of four categories: native arteriovenous fistula (AVF) – a surgically created 
anastamosis between artery and vein to create a robust port of access for 
haemodialysis, synthetic vascular access graft, tunnelled central venous catheter 
(TCVC) and non-tunnelled central venous catheter (NTCVC).  
 
Laboratory variables collected at study entry were haemoglobin, serum C-reactive 
protein (CRP), serum ferritin, serum albumin, serum adjusted calcium and phosphate 
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product, serum alkaline phosphatase, serum parathyroid hormone concentration and 
total serum cholesterol to high-density lipoprotein (HDL) cholesterol ratio.   
 
Outcomes 
 
Outcomes were ascertained over an 18-month period of follow up terminating on 1st 
of July 2005.   Bacteraemia events were determined by analysis of all positive in-
patient and out-patient blood culture results from the renal unit reported by the 
bacteriology laboratory during the period of study in conjunction with analysis of the 
patient’s clinical notes and electronic patient record.  Bacteraemia was regarded as 
significant if positive blood cultures were associated with a raised systemic 
inflammatory response (e.g. pyrexia, raised CRP, raised white-cell count).  Sub-
clinical bacteraemia was not evaluated.  This approach is in keeping with the 
consensus definition of clinically significant bacteraemia and consistent with that used 
in routine clinical practice.  Where patients were found to have developed a 
significant bacteraemia, the date of the first positive blood culture result was entered 
as the event date and the time to event subsequently calculated.  The patient was then 
removed from further bacteraemia analysis.  This study did not examine cases of 
recurrent bacteraemia and thus was a ‘time to first bacteraemia’ analysis.  In all cases 
of confirmed bacteraemia the causative organism was recorded and sensitivity profiles 
examined.  Patients who remained on haemodialysis throughout the observation 
period and did not develop bacteraemia had a census date of 1st July 2005 recorded.   
 
All patients who died during the follow up period had the date of death recorded as an 
endpoint.  All patients who were discharged, were transferred to another 
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haemodialysis unit or who switched renal replacement modality were assigned a 
census date corresponding to the date of discharge from the haemodialysis cohort. 
 
Our standard unitary protocol for catheter care was employed throughout the 
observation period.  Specifically, this demanded complete sterile barrier precautions 
during catheter insertion and when manipulating the catheter hub.  Following 
catheter-hub manipulation, the skin surrounding the insertion site was soaked with 
chlorhexidine solution prior to a sterile dressing being applied. All haemodialysis 
patients were on a standard regimen of 3 haemodialysis sessions per week, each of 
minimum 4 hours per session with subsequent increases in session length up to 5 
hours in order to achieve a target urea-reduction ratio of 70%.  This conforms to UK 
Renal Association Guidelines.  Water quality in the haemodialysis facilities was 
quantified on a pass/fail basis using a failure threshold of 0.25 endotoxin units per mL 
with pass rates for all reverse osmosis units in the unit typically averaging 98% with 
total viability counts averaging <10 cfu/ml. 
 
Analysis 
  
Sample size was determined by the size of the haemodialysis population within 
Glasgow Royal Infirmary Renal Unit on 01/01/2004.  No other similar patient 
populations were available for study in whom reliable data retrieval could be 
achieved.  Statistical analysis was performed by SPSSTM version 14.0 (SPSS Inc, IL, 
USA).  Normality testing was performed on all of the recorded continuous variables.  
Student’s t-testing and Mann-Whitney U testing were then used to assess differences 
between TCVC and NTCVC groups with AVF as a comparator.   
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Bacteraemia free survival and mortality rates for each access type was subject to 
Kaplan-Meier survival analysis and Log Rank testing with p<0.05 being regarded as 
statistically significant.  The remaining variables were subject to univariate analysis 
with Students t-testing and Mann-Whitney U testing as appropriate to test for 
associations between characteristics at study entry and the development of 
bacteraemia and mortality. The relationship between bacteraemia and subsequent 
mortality was subject to Pearson Chi-square testing.  After application of the 
bonferroni correction a p-value of <0.0025 was regarded as statistically significant in 
these univariate analyses.  Multivariate analysis was performed using a Cox 
proportional hazards model with a stepwise conditional method of analysis to test for: 
1) an independent association with the development of bacteraemia and 2) an 
independent association with mortality.  To avoid over fitting of the multivariate 
models the convention of limiting the number of independent variables entered to 
approximately 10% of the number of outcome events was followed.  In our analysis 
independent variables for entry into the models were selected according to their p-
values on univariate testing. On multivariate analysis all reported p-values <0.05 were 
regarded as significant. 
 
 
2.3 Results 
 
A search of the renal unit electronic patient record was conducted to identify all 
patients who underwent haemodialysis between 1st and 3rd of January 2004.  A total of 
265 patients were identified of whom 136/265 (51.3%) were male.  Mean age was 
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63.5 years (SD 14.6) whilst median duration of renal replacement therapy prior to 1st 
of January 2004 was 1076 days (range 7-12,829).  All patients were found to have 
established renal failure with none of the cohort on dialysis for acute renal failure.  
59/265 (22.3%) of the cohort had a diagnosis of diabetes mellitus.  At study entry 
206/265 (77.7%) were dialysing via native AVF, 31/265 (11.7%) were dialysing 
through a TCVC, 26/265 (9.8%) were dialysing through a NTCVC and 2/265 (0.8%) 
were dialysing through a synthetic vascular graft.  As only two patients were dialysing 
through a synthetic graft, they were not subject to further analysis.  Table 2.1 displays 
the characteristics of the full cohort whilst table 2.2 compares the clinical and 
laboratory characteristics for each vascular access type. 
  
Variable Data Values 
 
Age (years) 
 
 
63.5 (14.6)* 
Male  136/265 (51.3%)  
 
Female 
 
129/265 (48.7%) 
 
Diabetes 
 
59/265 (22.3%) 
Duration of RRT (days) 
 
1076 (376, 2095)** 
Haemoglobin (g/dL) 
 
11.3 (1.8)* 
Ferritin (ng/ml) 
 
356 (196, 568)** 
Albumin (g/L) 
 
37.5 (4.8)* 
C-reactive protein (mg/L) 
 
17.4 (2.9)* 
Alkaline phosphatase (U/L) 
 
203 (156, 304)** 
Parathyroid Hormone (pmol/L)                                            
 
22.0 (11.0, 40.0)** 
Calcium x phosphate product 
 
4.08 (1.34)* 
Cholesterol:HDL 
 
3.39 (1.24)* 
Haemodialysis blood flow (mL/min) 
 
300.0 (59.4)* 
Urea reduction ratio (%) 
 
71.3 (8.9)* 
 
Table 2.1 – Data values and descriptive statistics for the laboratory variables studied in the full cohort.  
Data values are expressed as value (%), *mean (SD) or **median (Q1, Q3). 
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Table 2.2 - Characteristics for each of the main vascular access groups.  All statistical testing of the tunnelled 
and non-tunnelled catheter groups was carried out in comparison with the characteristics of the arteriovenous 
fistula group.  Data values are expressed as value (%), *mean (SD) or **median (Q1, Q3). 
 Arteriovenous 
Fistula (n=206) 
Tunnelled Catheter  
(n=31) 
 
Non-Tunnelled 
Catheter (n=26) 
 
 
 
Clinical Features 
 
Age (years) 
 
 
 
 
 
63.8 (14.4)* 
 
 
 
 
63.5 (15.2)* 
 
 
 
 
p = 0.90 
 
 
 
 
62.8 (17.0)* 
 
 
 
 
p = 0.75 
Male 111 (53.9%) 10 (32.3%) p = 0.03 14 (53.8%) p = 0.99 
 
Female 
 
95 (46.1%) 21 (67.7%) p = 0.03 12 (46.2%) p = 0.99 
Diabetes 
 
43/206 (20.9%) 8/31 (25.8%) p = 0.49 7/26 (26.9%) p = 0.46 
Duration on RRT 
 
1138 (412, 2048)** 1511 (765, 5288)** p = 0.01 278 (55, 903)** p<0.001 
Haemodialysis blood flow 
(ml/min) 
309 (56.5)* 267 (60.9)* p<0.001 268.8 (58.6)* p = 0.001 
Urea reduction ratio (%) 
 
71.9 (8.9)* 70.45 (8.04)* p = 0.27 66.7 (8.73)* p = 0.01 
 
Primary Renal Diagnosis 
 
     
Primary Glomerulonephritis 
 
39/206 (18.9%) 6/31 (19.4%) p = 0.96 6/26 (23.1%) p = 0.61 
Interstitial Nephropathies 
 
57/206 (27.7%) 10/31 (32.2%) p = 0.60 5/26 (19.2%) p = 0.36 
Multisystem Disease 
 
28/206 (13.6%) 2/31 (6.5%) p = 0.27 2/26 (7.7%) p = 0.40 
Diabetic Nephropathy 
 
33/206 (16.0%) 4/31 (12.9%) p = 0.66 8/26 (30.8%) p = 0.06 
Laboratory Variables   
 
 
 
Haemoglobin (g/dL) 
 
11.4 (1.7)* 11.6 (1.98)* p = 0.74 10.2 (1.56)* p = 0.001 
Ferritin (ng/ml) 
 
357 (200.0, 578.0)** 467 (192, 575)** p = 0.94 253 (88.5, 432.5)** p = 0.06 
Albumin (g/L) 
 
37.9 (5.0)* 36.6 (3.13)* p=0.007 35.7 (4.1)* p= 0.005 
C-reactive protein (mg/L) 
 
15.7 (2.9)* 23.9 (3.0)* p = 0.06 24.5 (2.7)* p = 0.03 
Calcium x phosphate  
 
4.13 (1.36)* 4.03 (1.18)* p = 0.87 3.8 (1.5)* p = 0.20 
Alkaline phosphatase (U/ml) 
  
196 (156, 297)** 220 (154.5, 333.0)** p = 0.43 239 (153.0, 466.0)** p = 0.41 
Parathyroid hormone (pmol/L) 
 
35.5 (38.7)* 29.7 (29.8)* p = 0.37 24.7 (22.4)* p = 0.23 
Chol:HDL 
 
3.5 (1.3)* 2.73 (0.58)* p = 0.03 3.2 (1.0)* p = 0.34 
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As expected, patients dialysing through a TCVC had a significantly lower haemodialysis 
blood flow rate when compared to those dialysing through an AVF.  Otherwise, those using 
a TCVC demonstrated trends towards lower serum albumin, lower serum cholesterol to 
HDL ratios and longer median duration on RRT in comparison to those dialysing through 
an AVF.  26/31 patients were dependent on their TCVC as their only remaining option for 
vascular access whilst 5/31 patients were using a TCVC prior to definitive vascular access 
being created.   
 
Patients dialysing through a NTCVC had significantly lower haemoglobin and lower 
haemodialysis blood flow rates than those dialysing through either a TCVC or AVF.  14/26 
(53.7%) patients had been on dialysis for >3 months and had temporary vascular access 
problems that had required NTCVC insertion.  12/26 (46.2%) had started RRT for 
established renal failure within 3 months of study entry.  This proportion accounts for the 
significantly shorter duration on RRT in the NTCVC group when compared with the 
TCVC and AVF groups (p=0.001).  None of these patients had acute renal failure (i.e. 
recovered renal function within a 3 month period).  Patients dialysing through a NTCVC 
had trends towards lower albumin and urea-reduction ratios as well as higher CRP 
compared to the AVF group.   
 
During the observation period, 15 patients underwent renal transplantation, 5 transferred to 
other renal units, 2 patients switched to continuous ambulatory peritoneal dialysis (CAPD) 
and 1 patient recovered renal function and was subsequently discharged.   
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Bacteraemia  
 
45/263 (17.1%) patients developed at least one episode of bacteraemia over the 18-month 
period.  39/45 (86.7%) of cases were secondary to staphylococci of which 15/45 (33.3%) 
cases were due to coagulase-negative staphylococci and 5/45 (11.1%) cases were due to 
methicillin-resistant staphylococcus aureus (MRSA) infection.  3/45 (6.7%) cases were due 
to gram-stain negative bacteria and 3/45 (6.7%) were secondary to other bacterial 
subspecies.  The relative frequencies of cases of catheter-related bacteraemia from each 
pathogenic group are demonstrated in figure 2.1.   
 
Figure 2.1 – Frequency plot of the types of pathogenic organisms in cases of clinically significant 
bacteraemia demonstrated over the 18-month period of observation. 
 
Analysis of bacterial resistance profiles demonstrated that 9/13 (69%) cases of the 
coagulase-negative staphylococci where antibiotic sensitivities were available, were 
resistant to the antibiotic flucloxacillin.  Of the 45 patients who developed bacteraemia 17 
patients (37.8%) died during the 18-month observation period. 
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Univariate analysis was performed on the laboratory and clinical variables recorded at the 
start of the study period to examine whether there was an association with the development 
of bacteraemia.   The actuarial 18 month bacteraemia-free survival in the cohort dialysing 
via AVF at study entry was significantly higher than the cohorts dialysing through TCVC 
or NTCVC (88.8% v 54.8% v 69.2% respectively; p<0.001).  This is demonstrated 
graphically as a Kaplan-Meier plot in figure 2.2.   
 
 
 
 
 
 
 
 
 
 
Figure 2.2 – Kaplan-Meier plot of time to bacteraemia per haemodialysis vascular access type. ‘AVF’ = 
arteriovenous fistula, ‘Tunnelled CVC’ = tunnelled central venous catheter, ‘Non-tunnelled CVC’  = non-
tunnelled central venous catheter.  
 
No significant difference in bacteraemia event rates was found when directly comparing 
TCVCs with NTCVCs (p=0.29). Patients who developed bacteraemia were found to have 
trends towards higher CRP levels and lower serum albumin levels at study entry than their 
bacteraemia free counterparts but this did not reach the bonferroni corrected significance 
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level.  Age (bacteraemia 62.9yrs v no-bacteraemia 63.8yrs, p=0.74) and the presence of 
diabetes (bacteraemia 8/45 (17.8%) % v no-bacteraemia 34/218 (15.6%), p=0.66) were not 
associated with bacteraemia. 
 
Multivariate analysis demonstrated hazard ratios (HR) for the development of bacteraemia 
in patients dialysing with TCVCs and NTCVCs of 5.43 (95% CI 2.67-11.0, p<0.001) and 
3.14 (95% CI 1.32-7.48, p=0.01) respectively compared to those patients dialysing through 
an AVF.  There was also an independent association between elevated CRP at study entry 
and the risk of developing bacteraemia over an 18-month period with a HR of 1.49 (95% 
CI 1.12-1.98, p=0.006).  The results of the univariate and multivariate analyses for the 
outcome of bacteraemia are demonstrated in table 2.3.   
 
 
Table 2.3 – Factors that underwent both univariate and multivariate analysis and their association with the 
incidence of bacteraemia.  Data values are expressed as value (%) or *mean (SD) where appropriate.  ‘CRP’ 
= C-reactive protein, ‘HD’ = haemodialysis, a Pearson Chi-Square testing, b Student's t-test. 
 
Variable at Study Entry  
 
Univariate Analysis  Multivariate Analysis  
 Data Values  p-value Hazard Ratio 
(95% CI) 
 
p-value 
 
 
Tunnelled Catheter       Bacteraemia 
(n=31)                           No Bacteraemia 
 
 
14 (45.2%)   
17 (54.8%) 
 
P<0.001a 
 
5.43 (2.67, 11.0) 
 
p<0.001 
Non-tunnelled Catheter Bacteraemia 
(n=26)                           No Bacteraemia 
 
8   (30.8%)   
18 (69.2%) 
P=0.006a 3.14 (1.32, 7.48) p=0.01 
CRP                               Bacteraemia 
(mg/L)                            No Bacteraemia 
 
25.3 (2.9)*   
16.0 (2.9)* 
P=0.015b 1.49 (1.12, 1.98) p=0.006 
Albumin                         Bacteraemia 
(g/L)                               No Bacteraemia 
 
36.0 (4.9)*   
37.9 (4.7)* 
P=0.021b - - 
HD Flow                        Bacteraemia 
(ml/min)                         No Bacteraemia 
 
283 (56)*      
303 (60)* 
P=0.036b - - 
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Mortality 
 
65/263 (24.7%) patients died during the follow-up period and were found to have 
significantly elevated serum CRP, low serum albumin and increased age at study entry 
compared with those who survived.  The actuarial 18 month patient survival in the cohort 
dialysing via AVF at study entry was better than the cohorts dialysing through TCVC or 
NTCVC (79.1% v 64.5% v 57.7% respectively; p<0.019).  This is demonstrated 
graphically as a Kaplan-Meier plot in figure 2.3.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 – Kaplan-Meier survival plot of mortality per haemodialysis vascular access type. ‘AVF’ = 
arteriovenous fistula, ‘Tunnelled CVC’ = tunnelled central venous catheter, ‘Non-tunnelled CVC’  = non-
tunnelled central venous catheter. 
 
Trends of association with mortality by univariate analysis were seen with elevated serum 
alkaline phosphatase levels and lower levels of haemoglobin and the product of serum 
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associated with mortality (death occurring in 21/58 (36.2%) diabetics and 44/205 (21.5%) 
of non-diabetics, p=0.02) as was a diagnosis of dialysis related bacteraemia (death 
occurring in 17/45 (37.8%) bacteraemics and 48/218 (22.0%) of non-bacteraemics, 
p=0.026). 
 
Multivariate analysis demonstrated an independent association with death with the use of 
TCVCs and NTCVCs (HR 2.75; p=0.012 and HR 3.39; p=0.001 respectively) compared 
with AVFs, low serum albumin (HR 0.92, 95% CI 0.87-0.97, p=0.003), elevated alkaline 
phosphatase (HR 1.002, 95% CI 1.000-1.003, p=0.011) and increasing age (HR 1.04, 95% 
CI 1.02-1.07, p<0.001).  The results of the univariate and multivariate analyses for the 
outcome of mortality are demonstrated in table 2.4.   
 
Variable at Study Entry 
 
Univariate Analysis  Multivariate Analysis  
 Mean (SD)  p-value Hazard Ratio 
(95% CI) 
 
p-value 
Non-tunnelled     Dead 
Catheter                                                
 
11/26 (42%) p=0.015a 3.39 (1.67, 6.87) p=0.001 
Tunnelled            Dead 
Catheter                                                
 
11/31 (35%) p=0.016a 2.75 (1.25, 6.04) p=0.012 
Age                     Dead 
(Years)                Alive 
 
68.6 (13.2)* 
62.0 (14.7)* 
p=0.001b 1.04 (1.02, 1.07) p<0.001 
Alk phos              Dead 
(U/L)                    Alive 
 
221 (107, 976)** 
192 (58, 943)** 
p=0.003c 1.002 (1.000, 1.003) p=0.011 
Albumin              Dead 
(g/L)                    Alive 
 
35.8 (4.8)* 
38.1 (4.6)* 
p<0.001b 0.92 (0.87, 0.97) p=0.003 
CRP                    Dead 
(mg/L)                 Alive 
  
27.2 (2.8)** 
14.6 (2.8)** 
p<0.001b - - 
Table 2.4 – Factors that underwent both univariate and multivariate analysis and their association with the 
incidence of mortality.  Data values are expressed as value (%), *mean (SD) or **median (Q1, Q3). ‘Alk 
Phos’ = Alkaline Phosphatase, *Median (Q1, Q3), **Geometric Mean (SD), a Pearson Chi-Square testing, b 
Student's t-test, c Mann-Whitney U test. 
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2.4 Discussion 
 
This study examined bacteraemia and mortality in a cohort of haemodialysis patients with 
established renal failure that had a pattern of vascular access which was representative of a 
typical UK chronic haemodialysis population.  The rates of bacteraemia (17.1%) and 
mortality (24.7%) over the 18-month period of observation equate to those described in the 
literature to date (91).  Through a retrospective methodology an independent association 
between several commonly recorded clinical and laboratory variables and subsequent 
outcome was demonstrated. 
  
Of particular note was the finding that use of synthetic vascular access catheters had an 
especially strong association with risk of bacteraemia and death, an effect that was 
independent of known adverse factors such as age, sex, diabetes, anaemia, and the other 
clinical and laboratory variables that were studied and found to be not to be significantly 
associated with outcome on univariate testing (92).  Whilst tunnelled catheters were found 
to be used in patients who had been on dialysis longer, we found this to be a product of 
patients whose peripheral vasculature had been exhausted of attempts to create an 
arteriovenous fistula or graft.  None of the TCVC group had been exposed to bacteraemia 
in, at least, the period 3 months prior to commencement of the study.  Indeed, the 
demographics and co-morbidities of the tunnelled catheter group and arteriovenous fistula 
group were very similar and thus the conclusion that adverse outcomes are independently 
associated TCVC use when compared to AVFs would appear to be accurate.  When 
considering the NTCVC group, it was evident that this consisted of a higher proportion of 
patients who had commenced RRT for established renal failure within three months of 
study entry and in this setting the co-morbidities that often arise during this period may 
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contribute to the difference in clinical outcomes seen in this particular group compared to 
the others.  No difference in bacteraemia rates was seen between NTCVCs and TCVCs 
although higher mortality rates were seen in the NTCVC group.  It is difficult to draw any 
meaningful conclusions when comparing these groups due to the inherent limitations of the 
methodology employed. 
  
The limitations incurred by the retrospective study design and subsequent extrapolation of 
a ‘snapshot’ of vascular access related to long-term outcome have to be acknowledged.  In 
particular, this method of analysis was not sensitive to potential changes in vascular access 
type over the period of observation.  Many patients using NTCVCs would be reasonably 
expected to migrate onto TCVCs and then AVFs as they progress through the early months 
following commencement on RRT.  One would, however, expect that this potential 
confounding would weaken any association between vascular access and clinical outcome 
since risks presumably lower when patients convert from central venous catheter to 
arteriovenous fistulae.  Nonetheless, in such an observational study it must be remembered 
that the primary drive behind access choice was from the clinician responsible for each 
patient’s care.  Therefore, whilst access type has been associated with adverse events it 
should be assumed that each patient was on the optimal vascular access possible within 
their clinical situation.  Another limitation was the lack of detailed data on comorbidity, 
other than the data we included regarding age, duration on RRT and diabetes.  Whilst these 
variables will account for some of the main comorbidites experienced in this population, 
prospective study incorporating comorbidity-scored data would be of great benefit in 
bringing clarity to this perpetual confounder of vascular access studies. 
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Sample size was also a significant limitation in this study, especially when attempting to 
relate these results to the haemodialysis population within the UK.  As an example, the 
current UK haemodialysis population is approximately 20,000 patients.  To determine a 
hazard ratio with 95% confidence interval of 1.00 to 1.05 and significance level of p<0.05 
in such a large population size would require a sample size of over 8000 patients.  Clearly 
the sample size in this study falls short of such levels and this is reflected in the wide 
confidence intervals demonstrated when considering the hazard ratios in each of the access 
groups with both outcome measures. 
 
The significant role of transcutaneous vascular access devices in increasing risk of 
bacteraemia was further implicated by the finding that 86.7% of bacteraemia was 
secondary to staphylococci.  Within this cohort methicillin-resistant staphylococcus aureus 
(MRSA) accounted for 11.1% of all bacteraemia.  These rates are consistent with those 
published in the current literature where the vast majority of clinically significant infection 
in dialysis patients has been found to be secondary to staphylococcal sub-species derived 
from the surface of the skin (92-96).   
 
Not only is the identity of the causative organisms important, but the spectrum of antibiotic 
resistance is also of importance when determining appropriate first line antibiotic treatment 
(96).  Sub-analysis of the cohort demonstrated that two-thirds of all coagulase negative 
staphylococci isolated on blood cultures were flucloxacillin resistant.  This, in conjunction 
with an 11.1% prevalence of MRSA would suggest that current antibiotic protocols that use 
flucloxacillin as first line therapy may require re-consideration with regards local patterns 
of anti-microbial resistance.  
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The finding of an independent association between CRP at study entry and the 
development of subsequent bacteraemia, an association that remained after adjusting for 
several potential confounders on multivariate testing, was also of interest.  The exact nature 
of the relationship between infection, inflammation and outcome remains to be clarified.  
When considering inflammatory burden and mortality, several studies have demonstrated a 
significant association between increased inflammatory indices and heightened mortality 
rates, possibly through a process of vascular endothelial dysfunction, subsequent 
atherogenesis and a resultant tendency towards cardiovascular events (89, 97-100).  Other 
potential drivers of CRP release in haemodialysis patients include pre-existent, latent 
infection, underlying inflammatory conditions such as connective tissue disease, vasculitis 
and glomerulonephritis, and exposure to inflammatory triggers inherent with the 
haemodialysis process.  These include exposure to invasive procedures to assess the 
vasculature and establish vascular access, repeated exposure of blood to the extracorporeal 
circuit and exposure to low levels of endotoxin through dialysis water.  Such is the 
prevalence of vascular disease in the haemodialysis population, however, the link between 
CRP and underlying vascular endothelial damage is an attractive target to those keen to 
explore how CRP levels translate into increased numbers of cardiovascular and other 
adverse events.  Not all cardiovascular mortality in dialysis patients can be explained by 
traditional risk factors (97) and indeed sepsis and inflammatory burden could be plausible 
pre-disposing factors in many cardiovascular deaths (96).  Proving causation is, however, 
difficult given the wide variety of confounders that would need accounted for. 
 
In summary, this work demonstrates the prevalence of bacteraemia and mortality in a UK 
haemodialysis unit and provides an assessment of potential risk association across a 
spectrum of laboratory and clinical variables that is broader than most similar studies.  
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Many previous studies have been conducted in US populations which are demographically 
different and function through a different system of health care delivery to that of the UK 
population.  What this study therefore adds to the field is the demonstration of similar rates 
of bacteraemia and mortality alongside a similar profile of vascular access risk association 
in a UK population.  Similarly, the strength of association found with haemodialysis 
vascular access type compared to other routinely recorded clinical and laboratory variables 
is clearly demonstrated and comparable to that of other studies in different populations.  Of 
additional relevance and interest is the degree to which vascular access type translates into 
adverse risk compared with other variables, as is the finding of an association between 
baseline CRP and subsequent bacteraemia risk.  Whilst of interest, all these findings must 
be tempered by the inherent limitations of the study design, as noted above.  
 
 
2.5 Conclusion 
 
These data found that use of synthetic vascular access catheters had an especially strong 
association with risk of bacteraemia and death in a typical haemodialysis cohort, an effect 
that was independent of age, sex, diabetes, anaemia, and the other clinical and laboratory 
variables that were studied.  
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Chapter 3 
 
A Prospective Observational Study of Catheter-related 
Bacteraemia and Thrombosis in a Haemodialysis Cohort: 
Univariate and Multivariate Analyses of Risk Association 
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3.1 Background 
 
The work detailed in Chapter 2 demonstrated that central venous catheters compare poorly 
with arteriovenous fistulae when considering bacteraemia and mortality in patients on 
haemodialysis.  A strong, independent association with poor outcome was demonstrated 
after accounting for several known markers of comorbidity despite the limitations inferred 
by a retrospective study design not sensitive to changes in vascular access.  
 
Central venous catheters are, however, a fundamental component in delivering 
haemodialysis.  They may be inserted quickly and without use of surgical support.  Central 
venous catheters are thus especially useful when patients require dialysis urgently and have 
no pre-existent functioning vascular access.  Alternatively, catheters may be used in 
patients in whom sites for establishing arteriovenous fistulae or grafts have been exhausted.  
 
The two most common complications of catheterisation are catheter thrombosis and 
catheter-related bacteraemia (101).  Developing either of these complications incurs 
significant impact on both the functionality and lifespan of the catheter and confers high 
rates of morbidity and mortality notwithstanding considerable cost (82-84, 102).  The work 
in Chapter 2 highlighted some of the different demographics between patients using each 
of the vascular access types, differences that may change further when patients with acute 
renal failure are included.  Whether the complication profile seen in patients using catheters 
is a result of a higher burden of comorbidity seen in selected groups of complex patients is 
yet to be conclusively demonstrated.   
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To test this hypothesis in more detail, the work in this chapter examines rates of 
bacteraemia and thrombosis experienced with all types of vascular access catheter insertion 
conducted in an incident renal replacement therapy (RRT) cohort over a 2-year period of 
prospective observation.  Univariate and multivariate analyses were undertaken to identify 
and quantify independent risk association between clinical variables, laboratory variables 
and measures of comorbidity, with regard to both catheter thrombosis and catheter-related 
bacteraemia. 
 
3.2 Methods 
 
A prospective analysis of all incident vascular access haemodialysis catheter insertions 
over the period starting 05/08/2005 and ending 05/08/2007 was performed.  The date of 
each catheter insertion was recorded along with the type of catheter inserted, the 
anatomical location of catheter insertion and whether the catheter insertion was conducted 
as a catheter-exchange procedure over a guidewire.  Clinical casenotes and our unitary 
electronic patient record were used to obtain details of a number of clinical and laboratory 
variables that were routinely collected as part of our standard care, on the date of catheter 
insertion. 
  
Clinical variables including age, sex and concurrent antibiotic, anticoagulant, 
immunosuppressive and statin therapy were recorded.  Modified Charlson comorbidity 
scores (103-105), a diagnosis of diabetes, cause and duration of renal failure, body mass 
index, systolic blood pressure, diastolic blood pressure and haemodialysis blood flow on 
dialysis immediately following catheter insertion (as determined by dialysis machine blood 
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pump speed) were also obtained.  Laboratory variables including haemoglobin, platelet 
count, neutrophil count, lymphocyte count, CRP, albumin, adjusted calcium, phosphate and 
urea reduction ratio prior to catheter insertion were recorded. 
 
Outcomes 
 
Patients were prospectively followed up to the point of catheter removal or the cessation of 
the study.  During this period two main outcomes were assessed: catheter-related 
bacteraemia (CRB) and catheter failure with removal due to poor haemodialysis blood flow 
as a surrogate of catheter thrombosis.  All patients who died or were discharged to another 
renal unit with a central venous catheter in-situ were assigned a census date corresponding 
to the date of discharge from the renal unit.  Patients who remained on haemodialysis at the 
end of the observation period with a central venous catheter in-situ had a census date of 5th 
August 2007 recorded.   
 
CRB events were sought through analysis of all positive blood culture results from the 
renal patient population as reported by the bacteriology laboratory in conjunction with 
analysis of the patient’s clinical notes and electronic patient record.  CRB was defined as 
the presence of positive blood cultures associated with a raised systemic inflammatory 
response (e.g. pyrexia, raised CRP, raised white-cell count) and the absence of clinical or 
radiological signs of a non-catheter related source of infection.  Sub-clinical bacteraemia 
was not evaluated.  This approach is in keeping with the definition of CRB commonly 
reported in the literature and consistent with that used in routine clinical practice.  Where 
patients were found to have developed CRB, the date of the first positive blood culture 
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result was entered as the event date and the time to event subsequently calculated.  Catheter 
removal due to poor flow was defined as removal of a central venous catheter in response 
to low haemodialysis blood flows that consistently impaired effective haemodialysis 
delivery despite optimal anticoagulation and/or thrombolytic intervention.  This reflected 
routine clinical practice in the participating renal unit.  All decisions regarding catheter 
removal were made by the clinical team responsible for each patient’s care and were made 
independently from the investigator.  The standard unitary protocol for catheter care was 
employed throughout the observation period.  Specifically, this demanded complete sterile 
barrier precautions during catheter insertion and when manipulating the catheter hub.  
Following catheter-hub manipulation, the skin surrounding the insertion site was soaked 
with chlorhexidine solution prior to a sterile dressing being applied.  Between 
haemodialysis sessions all catheters were ‘locked’ with 5000iu/mL heparin of volume 
consistent with the manufacturer’s stated catheter luminal volume. 
  
All haemodialysis patients were on a standard regimen of 3 haemodialysis sessions per 
week, each of minimum 4 hours per session with subsequent increases in session length up 
to 5 hours in order to achieve a target urea-reduction ratio of >65%.   
 
Analysis 
 
Statistical analysis was performed using SPSSTM version 14.0 (SPSS Inc, IL, USA).  
Parametric testing with student’s t-test and non-parametric testing with the Wilcoxon-sign 
rank test were used in the assessment of continuous variables where appropriate.  
Categorical variables were assessed using Pearson Chi-square testing.  Rates of 
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bacteraemia free survival and catheter removal due to poor haemodialysis flow were 
compared by Kaplan-Meier survival analysis with log-rank testing with event rates 
expressed per 1000 catheter days.  When performing the univariate analyses, in view of the 
large number of variables assessed, Bonferroni’s correction was applied with a significance 
level of α < 0.0025. 
 
Multivariate analysis was performed using a Cox proportional hazards model with a 
stepwise conditional method of analysis to test for: 1) an independent association with the 
development of catheter-related bacteraemia and 2) an independent association with 
catheter failure due to poor haemodialysis blood flow.  To avoid over fitting of the 
multivariate models the convention of limiting the number of independent variables entered 
to approximately 10% of the number of outcome events was followed.  In our analysis 
independent variables for entry into the models were selected according to their p-values on 
univariate testing.  On multivariate analysis p-values <0.05 were regarded as significant. 
 
3.3 Results 
 
Over the 2-year period a total of 365 patients underwent 823 central venous catheter 
insertions.  Patients were of median age 66.4yrs (range 19.8, 87.1yrs) with 203/365 
(55.6%) male.  130/365 (35.6%) patients were found to have acute renal failure (ARF) 
defined as a recovery of renal function with cessation of dialysis within 90 days.  60/365 
(16.4%) patients underwent catheter insertion in the context of acute on chronic renal 
failure (A/CRF) whilst 175/365 (47.9%) patients underwent catheter insertion in the 
context of chronic renal failure (CRF).  Clinical and laboratory variables recorded at the 
point of catheter insertion are detailed in table 3.1. 
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Variable 
 
TCVC NTCVC IJug NTCVC Fem NTCVC IJug (G) NTCVC Fem (G) 
Patients 
 
N=301 N=313 N=136 N=60 N=13 
CRB events 
 
N=72 N=25 N=8 N=8 N=2 
Poor Flow events 
 
N=40 N=49 N=27 N=12 N=3 
ARF  
 
20 (6.6%) 109 (34.8%) 47 (34.6%) 35 (58.3%) 3 (23.1%) 
A/CRF  
 
21 (7.0%) 63 (20.1%) 23 (16.9%) 10 (16.7%) 1 (7.7%) 
CRF  
 
260 (86.4%) 141 (45.0%) 66 (48.5%) 15 (25.0%) 9 (69.2%) 
Diabetes   
 
129/301 (42.9%) 116/313 (37.1%) 48/136 (28.9%) 22/60 (36.7%) 5/13 (38.5%) 
Statin  
 
183/301 (60.8%) 150/313 (47.9%) 61/136 (44.6%) 22/60 (36.7%) 7/13 (53.8%) 
Anticoagulation 
 
231/301 (76.7%) 182/313 (58.1%) 83/136 (61.0%) 36/60 (60.0%) 10/13 (76.9%) 
Immunosuppression  
 
32/301 (10.6%) 35/313 (11.2%) 11/136 (8.1%) 7/60 (11.7%) 1/13 (7.7%) 
Antibiotic  
 
294/301 (97.7%) 128/313 (40.9%) 62/136 (45.6%) 32/60 (53.3%) 7/13 (53.8%) 
Modified Charlson  
score 
2 (0,13) ** 2 (0,8) ** 2 (0,9) ** 1 (0,4) ** 1.5 (0,8) ** 
Days on RRT 
 
531 (0,14061) ** 9 (0,13690) ** 4 (0,8653) ** 5 (0,3484) ** 482 (0,2551) ** 
Catheter days 
 
92 (1,692) ** 9 (0,200) ** 5 (0,34) ** 7 (0,97) ** 6 (0,32) ** 
Urea reduction ratio 
 
66.1 (11.5) * 68.4 (9.9) * 67.2 (7.2) * 65.4 (5.4) * 62.6 (10.0) * 
Dialysis blood flow 
(mls/min) 
300 (58, 350) ** 250 (120,375) ** 220 (100,350) ** 200 (150,330) ** 250 (160,400) ** 
SBP 
(mmHg) 
130 (28) * 137 (27) * 130 (28) * 135 (28) * 145 (20) * 
DBP 
(mmHg) 
74 (16) * 73 (16) * 71 (17) * 73 (18) * 84 (12) * 
BMI 
(kg/m2) 
27.2 (7.1) * 27.6 (6.6) * 26.6 (5.5) * 30.0 (6.5) * 28.2 (7.8) * 
Haemoglobin 
(g/dL) 
10.1 (1.9) * 9.6 (1.8) * 9.7 (2.0) * 9.2 (1.5) * 9.7 (1.8) * 
Platelet count 
(x109/L) 
240.5 (42,779) ** 241 (8, 728) ** 243 (21,592) ** 226.5 (41,587) ** 219 (163,419) ** 
Neutrophil count 
(x109/L) 
5.1 (1.0, 26.6) ** 7.1 (0.8,30.6) ** 7.1 (1.5,31.7) ** 8.6 (3.9,18.5) ** 5.9 (3.8,11.1) ** 
Lymphocyte count 
(x109/L) 
1.4 (0.3,3.9) ** 1.1 (0.3,19.7) ** 1 (0.2, 21.1) ** 1.2 (0.4,17.6) ** 1.3 (0.4,2.7) ** 
C-reactive protein 
(mg/L) 
27 (1,297) ** 53 (1,487) ** 64 (2,375) ** 91 (3,282) ** 23 (11,402) ** 
Albumin 
(g/L) 
29 (13,43) ** 26.5 (10,45) ** 27 (12,43) ** 25.5 (11,38) ** 29 (11,39) ** 
Calcium (Adjusted) 
(mmol/L) 
2.42 (0.18) *  2.31 (0.21) * 2.32 (0.24) * 2.26 (0.24) * 2.38 (0.16) * 
Phosphate  
(mmol/L) 
1.64 (0.56) * 1.83 (0.75) * 1.95 (0.73) * 1.67 (0.59) * 1.93 (0.61) * 
Calcium phosphate 
product 
3.98 (1.43) * 4.20 (1.77) * 4.49 (1.68) * 3.76 (1.35) * 4.58 (1.50) * 
Table 3.1 – Clinical and laboratory characteristics from the date of catheter insertion for each central venous catheter sub-
type.  Data values are expressed as value (%), *mean (SD) or **median (min, max). ‘TCVC’ = tunnelled central venous 
catheter. ‘NTCVC’ = non-tunnelled central venous catheter.  ‘IJug’ = internal jugular vein insertion site.  ‘Fem’ = femoral 
vein insertion site.  ‘(G)’ = catheter exchange procedure conducted over a guidewire.  ‘CRB’ = catheter-related 
bacteraemia.  ‘ARF’ = acute renal failure.  ‘A/CRF’ = acute on chronic renal failure.  ‘CRF’ = chronic renal failure.  
‘RRT’ = renal replacement therapy.  ‘Anticoagulation’ = warfarin or antiplatelet use.  ‘SBP’ = systolic blood pressure.  
‘DBP’ = diastolic blood pressure.  ‘BMI’ = body mass index. 
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In total, 301/823 (36.6%) of procedures were insertions of tunnelled central venous 
catheters (TCVC) whilst 522/823 (63.4%) were insertions of non-tunnelled central venous 
catheters (NTCVC).  Of the NTCVC insertions, 373/522 (71.5%) were inserted into the 
internal jugular veins with 149/522 (28.5%) inserted into the femoral veins.  73/522 
(14.0%) of NTCVC insertions were conducted as catheter-exchange procedures over a 
guidewire.  A total of 44,528 catheter days were accumulated over the study period during 
which time there were 115 cases of catheter-related bacteraemia (2.57 per 1000 catheter 
days) and 131 cases of catheter removal due to poor haemodialysis blood flow (2.94 per 
1000 catheter days).    
 
Bacteraemia 
 
115 cases of catheter-related bacteraemia occurred with 122 bacterial isolates identified on 
blood culture.  Staphylococcal sub-species accounted for the majority of cases with 47/122 
(38.5%) isolates of staphylococcus epidermidis, 29/122 (23.8%) isolates of methicillin-
sensitive staphylococcus aureus and 9/122 (7.4%) isolates of methicillin-resistant 
staphylococcus aureus.  Gram negative bacilli accounted for 19/122 (15.6%) isolates, other 
gram positive cocci in 14/122 (11.5%) bacterial isolates and gram positive bacilli in 4/122 
(3.3%) isolates. 
 
Rates of catheter-related bacteraemia were 1.77 per 1000 catheter days in the TCVC group, 
6.3 per 1000 catheter days in the internal jugular vein NTCVC group and 13.5 per 1000 
catheter days in the femoral vein NTCVC group.  Internal Jugular and femoral NTCVCs 
exchanged over a guidewire demonstrated catheter-related bacteraemia rates of 9.7 and 
 92 
21.5 per 1000 catheter days respectively.  Events occurred at median (range) of 54 (28, 
127) days in the TCVC group, 10 (5, 18) days in the internal jugular NTCVC group, 4 (4, 
5) days in the internal jugular guidewire exchange group, 6 (1, 8) days in the femoral 
NTCVC group and 8 days in the femoral guidewire exchange group. 
 
Using the TCVC group as a comparator, all types of NTCVC insertion procedure were 
significantly associated with catheter-related bacteraemia on univariate analysis (p<0.001).  
Other variables significantly associated with the subsequent development of catheter-
related bacteraemia included higher haemodialysis blood flow (265mls/min v 250mls/min, 
p=0.002) and shorter durations of catheter lifespan (50 days v 83 days, p<0.001).  This, 
however, reflects our unitary practice of removing catheters once a diagnosis of catheter-
related bacteraemia has been made unless there is a strong clinical reason to try and salvage 
the catheter.  Trends towards a significant association with catheter-related bacteraemia on 
univariate testing included higher serum adjusted calcium levels (p=0.004), an elevated 
Modified Charlson comorbidity score (p=0.005), being on antibiotic at the time of catheter 
insertion (p=0.008), a diagnosis of diabetes (p=0.011) and a longer duration on renal 
replacement therapy (p=0.013).  All other variables were not significantly associated with 
outcome on univariate analysis. 
  
Multivariate analysis demonstrated hazard ratios (HR) for the development of bacteraemia 
in patients dialysing with internal jugular NTCVCs of 2.93 (p<0.001), femoral NTCVCs of 
5.97 (p<0.001), 6.42 (p<0.001) for internal jugular NTCVCs exchanged over a guidewire 
and 9.84 (p=0.002) for femoral NTCVCs exchanged over a guidewire (figure 3.1).  There 
was also a significant independent association between an elevated modified Charlson 
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comorbidity score with a HR of 1.102 (p=0.034).  All other variables failed to reach 
statistical significance on multivariate testing (table 3.2).  
 
               
Figure 3.1 – Univariate Kaplan-Meier and Multivariate analysis adjusted catheter-related bacteraemia free 
survival plotted for each central venous catheter sub-type. 
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Variable Univariate Analysis 
(p-value) 
Multivariate Analysis 
(Hazard Ratio) 
P-value 
 
NTCVC Femoral (Guidewire) 
 
 
p<0.001 
 
9.84 
 
p=0.002 
NTCVC Internal Jugular (Guidewire) 
 
p<0.001 6.42 p<0.001 
NTCVC Femoral 
 
p<0.001 5.97 p<0.001 
NTCVC Internal Jugular 
 
p<0.001 2.93 p<0.001 
Modified Charlson Comorbidity Score 
 
p=0.005 1.102 p=0.034 
Haemodialysis Blood Flow (mls/min) 
 
p=0.002 - p=NS 
 
Table 3.2 – Variables entered into multivariate analysis and the associated risk of subsequent catheter-related 
bacteraemia. (Guidewire) refers to catheter exchange procedures over a guidewire. 
 
Poor Flow 
 
Rates of catheter removal due to poor flow were 0.98 per 1000 catheter days in the TCVC 
group, 12.3 per 1000 catheter days in the internal jugular vein NTCVC group, and 37.6 per 
1000 catheter days in the femoral vein NTCVC group.  Internal Jugular and femoral 
NTCVCs exchanged over a guidewire demonstrated failure rates of 20.2 and 32.3 per 1000 
catheter days respectively.   
 
Events occurred at median (range) of 57.5 (6, 337) days in the TCVC group, 6 (0, 22) days 
in the internal jugular NTCVC group, 5 (1, 10) days in the internal jugular guidewire 
exchange group, 3 (1, 10) days in the femoral NTCVC group and 1 (0, 2) days in the 
femoral guidewire exchange group. 
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Using the TCVC group as a reference for comparison, all types of NTCVC insertion 
procedure were significantly associated with catheter removal due to poor flow on 
univariate analysis (p<0.001).  Other variables significantly associated with catheter 
removal due to poor haemodialysis blood flow were low haemodialysis blood flow during 
the first dialysis following catheter insertion (237mls/min v 255mls/min, p<0.001) and 
elevated levels of CRP at the time of catheter insertion (61mg/dL v 40mg/dL, p<0.001).  
Patients who required catheter replacement due to poor flow were more likely to have their 
catheter removed earlier (36 days v 58 days, p<0.001). 
 
Trends towards a significant association with poor flow were seen with high platelet counts 
(p=0.067) and lower levels of serum albumin (p=0.087).  All other variables were not 
associated with outcome on univariate analysis. 
 
Multivariate analysis demonstrated hazard ratios (HR) for the removal of catheters due to 
poor haemodialysis blood flow in patients dialysing with internal jugular NTCVCs of 4.65 
(p<0.001), femoral NTCVCs of 9.23 (p<0.001), 5.56 (p<0.001) for internal jugular 
NTCVCs exchanged over a guidewire and 11.73 (p<0.001) for femoral NTCVCs 
exchanged over a guidewire (figure 3.2).   
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Figure 3.2 – Univariate Kaplan-Meier and Multivariate analysis adjusted catheter survival with regard 
episodes of catheter removal due to insufficient haemodialysis blood flow.  Survival plotted for each central 
venous catheter sub-type. 
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There was also a significant independent association between an elevated CRP with a HR 
of 1.004 (p<0.001) per unit increase in CRP and HR=0.992 with haemodialysis blood flow 
immediately following catheterisation (p<0.001) to subsequent removal of catheter due to 
poor flow (table 3.3).  
 
Variable Univariate Analysis 
(p-value) 
Multivariate Analysis 
(Hazard Ratio) 
P-value 
 
NTCVC Femoral (Guidewire) 
 
 
p<0.001 
 
11.73 
 
p<0.001 
NTCVC Femoral 
 
p<0.001 9.23 p<0.001 
NTCVC Internal Jugular (Guidewire) 
 
p<0.001 5.26 p<0.001 
NTCVC Internal Jugular 
 
p<0.001 4.65 p<0.001 
C-reactive Protein (mg/dL) 
 
p=0.002 1.004 p<0.001 
Haemodialysis Blood Flow (mls/min) 
 
p=0.002 0.992 p<0.001 
 
Table 3.3 – Variables entered into multivariate analysis and the associated risk of subsequent catheter 
removal due to poor haemodialysis blood flow.  (Guidewire) refers to catheter exchange procedures over a 
guidewire 
 
 
3.4 Discussion 
 
These data demonstrate the significant differences between tunnelled and non-tunnelled 
central venous haemodialysis catheter insertion procedures in terms of rates of catheter-
related bacteraemia and catheter failure due to poor haemodialysis blood flow.  
Importantly, they bring clarity to the debate of whether such adverse events develop as a 
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function of the characteristics of the catheterisation procedure in terms of tunnelling and 
site of insertion, or the characteristics of the patient receiving the catheter.   
 
From these data, it can be concluded that the characteristics of the catheterisation procedure 
in terms of tunnelling and site of insertion, had the greatest independent effect on risk of 
developing both catheter-related bacteraemia and catheter failure due to poor 
haemodialysis blood flow of all the variables studied.  The clear hierarchy of complication 
rates across different types of catheter insertion procedure were demonstrated as being 
independent of established measures of comorbidity in haemodialysis patients, including 
haemoglobin, bone biochemistry, dialysis dose, markers of inflammatory burden, in the 
setting of acute renal failure, diabetes and modified Charlson comorbidity index score 
(103-105).   
 
Of the variables studied, the only other factor independently associated with catheter-
related bacteraemia was an elevated modified Charlson comorbidity index score at the time 
of catheter insertion.  The only other factor independently associated with catheter failure 
due to poor haemodialysis blood flow was elevated CRP at the time of catheter insertion. 
 
The wide range of clinical and laboratory variables included in the analysis allowed many 
of the potential confounders to be taken into account.  Not all potential confounding 
variables were, however, included.  The number and type of vascular access procedures 
each patient had undergone prior to catheterisation was one variable that was not reliably 
recorded in the EPR and as such was not recorded during data collection.  It can be 
envisaged that patients with poor peripheral access or central venous stenosis may have a 
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higher turnover catheter insertions and thus may gradually depend more heavily on 
NTCVCs, use of insertion sites such as the femoral veins and/or use of guidewire catheter-
exchange procedures.  Such patients could account for the especially high hazard ratios 
found with these procedures.  Whilst the large number of procedures, long period of 
follow-up and inclusion of variables such as the patient’s duration on RRT may partly 
adjust for this issue in study design, this study does not sufficiently address this potentially 
important risk factor.  Closer scrutiny of the complex vascular access patient could be 
achieved by future studies adjusting for variables such as the number of previous vascular 
access procedures, and reporting subsequent rates of conversion onto a functioning AVF or 
graft and subsequent sustainability of that AVF or graft.   
 
The use of a clinical definition of CRB may also be regarded as a limitation.  The most 
formal definition of CRB requires concurrent line and peripheral blood cultures, both 
growing the same organism and with either 5 times as many colony forming units in the 
catheter culture or positive growth at least 2 hours before the peripheral culture.  For these 
criteria to be met requires the availability of dialysis unit nursing staff who are trained in 
peripheral venepuncture, patients with adequate peripheral veins to allow venepuncture to 
take place or in whom preservation of the peripheral veins for future arteriovenous fistula 
creation is not required, and suitable culture storage and analysis facilities on site.  Such 
requirements are a logistical hurdle in studies of simple observational design and thus may 
result in underreporting of clinically significant bacteraemia.  It was for these reasons that a 
clinical definition of CRB was used, albeit at the risk of over-reporting the rate of true 
bacteraemia arising from the catheter. 
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Another important limitation concerns the data on guidewire catheter-exchange procedures.  
The analysis was limited by not adjusting for the period of time spent with a catheter prior 
to it being exchanged via a guidewire.  In this regard, we cannot exclude that the higher 
event rates seen in this group do not simply reflect the effect of increased time with a 
catheter in-situ.  Whilst increased catheter lifespan was associated with a lower rate of 
CRB, this simply reflected the local unitary practice of removing a catheter once CRB had 
been diagnosed and as such does not help clarify this issue.  
 
How does catheter insertion site contribute to bacteraemia risk?  The pattern of these 
results suggest that catheters inserted into a site which has been previously used (i.e. a 
previous catheter tunnel used with a catheter exchange procedure over a guidewire) or in 
skin folds such as the femoral creases may herald locations where pathogens are more 
likely to reside.  How does catheter tunnelling relate to bacteraemia risk?  Our data show 
that catheters entering the vein close to the skin surface without a period of subcutaneous 
tunnelling are more likely to become complicated by infection and/or thrombosis.  The 
shorter physical distance between skin surface and vein, and thus a shorter length of 
exposure to innate immune defences may go some way to explain the better bacteraemia 
rates seen with subcutaneous tunnelling of the catheter.  With regard to the differences 
between catheter types due to poor haemodialysis flow, the tunnelled catheters used in this 
cohort were of greater diameter than their non-tunnelled counterparts and thus may account 
for the better thrombosis rates seen in this group.  Within the NTCVC groups, the main 
difference in flow rates was between catheters inserted into the internal jugular veins and 
the femoral veins.  This may simply reflect the different calibre, tortuosity and extrinsic 
compression of the venous tree in these locations.  Further study of these theories would be 
of benefit. 
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Several organisations have drawn up clinical guidelines to address the issue of optimal 
catheter practice.  The UK Renal Association Guidelines, for instance, suggest that less 
than 20% of patients on long-term haemodialysis should use tunnelled or non-tunnelled 
central venous catheters as their mode of vascular access (48).  NKF-KDOQI cite the lower 
complication rate associated with tunnelled central venous catheters compared with non-
tunnelled catheters in their recommendation that tunnelled catheters are used where the 
period of catheter use is likely to be longer than 3 weeks.  In cases of suspected catheter 
thrombosis or low-grade catheter-related bacteraemia in the absence of subcutaneous 
tunnel infection, NKF-KDOQI suggests that the catheter may be exchanged over a guide-
wire (47).  Our data suggest that future guidelines should give greater emphasis on early 
tunnelled central venous catheterisation where possible, minimising non-tunnelled central 
venous catheter use and limiting guidewire catheter-exchange to cases where re-
catheterisation at a separate site is unachievable. 
 
 
3.5 Conclusion 
 
In conclusion, our data suggest that tunnelled central venous catheter insertions are 
associated with lower complication rates than non-tunnelled central venous catheter 
insertions, independent of whether patients have acute or chronic renal failure, or high 
levels of comorbidity.  When considering central venous catheterisation, these data suggest 
that tunnelled catheter insertion be sought when patients have no pre-existing functioning 
arteriovenous fistula or graft.  In cases where tunnelled central venous catheterisation 
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cannot be performed, non-tunnelled catheterisation of the internal jugular veins should be 
sought.  Insertion of a non-tunnelled femoral venous catheter is associated with the next 
highest rates of bacteraemia and failure due to poor haemodialysis blood flow and therefore 
should be used in selected cases only.  The practice of catheter-exchange over a guidewire 
should be restricted to cases where primary catheterisation at a de novo site cannot be 
achieved.    
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Chapter 4 
A Prospective Randomised Controlled Trial Comparing the 
Effect of Heparinised Catheter Lock Solutions on Systemic 
Anticoagulation in Haemodialysis Patients   
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4.1 Background 
 
Haemodialysis catheter thrombosis is a common problem.  Thrombus formation on the 
catheter surface occurs within a matter of hours (106) and this may extend to involve 
thrombosis of the central veins the longer the catheter remains in-situ (107).   A clear 
association between thrombus formation and subsequent catheter-related bacteraemia has 
been demonstrated (108). 
 
Presently there are no published NKF-DOQI guidelines on evidence-based practice 
regarding the prevention of catheter thrombosis.  The majority of renal units simply rely on 
using heparin as a catheter-locking solution, where filling the internal lumens of the 
catheter with heparin solutions prevents the build up of thrombus.  Evidence to date 
suggests that heparin lock solutions significantly decrease catheter thrombosis, decrease 
bacterial colonisation of the catheter and may decrease catheter-related bacteraemia (109).   
 
The benefits of maintaining catheter patency with heparin-locking are, however, balanced 
against the risk of systemic heparinisation and subsequent bleeding.  Haemodialysis 
patients are already predisposed to bleeding because of uraemia or associated 
coagulopathy.  Several renal units in the UK have observed major haemorrhagic events 
requiring blood transfusion following central venous catheter locking with heparin.  The 
balance of risk versus benefit is, however, uncertain and thus heparin-locking practice is 
found to vary widely among renal units (110, 111).   Several studies have been performed 
to demonstrate the risks/benefits of different heparin locking practices however the 
majority of studies have been observational, non-blinded and retrospective in design (56).   
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In this study an investigator-blinded randomised controlled trial of heparin catheter lock 
solutions in non-tunnelled (temporary) central venous catheters was undertaken.  The 
working hypothesis was that higher concentrations of heparin solution would lead to 
significantly greater disturbance of systemic coagulation as measured by the change in 
activated partial thromboplastin time (APTT) at 10 minutes post catheter locking.  The 
study was designed with a primary endpoint of change in APTT at 10 minutes following 
catheter locking with heparin 1,000U/ml and 5,000U/ml.  Secondary study endpoints 
included subsequent catheter lifespan, catheter thrombosis rates and rates of catheter-
related bacteraemia between groups.   
 
4.2 Methods 
 
Full approval was granted for this study from our local research and ethics committee.  34 
consecutive patients requiring insertion of a temporary non-tunnelled dual lumen central 
venous haemodialysis catheter were approached of which 28 patients gave informed 
consent and were recruited into the study. Patients were either starting haemodialysis for 
the first time or were established on renal replacement therapy (RRT) and required 
temporary central venous catheterisation because of vascular access failure.  Patients with 
exposure to heparin in the previous 24 hours were excluded from the study and thus were 
not asked to take part.  On entry to the study, patients underwent third party randomisation 
to either heparin 5000iu/mL or heparin 1000iu/mL as catheter lock solution.  All members 
of the investigating team were blind to the allocation of heparin solution.   
 
Standard unitary protocol for catheter care was employed throughout the observation 
period.  Specifically, this demanded complete sterile barrier precautions during catheter 
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insertion and when manipulating the catheter hub.  Following catheter-hub manipulation, 
the skin surrounding the insertion site was soaked with chlorhexidine solution prior to a 
sterile dressing being applied.  
 
Once the catheter was inserted and sutured in-situ, a 5ml blood sample was taken from the 
catheter for measurement of the APTT.  Each lumen of the catheter was then flushed with 
20ml 0.9% Saline using a positive pressure technique to remove any blood from the lumen.  
Both lumens of the catheter were then slowly filled with a volume of the allocated heparin 
solution equal to the volume of each lumen as stated by the manufacturer.  A stop-clock 
was then started and at 10 minutes following catheter locking a peripheral venous blood 
sample taken for repeat measurement of the APTT.  The same concentration of heparin was 
used to lock the catheter after each successive dialysis session until the catheter was 
removed.   
 
At the time of catheter insertion baseline clinical, demographic and laboratory variables for 
each patient were retrieved from the unitary electronic patient records and clinical case 
records.  Where multiple measurements of a single variable had been recorded, the most 
recent value was used.  Clinical variables collected were age, gender, primary renal 
diagnosis, the presence or absence of diabetes, body mass index (BMI), systolic and 
diastolic blood pressure, anticoagulant use, statin use, immunosuppressant medication, 
length of time on renal replacement therapy, and vascular access flow rate on 
haemodialysis.  Laboratory variables collected at study entry were haemoglobin, platelet 
count, neutrophil count, lymphocyte count, serum C-reactive protein (CRP), serum 
albumin, serum adjusted calcium and phosphate product. 
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Outcomes 
 
Each patient was followed up for the period over which the catheter remained in-situ.  The 
primary outcome was the difference in APTT at 10 minutes following catheter locking 
between heparin 5000iu/mL and heparin 1000iu/mL.   Secondary outcomes included cases 
of catheter removal due to insufficient haemodialysis blood flow to maintain haemodialysis 
and cases of catheter-related bacteraemia (CRB).   
 
CRB events were determined by analysis of all positive blood culture results from the renal 
unit reported by the bacteriology laboratory during the period of study in conjunction with 
analysis of the patient’s clinical notes and electronic patient record.  Bacteraemia was 
deemed significant if positive blood cultures were associated with a raised systemic 
inflammatory response (e.g. pyrexia, raised CRP, raised white-cell count).  This approach 
is in keeping with the consensus definition of clinically significant bacteraemia and 
consistent with that used in routine clinical practice.   
 
Catheter removal due to poor flow was defined as removal of a central venous catheter in 
response to low haemodialysis blood flows that consistently impaired effective 
haemodialysis delivery despite optimal anticoagulation and/or thrombolytic intervention.  
This reflected routine clinical practice in the participating renal unit.  All decisions 
regarding catheter removal were made by the clinical team responsible for each patient’s 
care and were made independently from the investigator. 
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Analysis & Study Protocol 
  
Statistical analysis was performed by SPSSTM version 14.0 (SPSS Inc, IL, USA).  
Normality testing was performed on all of the recorded continuous variables.  Student’s t-
testing and Mann-Whitney U testing were then used to assess differences between groups 
where appropriate.  The primary outcome sought was the difference in the APTT ratio 
between groups after administration of the heparin lock solutions following catheter 
insertion as determined by student’s t-testing.  Bacteraemia-free survival and catheter 
failure secondary to poor haemodialysis blood flow survival rates for each group was 
assessed by Kaplan-Meier survival analysis and Log Rank testing with p<0.05 being 
regarded as statistically significant.  A sample size of 12 participants in each group was 
determined as providing 80% power to detect a 25% difference in mean APTT from 28s to 
35s with standard deviation of 6s and significance level of p<0.05.  Randomisation was 
undertaken independently by the clinical trials pharmacy unit at Glasgow Royal Infirmary.  
Block randomisation was used with the aim to recruit greater numbers than those 
determined by the power calculation in an effort to pursue suitable numbers of secondary 
outcome events.   
 
All aspects of the clinical trial were conducted in accordance with national guidance from 
the UK Medical Research Council and the Department of Health.  Trial sponsorship was 
undertaken by NHS Greater Glasgow as the employer of the chief investigator, Dr Robert 
Mactier.  The Research and Development department of Glasgow Royal Infirmary were 
consulted where permission was sought and granted for the study to be conducted within 
NHS Greater Glasgow.  The study protocol was further developed by the Glasgow Royal 
Infirmary clinical trials pharmacy unit.  During this time consultation was made with the 
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Medicines and Healthcare products Regulatory Agency where it was determined that 
studies of catheter lock solutions are regarded as studies of medical devices and thus 
MHRA approval was not required.  Following peer review the study protocol was 
submitted to the local research ethics committee where permission for the study to proceed 
was granted.  The study protocol is detailed in figure 4.1 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 – Flow chart detailing the study design from recruitment to collation of results. 
Potential subjects identified by renal unit ward 
medical staff 
Subjects approached, given patient information sheet and 
left alone to contemplate participation 
Prior to catheter insertion, consent sought by investigator and 
pharmacy contacted where randomisation and assignation to a 
heparin group conducted.  Stock delivered to ward. 
1 x 5mL blood sample taken to measure APTT 
prior to catheter insertion 
Patient undergoes dialysis with heparin continued catheter 
locking with allocated heparin between sessions.  
 
Monitoring of safety, adverse events and clinical progress of 
participants conducted in real-time. 
Secondary outcome measures assessed over 
lifespan of catheter 
Catheter ‘locked’ with allocated heparin and APTT 
re-checked peripherally 10 minutes later. 
Catheter removed, results collated and prepared for 
statistical analysis 
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4.3 Results 
 
28 patients who met the inclusion criteria provided informed consent to participate in the 
study.  16/28 (57.1%) patients were male.  Median age of the cohort was 68.0 years (range 
40.2 – 84.8).   
 
15/28 (53.6%) presented with acute renal failure, defined as a duration of renal replacement 
therapy (RRT) of less than 90 days with no known pre-existing renal disease.  7/28 (25.0%) 
presented with acute on chronic renal failure, defined as a duration of RRT less than 90 
days with known pre-existent renal disease.  6/28 (21.4%) patients had established renal 
failure with duration on RRT of median 737.5 days (range 329 - 7505 days).   
 
13 patients were randomised to the heparin 1000iu/mL group whilst 15 patients were 
randomised to the heparin 5000iu/mL group.  Details of all clinical and laboratory variables 
recorded on the date of study entry for each group are listed in table 4.1 below.  No 
statistically significant differences were demonstrated between the heparin 1000iu/mL 
group and the heparin 5000iu/mL group on univariate testing although trends towards a 
positive association were found when considering the proportion of patients known to have 
a diagnosis of diabetes with a greater proportion of such patients being demonstrated in the  
heparin 5000iu/mL group. 
  
 
 
 111 
Variable 
 
Heparin 1000iu/mL Heparin 5000iu/mL P-value 
 
No. of Patients 
 
 
N=13 
 
N=15 
 
- 
Male:Female 
 
7:6 9:6 p=0.99 
ARF  
(N) 
7/13 8/15 p=0.99 
A/CRF  
(N) 
5/13 2/15 p=0.20 
CRF  
(N) 
1/13 5/15 p=0.17 
Diabetes   
(N) 
4/13 11/15 p=0.06 
Statin  
(N) 
6/13 8/15 p=0.99 
Aspirin 
(N) 
5/13 7/15 p=0.72 
Clopidogrel 
(N) 
0/13 2/15 p=0.48 
Immunosuppression 
(N) 
2/13 1/15 p=0.58 
Duration on RRT 
(days) 
0 (0, 460) ** 9 (0, 7505) ** p=0.19 
SBP 
(mmHg) 
130 (24) * 133 (26) * p=0.78 
DBP 
(mmHg) 
72 (22) * 74 (13) * p=0.86 
BMI 
(kg/m2) 
34.6 (6.7) * 28.3 (5.2) * p=0.07 
Haemoglobin 
(g/dL) 
9.2 (1.2) * 9.2 (1.6) * p=0.99 
Platelet count 
(x109/L) 
214 (37, 366) ** 272 (73, 623) ** p=0.30 
Neutrophil count 
(x109/L) 
8.5 (4.4) * 8.4 (4.9) * p=0.95 
Lymphocyte count 
(x109/L) 
1.2 (0.5) * 1.4 (0.7) * p=0.35 
C-reactive protein 
(mg/L) 
52 (3, 220) ** 29 (3, 74) ** p=0.17 
Albumin 
(g/L) 
23 (14, 37) ** 29 (15, 42) ** p=0.27 
Calcium (Adjusted) 
(mmol/L) 
2.36 (0.17) * 2.29 (0.18) * p=0.29 
Phosphate  
(mmol/L) 
1.48 (0.55) * 1.84 (0.62) * p=0.11 
 
Table 4.1 – Clinical and laboratory characteristics of heparin 1000iu/mL and heparin 5000iu/mL groups.  
Data values are expressed as value (%), *mean (SD) or **median (min, max).  ‘ARF’ = acute renal failure.  
‘A/CRF’ = acute on chronic renal failure.  ‘CRF’ = chronic renal failure.  ‘RRT’ = renal replacement therapy.  
‘SBP’ = systolic blood pressure.  ‘DBP’ = diastolic blood pressure.  ‘BMI’ = body mass index.  Values 
recorded as mean (SD) or median (minimum, maximum). 
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The measured baseline APTT immediately prior to catheter heparin-locking did not 
significantly differ between groups with mean (SD) APTT of 28 (2.9) in the heparin 
1000iu/mL group compared to mean (SD) APTT of 27.7 (5.9) in the heparin 5000iu/mL 
group (p=0.88).  The measured APTT at 10 minutes post catheter heparin-locking was 
significantly different between groups with mean APTT of 40.8 in the heparin 1000iu/mL 
group compared with mean APTT of 129.7 in the heparin 5000iu/mL group (p<0.001).  
When expressed as the percentage rise in APTT from baseline to 10 minutes, there was a 
statistically significant difference between groups of median +22.2% (range 0, 210) rise in 
APTT in the heparin 1000iu/mL group compared with +373.7% (range 133, 800) in the 
heparin 5000iu/mL group (p<0.001).  This is demonstrated in table 4.2. 
 
Average catheter lifespan was 7 days in both heparin 1000iu/mL and heparin 5000iu/mL 
groups (p=0.90).  Catheter failure secondary to insufficient haemodialysis blood flow 
occurred in 3/13 cases in the heparin 1000iu/mL group compared with 4/15 cases in the 
heparin 5000iu/mL group (p=0.88).  The rates of catheter-related bacteraemia were similar 
with 2/13 cases in the heparin 1000iu.ml group compared with 2/15 cases in the heparin 
5000iu/mL group (p=0.83).  This is demonstrated in table 4.2.  
 
Recorded mean haemodialysis blood flow for the lifespan of the catheter was similar in 
both groups at 235mls/min in the heparin 1000iu/mL group compared with 231mls/min in 
the heparin 5000iu/mL group (p=0.77).  Median c-reactive protein measured over the 
lifespan of the catheter was similar in both groups at 51mg/L in the heparin 1000iu/mL 
group versus 47mg/L in the heparin 5000iu/mL group (p=0.39).  This is demonstrated in 
table 4.2. 
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Variable 
 
Heparin 1000iu/mL 
 
Heparin 5000iu/mL 
 
P-value 
 
APTT at 0mins 
(seconds) 
 
 
28 (2.9) * 
 
27.7 (5.9) * 
 
p=0.88 
APTT at 10mins 
(seconds) 
 
40.8 (18.6) * 129.7 (47) * p<0.001 
Change in APTT at 10mins 
(% ) 
 
+22.1% (0, 210) ** +373.8% (133, 800) ** p<0.001 
Catheter Lifespan 
(days) 
 
7 7 p=0.90 
Catheter-Related Bacteraemia 
 
N=2/13 N=2/15 p=0.88 
Catheter Thrombosis 
 
N=3/13 N=4/15 p=0.83 
Haemodialysis blood flow 
(mls/min) 
 
235 (26) * 231 (30) * p=0.77 
Mean c-reactive protein 
(mg/L) 
51 (6, 313) ** 47 (11, 91) ** p=0.39 
 
Table 4.2 – Comparison of outcomes between heparin 1000iu/mL and heparin 5000iu/mL groups.  ‘APTT’ = 
activated partial thromboplastin time. Values recorded as *mean (SD) or **median (minimum, maximum). 
 
 
4.4 Discussion 
 
This study has demonstrated that use of heparin as a catheter-locking agent in 
haemodialysis patients is associated with a significant degree of systemic heparinisation as 
demonstrated by prolongation of the activated partial thromboplastin time (APTT).  
Systemic heparinisation occurred in both groups despite only instilling a volume of heparin 
equal to the internal catheter luminal volume stated by the catheter manufacturer.  It is 
therefore likely that despite this method of heparin instillation, overspill of the injected 
heparin occurs.  As a result, patients in both groups were exposed to an increased risk of 
haemorrhage in the hours immediately following catheter insertion and after catheter-
locking following each haemodialysis treatment.  There were, however, no instances of 
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haemorrhage in either group over the course of the study, albeit within a relatively small 
cohort with a relatively short duration of follow-up. 
 
We found that the use of heparin 1000iu/mL conferred a significantly lower risk of 
systemic heparinisation than heparin 5000iu/mL.  These findings were demonstrated in the 
setting of a prospective, investigator-blinded, randomised study and confirm similar 
findings reported in non-randomised non-blinded observational studies (110, 111).  The 
lack of any significant difference between groups with regard to the secondary outcome 
measures of catheter-related bacteraemia and catheter failure due to poor haemodialysis 
blood flow is of limited value due to the small sample size, the lack of power to examine 
these outcomes, the heterogeneity of non-tunnelled catheter insertion sites and the 
relatively short duration of follow-up.  These limitations must also be considered when 
considering the primary outcome measure.  The mixture of acute and chronic renal failure 
patients, the presence of diabetes, concurrent comorbid conditions and anticoagulant and 
antiplatelet use could be accounted for more comprehensibly by greater numbers of study 
participants. 
  
These findings support those suggested by previous retrospective observational studies.  
The routine use of a 5,000U/ml heparin lock solution equal to the estimated catheter lumen 
volumes in 13 haemodialysis patients in an ICU setting in Scotland was associated with an 
APTT ratio >7 in 53% of the 32 paired samples available for analysis from these patients 
(111).  Several studies have observed good catheter patency rates when 1000iu/mL heparin 
lock solutions were used in the control group of prospective studies designed to examine 
the effect of antibiotic lock techniques on the incidence of catheter-related bacteraemia 
(112, 113).  Whether use of 1,000iu/mL heparin is a suitable alternative across a large 
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population of haemodialysis patients is uncertain as there is some evidence uncovered in 
larger populations that catheter patency may be compromised.  In a Canadian longitudinal 
study of 6940 haemodialysis sessions the use of a 1000iu/mL heparin lock solution in 
central venous haemodialysis catheters was not associated with higher rates of catheter 
malfunction compared with the use of 10,000iu/mL heparin solution but the 1000iu/mL 
group did require greater anti-thrombotic intervention with thrombolytic drugs (56).   
 
 
4.5 Conclusion 
 
The optimal method of heparin-locking dialysis catheters remains uncertain.  Balancing the 
risks of catheter-thrombosis and subsequent catheter failure due to under-anticoagulation 
against the risk of bleeding and haemorrhage associated with increasingly concentrated 
heparin catheter lock solutions is of primary importance.  By demonstrating the 
significantly higher risk of systemic heparinisation with heparin 5000iu/mL compared to 
heparin 1000iu/mL, this randomised, investigator-blinded controlled trial helps quantify the 
contribution heparin concentration makes to one side of this debate, that of increased risk 
of bleeding. This work also demonstrates the need for a large randomised controlled trial to 
determine the optimal concentration of heparin solution with regard to risk of catheter-
thrombosis, catheter-related bacteraemia and significant haemorrhage. 
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Chapter 5 
An In-Vitro Analysis of Vancomycin in Combination with 
Heparin as an Antimicrobial Haemodialysis Catheter Lock 
Solution 
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5.1 Background 
 
The work detailed in chapters 2 and 3 demonstrate staphylococcal sub-species to be the 
most prevalent of pathogens in haemodialysis patients with bacteraemia.  The high 
prevalence of Staphylococcus epidermidis and Staphylococcus aureus bacteraemia in 
patients with catheter-related infection has been demonstrated in similar studies of patients 
with catheter related infection (114).   These bacteria are endemic on the skin surface and 
constitute normal skin flora.  If, however, a patient has an indwelling medical device such 
as a catheter this may become colonised by these flora.  Initially a catheter may be 
colonised by only one single organism, for example, S. epidermidis, however, the longer a 
catheter remains in place, more diverse microbial communities may form and involve other 
organisms such as klebsiella pneumoniae and proteus mirabilis (115).  Many of these 
organisms have the ability to form biofilm which has been found to be the underlying 
substrate to catheter infection, bacteraemia and resultant systemic infection (116, 117). 
 
Biofilms were first identified in 1943 by Zobell however it was not until the 1970s that 
their role in causing infection was realised (118).  Many definitions of biofilms have 
evolved over the years as understanding and knowledge of biofilm structures has 
developed.  A biofilm is said to be a complex community of sessile cells that attach to a 
substratum and to each other.  They are embedded within a matrix of self-producing 
polymeric substances and they have altered phenotypes due to differences in growth rates 
and gene transcription in comparison to their planktonic counterparts (115).  Some bacteria, 
such as certain types of staphylococci produce extracellular slime which may interfere with 
the phagocytic activity of macrophages and thus make bacteria within the biofilm more 
resistant to innate immune responses such as killing by active oxygen species in 
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leukocytes.  These mechanisms allow biofilms to develop resistance to biocides, 
phagocytes and antimicrobials with the degree of resistance correlating with the maturity of 
the biofilm (119-121).  It is well recognised that successful treatment of CRB requires the 
successful eradication of biofilm (119). 
 
The antibiotic lock technique has been developed as a method of preventing and 
eradicating biofilm on the endoluminal surface of haemodialysis catheters.  This involves 
instillation of a concentrated antibiotic-anticoagulant into the catheter lumen that is left to 
dwell between haemodialysis sessions.  This method delivers a small absolute amount of 
antibiotic to the patient but achieves a high local concentration in the catheter lumen that is 
100 to 5,000 times higher than the minimum inhibitory concentration (MIC) for the 
infecting bacterium.  Use of antibiotic lock solutions as a primary prevention strategy has 
raised concerns regarding the risks of developing antimicrobial resistance with leakage of 
the antibiotic-lock solution into the circulation.  Using antibiotic-lock solution as a 
secondary adjunctive measure to systemic antibiotics in treating catheter-related 
bacteraemia (CRB) is, however, less contentious.   
 
The antibiotic-lock technique requires the safe and efficacious combination of an antibiotic 
and an anticoagulant.  Heparin is a well-established anticoagulant used for locking 
haemodialysis catheters.  It is stable in combination with antimicrobials (122) although 
does not demonstrate anti-microbial activity itself (123).  Several studies have used heparin 
in conjunction with various antibiotics and demonstrated stability in combination and 
positive in-vitro and in-vivo benefits in preventing and treating infection over the short 
term (122, 124, 125).  Whilst this area continues to evolve, our understanding of how 
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combinations of anticoagulant and antimicrobial interact is limited.  In this study the effect 
of heparin on the bactericidal activity of the glycopeptide vancomycin on free floating 
planktonic and biofilm-associated staphylococci was examined.  The work was conducted 
with a null hypothesis of heparin having no significant effect on the ability of staphylococci 
to interact with vancomycin.  
 
 
5.2 Methods 
 
Bacterial Strains 
 
Six clinical isolates of S. aureus, obtained from the Scottish MRSA Reference Laboratory 
(SMRSARL) (Stobhill Hospital, Glasgow, UK), were selected on the basis of their 
recognised capacity to form biofilm.  These isolates had been genotyped at the SMRSARL 
using either pulsed-field gel electrophoresis (PFGE) for methicillin resistance S. Aureus 
(MRSA) isolates using the Harmony method or a PCR-ribotyping technique for methicillin 
sensitive (MSSA) strains.  These genotyped isolates consisted of three MRSA isolates; 
MRSA1 (epidemic MRSA-15), MRSA100 (epidemic MRSA-16), MRSA546 (epidemic 
MRSA-15) and three MSSA isolates; MSSA51, MSSA55 MSSA62. S. epidermidis RP62A 
(ATCC 35984), a known biofilm-forming strain, was used as a positive control in biofilm 
assay and S. aureus National Collection of Type Cultures (NCTC) 6571 (Oxford strain) 
was used as a control for antibiotic susceptibility testing assays.  
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All isolates were stored in Microbank® storage vials (Pro-Lan Diagnostics) at -70°C and 
sub-cultured on brain heart infusion (BHI) agar (Oxoid, Basingstoke, UK) prior to each 
assay. Stock solutions were prepared by overnight incubation in BHI broth before 1ml of 
each bacterial suspension solution was centrifuged to create a pellet.  100µL of each pellet 
was diluted in BHI to a solution with an optical density (OD) of 0.03 for planktonic work. 
 
Biofilm Formation 
 
Biofilm formation was performed by the method described by Shanks et al (126).  Cultures 
of staphylococcal sub-species NCTC 1, 100, 546, 51, 55, 62 and RP62 were incubated 
overnight in BHI broth before 5ml of each bacterial suspension solution was centrifuged to 
create a bacterial pellet of each organism.  100µL of each pellet was diluted in BHI to a 
solution with OD of 0.07 at 590nm.  150µL of each bacterial suspension was then added to 
a row of 12 individual wells of a 96-well microtitre dish.  The final row of the 96-well 
microtitre dish was filled with 150µL of uninoculated BHI broth as a control.  A 
corresponding 96-peg lid plate was then placed over the 96-well dish with each peg 
‘dipped’ within its corresponding solution-filled well.  The peg lid and well dish was then 
sealed and incubated at 37.0oC on a ‘rocking’ incubator tray for 48 hours.  On removal 
from the rocking incubator the 96-peg lid was then washed in phosphate buffered saline to 
remove adherent cells with only biofilm remaining adherent to each peg. 
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Preparation of Antibiotic and Anticoagulant Solutions 
 
A range of stock vancomycin solutions: 10,000mg/L, 1000mg/L, 100mg/L and 10mg/L, 
were prepared using sterile distilled water as a diluent, in accordance with the British 
Society for Antimicrobial Chemotherapy guidelines (127).    
 
Using these stock solutions, each column of a 96-well microtitre dish was instilled with 
75µL vancomycin solution of increasing concentration. Each well in column 1 contained 
75µL 0.015mg/L vancomycin solution with the concentration of vancomycin doubled in 
each successive column up to a concentration of 16mg/L in column 11.  Each well in the 
column 12 of the microtitre plate was filled with 75µL sterile water to act as control.  These 
vancomycin-filled 96-well microtitre plates were used as the basis on which the 
experiments on planktonic bacteria were conducted. 
 
Stock heparin solutions: 1000iu/mL and 2000iu/mL, were prepared using heparin sodium 
1000iu/mL solution. 
 
Three separate incubation media were created.  Media A contained 80ml Mueller-Hinton 
(MH) broth and 20ml heparin 5000iu/mL solution, creating a MH-heparin 1000iu/mL 
broth.  Media B contained 60ml MH broth and 40ml heparin 5000iu/mL solution, creating 
a MH-heparin 2000iu/mL broth.  Media C consisted of 100ml MH broth without heparin. 
When conducting the analysis of combined vancomycin-heparin solutions, 75µL of 
heparin-based media was added to each well of the vancomycin-primed 96-well microtitre 
plates described above. 
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Planktonic MIC evaluation 
 
To demonstrate the MIC of vancomycin against planktonic microbes, stock solutions of 
MRSA 1, 100, 546 and MSSA 51, 55, 62 and Oxford 6571 were prepared in the method 
described above to an OD of 0.3 at 590nm in Mueller-Hinton (MH) broth.  These solutions 
were diluted by a factor of 1 in 10 and 75µL of this solution was added to each well of the 
pre-prepared vancomycin plates, thus equating with approximately 5x105 Colony Forming 
Units (CFU)/ml, the recommended inoculum for MIC assays (127).  The experiment was 
repeated on a separate, duplicate 96-well vancomycin-inoculated dish.  The dishes were 
then sealed and incubated overnight.  After a 16-hour incubation period the OD of the well 
plates was read to assess the degree of bacterial growth. 
 
To demonstrate the MIC of vancomycin-heparin against planktonic microbes, stock 
solutions of MRSA 1, 100, 546 and MSSA 51, 55, 62 and Oxford 6571 were prepared to an 
OD of 0.03 at 590nm using the MH-heparin 1000iu/mL (Media A) stock broth solution.  
75µL of this solution was added to each well of the pre-prepared vancomycin plates.  The 
dishes were then sealed and incubated overnight.  After a 16-hour incubation period the 
OD of the well plates was read to assess the degree of bacterial growth.  The experiment 
was then repeated using MH-heparin 2000iu/mL (Media B) stock broth solution.  Both 
experiments were carried out in duplicate. 
 
To demonstrate the effect of heparin on planktonic microbial growth, stock solutions of 
MRSA 1, 100, 546 and MSSA 51, 55, 62 and Oxford 6571 were then prepared to an optical 
density of 0.3 at 590nm in Mueller-Hinton (MH) broth.  These solutions were diluted by a 
factor of 1 in 10 with 75µL of each solution then added to columns of eight duplicate wells 
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of a 96-well microtitre dish prepared with 75µL control MH broth alone, 75µL heparin 
1000iu/mL solution (Media A) or 75µL heparin 2000iu/mL solution (Media B).  A 
duplicate set of 96-well microtitre dishes were prepared, with both sets incubated 
overnight.  After a 16-hour incubation period the optical density of the well plates was read 
to assess the degree of bacterial growth. 
 
Biofilm MIC evaluation 
 
Biofilm growth was conducted by the method described above using bacterial suspension 
of staphylococcal sub-species NCTC 1, 100, 546, 51, 55, 62, Oxford 6571 and the control 
strain RP62. 
 
Each column of a separate 96-well microtitre dish was instilled with 75µL vancomycin 
solution in the method described above with each well in column 1 containing 75µL 
0.25mg/L vancomycin solution and the concentration of vancomycin doubling in each 
successive column up to a concentration of 256mg/L in column 11.  Each well in the 
column 12 of the microtitre plate was filled with 75µL sterile water to act as control.  Each 
well was then inoculated with 75µL Media A containing the MH-heparin 1000iu/mL broth.  
The biofilm-containing peg plate was then dipped into the well plates and incubated on a 
rocking incubator tray for 16 hours. 
 
To assess biofilm production, the prepared biofilm-impregnated 96-peg lids were dipped 
into 0.5% crystal violet solution with contact time of 2 minutes before gently washing with 
sterile water (figure 5.1). The 96-peg lid was then dipped into a 96-well plate, each well 
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containing 150µL 70% ethanol solution so as to leach the absorbed crystal violet from the 
cells. The absorbance of the resultant solution was measured at 570 nm using a microtitre 
plate reader (BMG LUMIstar* plate reader, BMG, Germany).  
 
  
Figure 5.1 – An example of a biofilm-impregnated 96-peg lid having been dipped into 0.5% crystal violet 
solution for contact time of 2 minutes. 
 
The experiment was then repeated using MH-heparin 2000iu/mL (Media B) stock broth 
solution and the heparin free MH broth solution (Media C).  All experiments were carried 
out in duplicate.  
 
Statistical Analysis 
 
Statistical analysis was performed by SPSSTM version 14.0 (SPSS Inc, IL, USA). 
Parametric testing with student’s t-test and non-parametric testing with the Wilcoxon-sign 
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rank test were used in the assessment of continuous variables where appropriate.  All 
reported p-values were based on two-sided testing with a significance level set at α < 0.05. 
 
 
5.3 Results 
 
In all the planktonic studies the MIC for the reference strain S. aureus NCTC 6571 Oxford 
strain was demonstrated at 1mg/L and was thus within one well dilution of the accepted 
MIC as determined by Andrews et al (127) and hence a valid control.  In all the biofilm 
studies, the reference strain of S. epidermidis NCTC RP62 grew biofilm as demonstrated 
by a significantly greater OD than the MH control wells (see below).  
 
Demonstrating the MIC of Vancomycin against planktonic microbes (pMIC) 
 
With regard to the MRSA sub-species, the pMIC of vancomycin was found to be 2mg/L 
for NCTC 1 and 1mg/L for NCTC 100 and 546.  With regard to the MSSA sub-species the 
pMIC of vancomycin was found to be 1mg/L for NCTC 51 and 55, and 2mg for NCTC 62. 
 
Demonstrating the pMIC of Vancomycin-Heparin  
 
When incubated in MH-heparin 500iu/mL solution, the pMIC of vancomycin was 
demonstrated at 0.5mg/L for MRSA NCTC 1, 100 and 546.  With regard to the MSSA sub-
species the pMIC of vancomycin was found to be 1mg/L for NCTC 51, 55 and 62. 
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Demonstrating the effect of Heparin on planktonic microbial growth 
 
There was no significant change in OD following the addition of heparin to culture media 
for isolates of MSSA NCTC 55, 51 and MRSA NCTC 100.   
 
There was a significant increase in OD of both heparin-containing culture media with S. 
aureus NCTC 6571 compared to the MH control (MH control OD=0.628 v MH-heparin 
500iu/mL OD=0.695, p=0.01; MH-heparin 1000iu/mL OD=0.718 p=0.001).   
 
MRSA NCTC 1 demonstrated a significant decrease in OD when incubated with MH-
heparin 1000iu/mL culture media compared to MH-heparin 500iu/mL and MH control 
(MH-heparin 1000iu/mL OD=0.348 v MH-heparin 500iu/mL OD=0.419, p<0.001; MH 
control OD=0.408, p<0.001).  
 
MRSA NCTC 546 demonstrated a significant decrease in OD when incubated with MH-
heparin 1000iu/mL culture media compared to MH-heparin 500iu/mL and MH control 
(MH-heparin 1000iu/mL OD=0.164 v MH-heparin 500iu/mL OD=0.244, p<0.001; MH 
control OD=0.235, p<0.001).  
 
MSSA NCTC 62 demonstrated a significant decrease in OD when incubated with MH-
heparin 1000iu/mL culture media compared to MH-heparin 500iu/mL and MH control 
(MH-heparin 1000iu/mL OD=0.467 v MH-heparin 500iu/mL OD=0.646, p<0.001; MH 
control OD=0.597, p<0.001).  
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The comparison of OD between culture media for each bacterial isolate is demonstrated 
and summarised below in table 5.1.   
 
 
Table 5.1 – Mean optical density at 590nm of suspensions incubated in MH, MH-heparin 500iu/mL and MH-
heparin 1000iu/mL broth.  P-values quoted refer to statistical comparison with MH control. *Significant 
difference in comparison with MH-heparin 500iu/mL group with p<0.001. 
 
Assessment of Biofilm Production 
 
Mean OD for the BHI broth control was 0.210.  When compared to the BHI control the 
mean OD for each of the MRSA isolates was 0.253 for NCTC 1 (p=0.09), 0.318 for NCTC 
100 (p<0.001) and 0.346 for NCTC 546 (p<0.001). For each of the MSSA isolates, the 
mean OD was 0.668 for NCTC 51 (p<0.001), 0.389 for NCTC 55 (p<0.001) and 0.920 for 
NCTC 62 (p<0.001).  The mean OD for S. epidermidis RP62 was 0.288 (p=0.01) when 
compared with the BHI control.  Full results are reported in table 5.2. 
 
 
 
Media 
 
MRSA 
1 
MRSA 
100 
MRSA 
546 
MSSA 
51 
MSSA 
55 
MSSA 
62 
Oxford 
6571 
 
MH 
 
 
0.408 
 
 
0.504 
 
 
0.235 
 
 
0.546 
 
 
0.684 
 
 
0.597 
 
 
0.628 
 
 
 
MH + Heparin 500iu/mL 
 
 
0.419 
 
 
0.495 
 
 
0.244 
 
 
0.587 
 
 
0.603 
 
 
0.646 
 
 
0.695 
(p=0.01) 
 
 
MH + Heparin 1000iu/mL 
 
 
0.348 
(p<0.001)* 
 
0.487 
 
 
 
0.164 
(p<0.001)* 
 
0.58 
 
 
0.688 
 
 
 
0.467 
(p<0.001)* 
 
 
0.718 
(p=0.001) 
 
 128 
 
 
Table 5.2 – Optical density at 590nm recorded in each well of a 96-well microtitre dish to assess biofilm 
formation of each bacterial strain in comparison with a control of BHI broth. 
  
Demonstrating the MIC of Vancomycin-Heparin against microbes in biofilm (bMIC) 
 
Biofilm production was assessed in MH broth. When assessing the bMIC of vancomycin 
against staphylococcal biofilms only MRSA NCTC 1 and 546 grew sufficient biofilm in 
the control wells to be suitable for assessment.  The bMIC of vancomycin was determined 
at 4mg/L for MRSA NCTC 1 and 8mg/L for MRSA NCTC 546. 
 
Biofilm production was then assessed in MH-heparin 500iu/mL broth.  All staphylococcal 
strains produced biofilm in the control wells.  The bMIC of vancomycin decreased to 
<0.25mg/L for MRSA NCTC 1 and decreased to 2mg/L for MRSA NCTC 546.  The bMIC 
of vancomycin was determined at less than 0.25mg/L for MRSA NCTC 100 and MSSA 
NCTC 51, 55 and 62. 
 
Bacterial 
Strain 1 2 3 4 5 6 7 8 9 
 
 
10 
 
 
11 
 
 
12 
 
Mean 
OD  
 
P-value 
Control 
 
0.172 0.195 0.23 0.215 0.259 0.212 0.226 0.216 0.203 0.203 0.204 0.188 0.210 
 
- 
MRSA 1 
 
0.167 0.205 0.392 0.397 0.199 0.234 0.156 0.263 0.268 0.188 0.244 0.327 0.253 
 
p=0.09 
MRSA 100 
 
0.22 0.281 0.283 0.401 0.312 0.332 0.307 0.291 0.425 0.271 0.264 0.431 0.318 
 
p<0.001 
MRSA 546 
 
0.251 0.358 0.33 0.249 0.516 0.345 0.328 0.252 0.461 0.385 0.31 0.363 0.346 
 
p<0.001 
MSSA 51 
 
0.302 0.397 0.647 0.465 1.005 1.195 0.74 0.339 0.62 0.931 0.69 0.689 0.668 
 
p<0.001 
MSSA 62 
 
0.885 0.87 0.465 1.716 2.545 0.801 1.075 0.617 0.544 0.537 0.72 0.262 0.920 
 
p<0.001 
MSSA 55 
 
0.3 0.305 0.505 0.283 0.305 0.487 0.354 0.584 0.434 0.382 0.383 0.343 0.389 
 
p<0.001 
StaphRP62 
 
0.208 0.22 0.248 0.445 0.267 0.448 0.198 0.206 0.24 0.38 0.245 0.354 0.288 
 
p =0.01 
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Biofilm production was then assessed in MH-heparin 1000iu/mL broth.  All staphylococcal 
strains produced biofilm in the control wells.  The bMIC of vancomycin remained 
<0.25mg/L for MRSA NCTC 1 and at 4mg/L for MRSA NCTC 546 was within one 
dilutional well of the MIC determined in MH-heparin 500iu/mL.  The MIC of vancomycin 
was determined at less than 0.25mg/L for MRSA NCTC 100 and MSSA NCTC 51, 55, 62.   
 
Full results for both pMIC and bMIC are demonstrated below in table 5.3. 
 
 
Table 5.3 – The minimum inhibitory concentration (MIC) of vancomycin to each staphylococcal sub-species 
in the presence of vancomycin alone or heparin in combination with vancomycin.  ‘pMIC’ minimum 
inhibitory concentration against planktonic bacteria.  ‘bMIC’ minimum inhibitory concentration against 
biofilm-embedded bacteria. 
 
Bacterial 
Strain 
 
pMIC 
Vanc alone 
(mg/L) 
pMIC 
Vanc/Hep 500iu/mL 
(mg/L) 
bMIC 
Vanc alone 
(mg/L) 
bMIC 
Vanc/Hep 500iu/mL 
(mg/L) 
bMIC 
Vanc/Hep 1000iu/mL 
(mg/L) 
 
MRSA 1 
 
2 0.5 4.0 <0.25 <0.25 
MRSA 100 
 
1 0.5 - <0.25 <0.25 
MRSA 546 
 
1 0.5 8.0 2.0 4.0 
MSSA 51 
 
1 1 - <0.25 <0.25 
MSSA 55 
 
1 1 - <0.25 <0.25 
MSSA 62 
 
2 1 - <0.25 <0.25 
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5.4 Discussion 
 
Several important themes arise from these data when relating them to the study of 
antibiotic lock solutions.   
 
Whilst published work in animal models suggests that heparin has minimal impact on 
antimicrobial activity against staphylococci (123).  These in-vitro data demonstrated some 
planktonic staphylococci to have decreased suppression of growth whilst others 
demonstrate heightened suppression of growth when heparin was added to incubation 
solution.   
 
Interestingly when introducing a fixed concentration of heparin to a range of vancomycin 
concentrations, heparin appeared to lower the minimum inhibitory concentration (MIC) of 
vancomycin in several instances.  The accepted convention in experiments to establish the 
MIC of antimicrobial solutions, however, allows the MIC to be reproducibly within one 
well dilution.  Consequently, whilst a drop in MIC occurred in four out of six staphylococci 
examined, only MRSA NCTC 1 developed a greater than 2-well, and thus significant, 
dilution drop in MIC. 
  
When considering biofilm MIC experiments, the addition of heparin again appeared to 
significantly lower the MIC of vancomycin in the cases of MRSA NCTC 1 and 564.  The 
effect of heparin on the MIC of vancomycin of the other staphylococcal sub-species was 
unable to be fully assessed in this short study.  When heparin 500iu/mL was compared with 
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heparin 1000iu/mL, the MIC of vancomycin was unchanged.  This would suggest that if 
heparin does potentiate the efficacy of vancomycin, the effect would appear not necessarily 
to be dose dependent under these conditions. 
 
Consequently, it can be concluded that under these conditions, heparin may independently 
heighten or suppress bacterial growth when used on its own, depending upon the 
staphylococcus studied.  Across a range of vancomycin concentrations, the addition of 
heparin appears to have the effect of lowering the MIC in certain instances.  This suggests 
that heparin could modulate bacterial growth when combined with the antimicrobial 
vancomycin.  This hypothesis could be proven by performing viability counts when 
repeating these experiments, demonstrating whether there is an increased killing effect.   
 
The second significant finding of interest was the demonstration of the absolute MIC 
values for planktonic staphylococci exposed to vancomycin being lower than those 
determined for biofilm embedded staphylococci exposed to vancomycin.  Biofilm produces 
a physical barrier between antimicrobials and bacteria and thus is more resistant to 
eradication than planktonic bacteria.  To eradicate biofilm embedded bacteria, the 
antimicrobial must penetrate the glycoprotein calyx before binding with the bacteria.  The 
introduction of heparin appears to enhance the action of vancomycin.  This could arise 
from either increased delivery of vancomycin to biofilm embedded bacteria, possibly 
through heparin neutralising the electrical barriers to vancomycin penetration, or increased 
delivery of bacteria to vancomycin, possibly through the negatively charged heparin 
preventing further biofilm formation or increasing bacterial release from biofilm (128). 
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All these findings, however, must be tempered by the methodological limitations of the 
study.  This was a small study of only seven laboratory-grown staphylococcal isolates, 
albeit known biofilm producers and thus potential pathogens for catheter-related 
bacteraemia.  An evaluation of staphylococcal isolates taken from cases of proven 
staphylococcal catheter-related bacteraemia would have greater clinical validity.  Another 
important point to be considered is the relatively small number of duplicate experiments to 
ensure accuracy of the results.  Whilst the model of biofilm colonisation on the 96-peg 
plates appeared effective and reproducible, in some instances the biofilm yield was poorer 
than expected and thus could be optimised by refinement of the technique with duplication 
of the experiments in greater numbers.   
 
The use of vancomycin as the antimicrobial under study may also be seen as a limitation.  
The choice of vancomycin was primarily driven due to its use as the antimicrobial of 
choice within the Glasgow Royal Infirmary Renal Unit when empirically treating catheter-
related bacteraemia.  Since this study was designed, the development of vancomycin-
resistant enterococci has led to gentamicin becoming a more commonly used antimicrobial 
for constructing catheter lock solutions.  Our use of vancomycin may, therefore, be seen as 
being of lesser clinical relevance than initially intended. 
 
Nonetheless the clinical relevance of these findings remains of interest.  When using 
heparin alone, there may be varied degrees of infection risk depending on the type of 
staphylococcal pathogens expressed with a haemodialysis population.  When considering 
combined antimicrobial-anticoagulant solutions, in clinical practice the catheter lock 
solution may be 5mLs in volume and contain 500mg of vancomycin, making an especially 
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high local concentration of antimicrobial targeted against the biofilm within the lumen of 
the catheter – several higher than the MICs of the organisms expected to be pathogenic.  
We now know, however, that these solutions leak into the systemic circulation where the 
volume of distribution may be as high as 5 litres, and bathes the outer portions of the 
catheter where biofilm may congregate.  There may therefore be a theoretical disadvantage 
of these solutions – excellent intraluminal suppression of biofilm but at the expense of poor 
suppression of planktonic bacterial grown in the blood stream and biofilm production on 
the outside of the catheter derived from increasingly resistant populations of organisms.  
These theoretical limitations merit scrutiny as part of randomised controlled trials using 
bacteraemia, resistance patterns, adverse events, catheter thrombosis and mortality as 
outcomes over both short and long-term periods of follow-up. 
 
 
5.5 Conclusion 
 
Currently, the evaluation of potential antibiotic lock solutions in-vitro is widely applied but 
its execution variable.  There is great heterogeneity in the types of organism studied, 
whether they are studied in planktonic or biofilm models, the type and dose of 
antimicrobial and the type and dose of anticoagulant.  It is widely accepted that biofilm is 
the underlying substrate to catheter-related bacteria.  The results of this work suggest that 
there are differing magnitudes of response to vancomycin and heparin between planktonic 
and biofilm-embedded staphylococci.  Consequently, in-vitro assessment of antibiotic-lock 
solutions should be based uniformly on biofilm models, be centred on their response to 
combinations of the antibiotic and anticoagulant at clinically relevant doses and be 
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conducted against organisms commonly implicated in the pathogenesis of catheter-related 
bacteraemia.  It should be on this platform that clinical evaluation of successfully 
performing catheter-lock solutions should be carried forward into in-vivo work. 
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Chapter 6 
Contrast-Enhanced Magnetic Resonance Venography of 
Central Veins for Assessment of Haemodialysis Vascular Access 
– A Six-Year Case Series  
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6.1 Background 
 
Patients with established renal failure (ERF) may undergo a large number of vascular 
access procedures during the course of their time on renal replacement therapy (RRT).  One 
of the most frequently complicated vascular access procedures is insertion of a central 
venous catheter (CVC) (54, 129-131).  CVCs are inserted under many different 
circumstances.  Up to 40% of ERF patients present late and require urgent commencement 
on haemodialysis which may only be secured with the placement of a CVC.  Many patients 
established on RRT may rely on CVC insertion when vascular access, in the form of an 
arteriovenous fistula or graft, has failed, is yet to be established or is immature. 
 
Occult central venous stenosis and/or thrombosis may complicate what was initially 
thought a straightforward catheter insertion in up to 65% of patients (132) and in many 
cases leads to distortion of the central venous architecture.  Furthermore, ERF patients have 
a tendency towards a hypercoaguable state arising from intrinsic defects in both platelet 
function and plasma factor abnormalities (133) which may contribute to limiting the 
lifespan of a CVC.  In patients who have suffered from complications of CVC insertion, 
subsequent vascular access provision with catheters, fistulae and grafts may become 
technically more demanding.  
 
Clinicians have been using imaging techniques to assist in vascular access provision for 
many years.  One such technique, contrast-enhanced magnetic resonance venography (CE-
MRV) using gadolinium chelates, has been available for some years now with proven 
speed, accuracy and reproducibility in the detection and evaluation of central venous 
thrombosis and stenosis (54, 134, 135).  Recently CE-MRV has come under close scrutiny 
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following reports indicating an association between the administration of gadolinium-based 
contrast agents and the development of the rare condition nephrogenic systemic fibrosis 
(NSF) (55, 77, 136-138).  The exact nature of this association is studied and described in 
detail in Chapter 7 of this thesis.   
 
Current recommendations limit the use of gadolinium contrast agents to patients with a 
creatinine clearance of >30mls/min/1.73m2 which has effectively prevented the use of CE-
MRV in the established renal failure (ERF) population.  The value of CE-MRV in these 
patients is acknowledged and thus the use of non-linear gadolinium chelates, contrast 
removal strategies and non-contrast based MR imaging are now being explored as possible 
methods of delivering imaging of the vascular tree to this vulnerable patient group.  
 
Whilst the risk of developing NSF is now fully appreciated, the benefits CE-MRV has 
made to vascular access provision have yet to be formally quantified.  The aim of this 
report is to clarify the contribution that CE-MRV made to the management of ERF patients 
in Glasgow Royal Infirmary over a 6-year period ending when the association with NSF 
was reported.  The indications, findings and contributions made in a historical case series 
of CE-MRVs are described and the relationship between a number of routinely recorded 
parameters taken at the time of imaging and findings reported on CE-MRV is investigated.  
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6.2 Methods 
 
Patients 
 
A retrospective analysis of all patients who received haemodialysis for ERF and underwent 
gadolinium CE-MRV between 1st January 2000 and 1st January 2006 was performed.  This 
cohort was derived by searching our renal unit electronic patient record for details of all 
patients who had received haemodialysis for ERF during this time period and had a record 
of having undergone magnetic resonance imaging at any time in the past.  To ensure no 
eligible patients were overlooked, an additional search of the hospital Radiology 
Information System (RIS – CRIS3, Healthcare Software Systems, Mansfield Woodhouse, 
Nottinghamshire, UK) was conducted for all patients who had undergone CE-MRV and 
this list cross-referenced with the renal unit records of ERF patients.  
 
Clinical data from the date at which CE-MRV was undertaken was retrieved from the renal 
unit electronic patient record and recorded for each patient.  This included records of age, 
blood pressure, presence of diabetes mellitus, underlying cause of renal failure, duration of 
renal replacement therapy, haemodialysis blood flow, urea-reduction ratio and the number 
and type of vascular access procedures that had been undertaken prior to CE-MRV.  From 
review of both the radiology records of the CE-MRV studies and the electronic patient 
records, the initial indications for requesting CE-MRV in each case were recorded as 
either; 1) investigation of clinically suspected venous stenosis, thrombosis and/or venous 
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occlusion, or 2) a search for suitable site for vascular access provision. 
 
CE-MRV 
 
All examinations were performed on a 1.5 T MRI system (Gyroscan ACS NT, Philips 
Medical Systems, Best, The Netherlands) with the patient supine using a 4-element phased 
array body coil for signal reception over the thorax and upper arms in anatomical position 
(a minority of patients underwent imaging of the abdomino-pelvic veins with coils over the 
abdomen and pelvis in a similar manner).  The exact details of the CE-MRV protocol 
evolved over the course of the study period consequent upon hardware and software 
upgrades.  CE-MRV was always performed using a breath-hold coronal multiphase 
gadolinium contrast-enhanced technique with first acquisition timed using bolus tracking to 
systemic arterial phase upon contrast arrival in the aortic arch for thoracic studies.  At least 
two successive breath-hold acquisitions were subsequently performed for equilibrium / 
venous phases, the first as soon after the first arterial dynamic phase as repeat breath-
holding would allow and the last within 3 minutes of contrast agent injection.  In essence 
this is an indirect CE-MRV technique imaging the central veins in phases after vascular 
distribution. 
 
Consultant vascular radiologists with a specific interest in MR angiography interpreted all 
CE-MRV studies on a dedicated MRI workstation (EasyVision & ViewForum, Philips 
Medical Systems, Best, The Netherlands). 
 
 140 
Outcomes 
 
Radiological outcomes were derived from the radiologist’s report of the images and 
categorised as to whether there was evidence of venous thrombosis alone, venous stenosis 
alone, venous thrombosis and stenosis in combination or whether the scan did not 
demonstrate any such abnormality.  
 
Clinical outcomes were sought from the renal unit electronic patient record which was 
interrogated to determine what subsequent vascular access management had been instituted 
in the period following CE-MRV as derived from clinic letters, discharge summaries and 
records of vascular access intervention.  Findings were summarised and recorded on the 
basis of whether following CE-MRV there was an immediate change in vascular access 
management (defined as within 2 weeks of CE-MRV), a future change in vascular access 
management (greater than 2 weeks and less than 6 months post CE-MRV) or whether no 
change in management occurred within 6 months of CE-MRV.  
 
In light of the subsequently published association between gadolinium contrast agents and 
NSF in this group of patients (55, 77, 136-138) any instances of NSF were deliberately 
sought in this cohort by review of all case records and related pathology reports.   
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Interpretation of Outcomes 
 
Tests of association between the outcomes of venous stenosis and venous thrombosis and 
the clinical and laboratory variables recorded at the time of CE-MRV were conducted by 
parametric and non-parametric testing as appropriate.  Students t-testing and Mann-
Whitney U testing were used in the analysis of continuous variables and Chi-square testing 
of categorical variables.  For all statistical analyses the reported p-values were based on 
two-sided testing with a significance level set at α < 0.05. 
 
 
6.3 Results 
 
Patient Data 
 
During the period 2000-2006 the renal unit and associated satellite haemodialysis units 
referred 62 patients in whom a total of 78 CE-MRVs were performed.  All CE-MRVs were 
requested to assess the central veins and aid in management of haemodialysis vascular 
access.  A total of 29/62 (46.8%) patients were male and 33/62 (53.2%) female with mean 
age 58.9yrs (16.14 SD). 18/62 (29.0%) patients were known diabetics.  Median length of 
time on renal replacement therapy was 804 days (range 26, 5982) (table 6.1).  
 
All patients had chronic renal failure requiring RRT with 12/62 (19.4%) having a primary 
glomerulonephritis, 17/62 (27.4%) an interstitial nephritis, 8/62 (12.9%) renal failure as 
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part of a multi-system disease, 10/62 (16.1%) with diabetic nephropathy and 15/62 (24.2%) 
with a non-specified or unclassifiable cause for their renal failure.  
 
 
 
 
 
 
 
  
 
 
 
 
Table 6.1 – Baseline characteristics of the cohort immediately prior to undergoing CE-MRV. MABP = mean 
arterial blood pressure, AVF = arteriovenous fistula, CVC = central venous catheter. *Median (min, max). 
 
Of the patients studied, arteriovenous fistula or graft surgery had been undertaken on a 
median of 2 (range 0 to 8) occasions per patient prior to CE-MRV (figure 6.1).  Successful 
central venous catheterisation had been undertaken on a median of 5 (range 0 to 22) 
occasions prior to CE-MRV (figure 6.2). 
Variable 
 
Mean (SD) 
Age (years) 
 
58.9 (16.1) 
Male / Female 
 
29/62 (46.8%) / 33/62 (53.2%) 
Diabetes 
 
18/62 (29%) 
Duration of RRT (days) 
 
804 (26, 5982)* 
Haemodialysis blood flow (ml/min) 
 
255.8 (59.9) 
Urea reduction ratio (%) 
 
67.5 (7.3) 
MABP (mmHg) 
 
96.6 (14) 
AVF / Graft creations 
 
2 (0,8)* 
CVC insertions 
 
5 (0, 22)* 
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Figure 6.1 – Frequency plot of arteriovenous (AV) fistula and arteriovenous graft creation procedures 
undertaken prior to CE- MRV. 
 
 
 
 Figure 6.2 - Frequency plot of number of central venous catheters inserted per patient prior to CE-MRV. 
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Indications for CE-MRV 
 
Of the 78 CE-MRVs undertaken, the majority (72/78, 92.3%) were for assessment of the 
central veins of the neck and thorax with only a minority (6/78, 7.7%) studying the femoral 
and iliac veins plus inferior vena cava.  In a total of 46/78 (59.0%) investigations CE-MRV 
was requested in patients in whom there was clinical suspicion of veno-occlusive disease 
secondary to previously established vascular access. 32/78 (41.0%) CE-MRVs were 
performed in order to establish suitable sites for future vascular access provision. 
  
Radiological Outcomes 
 
Of the 78 CE-MRVs undertaken 32/78 (41.0%) demonstrated venous stenosis alone, 6/78 
(7.7%) demonstrated venous thrombosis alone, 20/78 (25.6%) demonstrated both localised 
venous stenosis and venous thrombosis within the large veins and 20/78 (25.6%) 
demonstrated no abnormalities of the central venous system. 
 
In patients where CE-MRV confirmed venous stenosis, univariate testing demonstrated a 
significant association with increased incidence of surgery for arteriovenous fistulae or 
synthetic arteriovenous grafts (stenosis=2.0 v no stenosis=1.0, p=0.040) and central venous 
catheterisation (stenosis=6.0 v no stenosis=4.5, p=0.034).  There was no association 
between venous stenosis and patient age, gender, urea-reduction ratio, haemodialysis flow, 
mean arterial blood pressure, duration on renal replacement therapy or the presence or 
absence of diabetes mellitus. 
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In patients where CE-MRV confirmed venous thrombosis, univariate testing demonstrated 
significantly lower haemodialysis flow rates (thrombosis 217.5mls/min v no thrombosis 
275mls/min, p=0.002) and a higher mean monthly arterial blood pressure (thrombosis 
101.5mmHg v no thrombosis 94.2mmHg, p=0.046).  There was no association 
demonstrated between venous thrombosis on CE-MRV and the number of previous 
arteriovenous fistulae or grafts, the number of previous central venous catheters, patient 
age, gender, urea reduction ratio, duration on renal replacement therapy or the presence or 
absence of diabetes mellitus. 
 
Clinical Outcomes 
 
In 36/78 (46.2%) of cases changes to vascular access management occurred within a two 
week period of CE-MRV.  In nearly 30 cases this was achieved through the insertion of a 
tunnelled central venous haemodialysis catheter, in 3 cases through percutaneous 
angioplasty/stenting of the central veins, in 2 cases patients were anticoagulated and in 1 
patient previously scheduled endovascular intervention was prevented from being 
unnecessarily attempted. 
 
In 27/78 (34.6%) of cases changes to vascular access management occurred within the 
period from two weeks to six months following CE-MRV.   
 
In 15/78 (19.2%) cases there was no documented evidence from the patient records that 
CE-MRV had directly influenced subsequent patient management. 
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Patients who had abnormalities on MRV were more likely to undergo vascular access 
intervention in the 6 months following imaging than those with a normal CE-MRV 
(Abnormal MRV 50/58 (86.2%) v Normal MRV 12/20 (60%), p=0.031). 
 
From the whole cohort of 62 patients 4 were identified as having developed suspected NSF 
(51, 70, 128-130), each had received 30 ml gadodiamide for their CE-MRV studies or other 
MRI investigations (in one patient on 3 occasions in total) prior to the onset of symptoms 
attributed to NSF.  No patients in our series receiving gadobenate dimeglumine 
(Multihance) alone are suspected of having developed this condition to date.  These cases 
are analysed in detail as part of a case-control study described in Chapter 7 (55). 
 
 
6.4 Discussion 
 
Arteriovenous fistulae are widely recognised as the gold standard in haemodialysis 
vascular access due to their lower rate of infective and thrombotic complications when 
compared to central venous haemodialysis catheters (139).  However, in settings where 
interim haemodialysis is required the advantage conferred by central venous catheterisation 
as a means of gaining quick, durable and reliable access to the vascular tree often 
outweighs these relative disadvantages.  Consequently central venous catheterisation 
remains a cornerstone in the maintenance of patients on haemodialysis.  Central venous 
catheterisation, however, may give rise to structural complications which may impact on 
the provision of future vascular access.  The demographics of this cohort describe such a 
 147 
group. In general, the majority of patients studied had been on renal replacement therapy 
for many months or years, had been exposed to multiple vascular access procedures and in 
whom the maintenance of vascular access had become actively problematic.  In the vast 
majority of cases CE-MRV gave a definitive assessment of venous patency that had proven 
difficult to quantify by clinical or other radiological means. 
 
The methodology used was observational, retrospective and in a select group of 
problematic patients and thus has to be taken carefully in this context.  No control group 
was studied and thus these findings are purely observational and without any direct 
comparator.  Patient selection, the pattern of vascular access usage, the threshold for 
imaging and the availability of CE-MRV are features that will vary across different 
haemodialysis patient populations.  As such, MRV findings reported in this group may not 
be directly transferable to other haemodialysis populations and have to be observed within 
these limitations.  Despite these issues several important themes have been demonstrated.   
 
A total of 74% of CE-MRVs demonstrated abnormalities in the form of venous thrombosis, 
venous stenosis or both.  Patients with an abnormal CE-MRV were significantly more 
likely to have successful vascular access establishment in the 6 months following scanning 
than those with a normal CE-MRV.  This included instances where CE-MRV demonstrated 
positive findings that led to percutaneous venous angioplasty and stent insertion in three 
cases.  In another instance a patient was spared previously planned percutaneous venous 
angioplasty and stent insertion after CE-MRV failed to demonstrate a suitable central 
venous anatomical abnormality.  Negative findings on CE-MRV for the central veins also 
proved useful with several patients who would have been considered for anticoagulation 
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being spared unnecessary treatment.  These findings suggest that the anatomical data 
generated by CE-MRV was an important contributor in the management of vascular access 
in this patient group.  
 
This case series also studied trends of association between baseline clinical variables and 
the vascular access complications found on CE-MRV.  The findings were consistent with 
the published literature to date, albeit in patient populations without ERF.  The association 
between low haemodialysis blood flow and central venous thrombosis is to be expected in 
an analysis such as this with low haemodialysis blood flow likely to be both a cause and 
effect of localised central venous thrombosis.  What is more difficult to explain is the 
positive association between an increased mean arterial pressure and venous thrombosis.  A 
potential explanation is that elevated mean arterial pressure is a marker of underlying 
cardiovascular disease and is hence associated with both vascular endothelial dysfunction 
and an underlying thrombogenic state.  This is an area that is not addressed by this 
particular study design but would merit future investigation.  
 
A further interesting finding is a positive association between the number of previous 
arteriovenous fistulae or synthetic graft procedures and the development of central venous 
stenosis.  These methods of vascular access often deliver high velocities of turbulent blood 
flow back into the venous tree that could theoretically give rise to local vascular endothelial 
dysfunction and create a predisposition to an increased thrombogenic state.  A prospective 
examination of the relationship between arteriovenous fistulae or synthetic grafts, markers 
of vascular endothelial function and the development of mechanical complications such as 
venous thrombosis and stenosis would be required to investigate this.  Such work would 
help build a definition of the ‘at-risk’ patient and therefore identify those most likely to 
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derive benefit from vascular access planning and targeted intervention. 
 
Several reports have compared the utility of CE-MRV with venography and ultrasound in 
patients who have required vascular access to administer fluid, chemotherapeutic drugs or 
nutrition or who have been clinically suspected of having central vein thrombosis (140-
145).  These reports indicated CE-MRV to be superior in demonstrating differing degrees 
of venous stenosis, thrombosis and anatomical variation when compared to ultrasound 
(140-142).  In comparison with traditional venography, CE-MRV was found to be 
equivalent in assessing venous patency and better at demonstrating venous anatomy and 
blood flow whilst being less invasive, avoiding radiation and avoiding exposure to 
potentially nephrotoxic iodinated contrast (141-145).  The finding of venous stenosis in 
66.6% of the study population is approximately equitable to the prevalence of venous 
stenosis seen in similar patient populations who have used venography (132).  Differing 
prevalence of stenosis and thrombosis in such studies may be accounted for by patient 
selection, different patterns of vascular access usage, differing thresholds for imaging and 
variability in access to imaging. 
 
CE-MRV was however found to be associated with significant health risk with four 
patients within the cohort being subsequently found to have developed NSF.  These 
patients underwent gadolinium contrast-enhanced studies prior to the issuing of the FDA 
and ACR guidelines on the use of gadolinium-based contrast agents in patients with renal 
dysfunction (146, 147).  The association between the administration of different 
gadolinium contrast agents in patients with ERF and the development of NSF was clearly 
of concern and was investigated further, the details of which are described in the next 
chapter.   
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Clearly, however, CE-MRV would appear to have been of value in the majority of patients 
in this cohort.  Alternatives to traditional gadolinium CE-MRV where the risk of NSF is 
minimised and the quality of anatomical data generated preserved, should be explored.  
This may be achieved by focussing on the use of non-linear gadolinium chelates, contrast 
removal strategies and non-contrast based MRI.  These methods are now being explored as 
possible means of imaging the vascular tree to this vulnerable patient group.  
 
 
6.5 Conclusion 
 
These data have demonstrated that CE-MRV has been an effective imaging modality in the 
assessment, planning and maintenance of haemodialysis vascular access with central 
venous catheters. Use of CE-MRV has been shown to be associated with significant 
changes to vascular access management and clinical decision-making whilst offering what 
appeared until recently to be a more acceptable side-effect profile than the previous gold-
standard technique of contrast venography in patients with renal failure.  These advantages, 
however, must now be considered against the risk association with the use of specific 
gadolinium-based contrast agents in ERF.  Only once the NSF issue is resolved can CE-
MRV have an effective role in patients with problematic vascular access. 
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Chapter 7 
Gadolinium-Enhanced Magnetic Resonance Imaging and 
Nephrogenic Systemic Fibrosis – A Retrospective Study of a 
Renal Replacement Therapy Cohort 
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7.1 Background 
 
Nephrogenic systemic fibrosis (NSF) (previously labelled nephrogenic fibrosing 
dermopathy) was first described in 2000.  The earliest published cases described a 
scleromyxoedema-like condition affecting patients with advanced kidney disease.  
Typically, the condition presents cutaneously with thickening, oedema, induration or 
discolouration of the skin of the limbs and trunk, although most commonly with facial 
sparing.  Progressive disease may result in joint contractures and subsequent loss of limb 
function.  Fibrosis of other organ systems may occur with resultant end-organ dysfunction 
(148-150).  Mortality has been noted to be high although anecdotal improvement in both 
morbidity and mortality has been reported following recovery of renal function, either 
spontaneously or after renal transplantation, or with immunomodulatory treatments 
including extracorporeal photophoresis and phototherapy (151-154). 
 
The diagnosis of NSF was made initially on clinical grounds alone although histological 
features which may support the diagnosis are now widely accepted.  Skin lesions 
demonstrate dermal thickening, which stains positive for mucin, and with collagen bundles 
which traverse down into the superficial fascia (155).  Fibrous bundles contain 
CD34/procollagen expressing fibroblast-like cells and CD68/FactorVIIIa expressing 
dendritic-like cells.  The combination of these typical pathological and laboratory features 
distinguishes NSF from similar conditions including systemic sclerosis, scleromyxoedema 
and eosinophilic vasculitis. Indeed, to fully confirm a diagnosis of NSF, the absence of 
scl70 and anti-centromere antibodies as well as a normal serum electrophoresis (136, 156) 
should be obtained. 
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To date, 304 patients have been reported to the NSF registry (155, 157).  Demographically, 
these patients have been found to be similar to the general established renal failure (ERF) 
population although mean age is lower (136, 158).  Vascular disease, thrombotic events, 
chronic liver disease and the presence of anti-phospholipid antibodies have been associated 
with NSF, although not directly implicated in its pathogenesis (156, 159-163).  
 
Since 1998 the increasing use of gadolinium-enhanced magnetic resonance imaging (MRI) 
in ERF to avoid iodinated contrast exposure has paralleled the description of patients with 
NSF.  Several case series have since explored the association between NSF and exposure to 
gadolinium containing contrast agents, reporting a relatively high frequency of gadolinium-
enhanced MRI in patients prior to developing NSF (77, 164-168).   
 
This retrospective study was designed to compare the frequency of administration and 
cumulative dose of gadolinium contrast agent in a cohort of dialysis dependent patients 
who did and did not develop NSF.   
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7.2 Methods  
 
Patients 
 
A retrospective analysis of all patients who received renal replacement therapy (RRT) for 
established chronic renal failure (Stage V Chronic Kidney Disease, eGFR<15mls/min) 
within the renal units of two city teaching hospitals and associated satellite units in the 
West of Scotland, between 1st January 2000 and 1st July 2006 was conducted.  Patients 
were analysed as to whether they had a diagnosis of NSF and with regards their previous 
exposure to gadolinium contrast-enhanced MRI.  The local ethics committee granted a 
waiver of review for the study and also waived the need for informed consent. 
 
The patient cohort was obtained through a search of the unitary electronic patient record 
(EPR), a computerised database containing details of all patients who have ever been 
referred to either of the two units.  An EPR search was conducted to determine all patients 
within the two hospitals who had undergone RRT for stage V CKD between 1st January 
2000 and 1st July 2006.  Patients who had functioning renal grafts throughout the study 
period and thus did not receive dialysis and all patients who received RRT for acute renal 
failure for less than 90 days were excluded.  Age, gender, underlying renal diagnosis, time 
on RRT, mode of RRT and mortality were recorded from the EPR for each patient in the 
cohort.  
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Database Interrogation 
 
Diagnosis entries on the EPR for all patients on RRT with stage V CKD were then 
searched for the terms “nephrogenic”, “systemic”, “fibrosis”, “fibrosing”, “dermopathy”, 
“scleroderma”, “scleromyxoedema” and “sclerosis”.  All patients with a positive match for 
any of these search terms were reviewed thoroughly with respect to the clinical history and 
histopathological records to determine those patients with a diagnosis of NSF.  Where the 
original biopsy specimens were available they underwent further review by a pathologist to 
ensure the validity of the original diagnosis.  Age at starting RRT, age at diagnosis, sex, 
cause of renal failure, dialysis modality, time on RRT, the presence of a confirmatory skin 
biopsy, serum bicarbonate (mmol/l) at time of MRI, weight (kg) at time of MRI, 
subsequent treatment, whether they recovered renal function, clinical outcome, duration of 
follow-up and the time period between imaging and a subsequent diagnosis of NSF were 
recorded for each NSF patient.  
 
The EPR was then interrogated with regard to the cohort’s previous exposure to MRI.  The 
type of MRI scanner used, number and type of gadolinium-enhanced MRI studies, 
cumulative gadolinium dosage (mls), cumulative gadolinium dosage adjusted for weight 
(mmol/kg), average dose per scan (mmol/kg/scan) and type of gadolinium chelate was 
recorded for each patient.  Where complete data was not provided in the radiology reports 
held on the EPR, hand searching of the radiology departmental records was conducted.  
Gadolinium exposure was calculated over the six and a half-year period for all non-NSF 
patients and for the period 1st January 2000 until the first presentation of disease for all 
patients in the NSF group.  Weight adjusted dose was calculated by using the dry weight at 
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the time of imaging in the case of haemodialysis patients or recorded weight within six 
weeks of imaging.  The number of MRI scans undertaken prior to and following the 
diagnosis of NSF was recorded for each NSF patient.  The cumulative frequency of 
gadolinium-enhanced MRI and NSF cases was recorded for the study period. 
 
Statistical Analysis 
 
Statistical analysis was performed by SPSSTM version 14.0 (SPSS Inc, IL, USA).  Shapiro-
Wilk testing for normality was performed on continuous variables with rejection of the null 
hypothesis of normality at a significance level of α < 0.05.  Testing for equality or 
homogeneity of variance was conducted using Levene's tests.   
 
Difference in mean age between NSF and non-NSF patients was assessed by Students’ t-
test.  Prevalence of gadolinium-enhanced MRI exposure between NSF and non-NSF 
groups was assessed by Chi-square testing.  Differences between median number of 
gadolinium-enhanced MRI, median cumulative dose of gadolinium contrast (mls and 
mmol/kg) and median dose of gadolinium contrast (mls/kg/scan) in NSF and non-NSF 
groups were assessed by Wilcoxon rank sum testing.  Differences in gender and mortality 
were assessed by Chi-square testing.  All reported p-values were based on two-sided testing 
with a significance level set at α < 0.05. 
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7.3 Results 
 
Patients 
 
1826 stage V chronic kidney disease patients who had received RRT for ERF in North 
Glasgow Renal Units during the study period were identified.  The mean age at starting 
RRT was 58.8 years and 1053/1826 (57.7%) patients were male.  In total, 253/1826 
(13.9%) commenced RRT due to ERF as a result of a primary glomerulopathy, 374/1826 
(20.5%) with an interstitial nephropathy, 336/1826 (18.4%) with a multi-system disease, 
281/1826 (15.4%) with diabetic nephropathy and 582/1826 (31.9%) with an unknown or 
unclassifiable cause of their renal failure. 
 
MRI characteristics  
 
Over the 6 and a half-year period, 421/1826 (23.1%) patients underwent a total of 542 
gadolinium-enhanced MRI.  Examinations performed using contrast-enhanced MRI 
included angiography (430/542, 79.3%), cardiac studies (90/542, 16.6%) and central 
nervous system imaging (22/542, 4.1%).  A total of 379/542 (69.9%) contrast enhanced 
MRI examinations were performed on 1.5T superconducting systems whilst 163/542 
(30.1%) were performed on 1.0T superconducting systems.  Most examinations were 
assigned 30-minute appointments except for cardiac studies, which were usually scheduled 
1.5 hours.  However, the exact time duration for static RF field and pulse sequence varying 
fields would have been variable and was not recorded.  480/542 (88.6%) MRI scans were 
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performed with gadodiamide (Omniscan, GE Healthcare, Chalfont St Giles, UK) with a 
median dose volume of 30ml, reflecting the predominant use of this agent in the West of 
Scotland since 1998.  62/542 (11.4%) scans were performed using other gadolinium-
containing contrast agents as follows: 41/542 (7.6%) MRI used gadobenate dimeglumine 
(Multihance, Bracco S.p.A., Milan, Italy) as the contrast agent with median dose volume of 
15ml.  13/542 used gadopentetate dimeglumine with a median dose of 15mls (Magnevist, 
Berlex, Canada), 6/542 gadobutrol with a median dose of 15mls (Gadovist, Schering, West 
Sussex, UK) and 2/542 gadofosvest trisodium with a median dose of 10mls (Vasovist, 
Schering, West Sussex, UK).  The annual incidence of gadolinium-enhanced MRI among 
the cohort steadily increased until 2004 with fewer scans undertaken in 2005 and a 
subsequent reduction in contrast-enhanced MRI in patients on RRT in response to the FDA 
warning issued in June 2006.  The incidence of NSF parallels the rise in MRI imaging in 
the RRT cohort and is demonstrated in figure 7.1. 
 
 
 
 
 
 
 
  
 
Figure 7.1 - Frequency of MRI and NSF incidence from January 2000 to July 2006 (x-axis), number of 
gadolinium-enhanced MRIs (line) and incidence of NSF (square dots). The increasing use of MRI parallels 
the identification/development of patients with NSF. 
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NSF versus non-NSF cases  
 
The clinical and laboratory characteristics of the patients with NSF are demonstrated below 
in table 7.1 
Patients 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Sex M F M F M F F M F F M F F F 
Primary 
diagnosis 
U P DM GN DM GN U AP DM P DM P GN GN 
Skin biopsy Y Y Y Y Y Y Y N Y Y Y Y N Y 
Age (years) 63.2 61.0 43.5 54.3 67.1 49.0 63.7 43.7 37.7 20.5 60.4 58.5 59.8 73.2 
Age starting 
RRT (years) 
61.6 56.6 42.4 22.2 67.0 49.0 56.7 38.9 35.1 17.0 59.9 51.7 59.1 66.2 
Time on RRT 
(years) 
1.6 4.4 1.1 32.1 0.1 0.0 7.0 4.8 2.6 3.5 0.5 6.8 0.7 7.0 
RRT mode PD HD HD HD HD HD HD HD HD HD HD HD PD HD 
HCO3 
(mmol/l) 
22 24 26 25 18 28 18 36 17 25 23 26 29 21 
Photophoresis  Y   Y          
Renal function - - - - - Sp - - - - - Tx - - 
Follow up 
(days) 
691 2006 72 105 80 1863 178 252 30 460 257 799 533 50 
Outcome S I D D S I D D na D D S S na 
 
Table 7.1 - Baseline characteristics of NSF patients.  M, male; F, female; U, unknown; P, pyelonephritis; 
DM, diabetes mellitus; GN, glomerulonephritis; AP, adult polycystic kidney disease; Y, yes; N, no; Time on 
RRT, at diagnosis with NSF; RRT mode, at the time of NSF diagnosis; PD, peritoneal dialysis; HD, 
haemodialysis; HCO3, serum bicarbonate level within 30 days of MRI; -, no change; Sp, spontaneous 
improvement; Tx, renal transplant; Outcome, of NSF; S, stable; I, improved; D, dead; na, not 
applicable/follow up time too short for comment. 
 
From the full cohort, a total of 14/1826 (0.77%) patients had an established diagnosis of 
NSF as evident by clinical and pathological findings noted within the clinical records and 
on further review of the biopsy material where available.  Despite skin biopsy not being 
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performed in two patients the clinical picture, based on examination and laboratory tests, 
was considered consistent with the diagnosis of NSF by both a dermatologist and 
nephrologist.  With the caveat that the NSF group were relatively few in number in 
comparison to the non-NSF group, the mean age at starting RRT was significantly lower 
for NSF patients at 48.3yrs (p=0.022) and the median time on RRT at diagnosis was 3 
years.  A comparison of the characteristics of patients with NSF and without-NSF is 
detailed in table 7.2 below. 
 
Table 7.2 - Clinical characteristics of the complete RRT cohort comparing those with a diagnosis of NSF to 
those without.  All variables expressed as value (%). *Variable expressed as mean (SD). 
 
 
  
 
Characteristic NON-NSF  NSF  Significance 
Level 
 
Number of patients 
 
n=1812 n=14 - 
Age 58.8yrs (16.9)* 
 
48.3yrs (15.1)* p=0.022 
Prevalence of Gadolinium MRI 408/1812 (22.5%) 13/14 (92.9%) p<0.001 
EDTA Diagnosis  
     Primary Glomerulonephritis 
     Interstitial Nephropathy 
 
     Multisystem Disease 
 
     Diabetic Nephropathy 
 
     Unknown/Unclassifiable 
 
n=249/1812 (13.7%) 
 
n=370/1812 (20.4%) 
 
n=336/1812 (18.5%) 
 
n=277/1812 (15.3%) 
 
n=580/1812 (32.0%) 
 
 
n=4/14 (28.6%) 
 
n=4/14 (28.6%) 
 
n=0/14 
 
n=4/14 (28.6%) 
 
n=2/14 (14.3%) 
 
- 
 
- 
 
- 
 
- 
 
- 
Proportion Male:Female 
 
1.37 0.55  p=0.095 
Mortality at end of study period 707/1812 (39.0%) 6/14 (42.9 %) p=0.77 
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The prevalence of and relative dosing of gadolinium-enhanced MRI within the cohort and 
amongst NSF patients is described in tables 7.3 and 7.4 respectively. 
 
Characteristic 
 
NON-NSF NSF Significance Level 
Prevalence of Gadolinium-MR n=408 n=13 P<0.001 
Gadodiamide Dose (ml) 30 45 P<0.001 
Gadodiamide Dose (mmol/kg) 0.23 0.39 P=0.008 
Gadodiamide Dose (mmol/kg/scan) 0.21 0.20 P=0.83 
Scan Number 1 (1, 6) 2 (1, 3) P=0.009 
MRA/V 323/455 (71.0%) 16/25 (64.0%) P=0.46 
 
Table 7.3 - Pattern of MRI and gadodiamide dosage for the complete RRT cohort.  Gadodiamide doses and 
scan number are given as medians. MRA/V, proportion of MRI performed for angiography. 
 
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
MRI Imaging Y Y Y N Y Y Y Y Y Y Y Y Y Y 
Total Dose (ml) 90 90 40 na 30 30 90 45 45 60 45 40 58 75 
Total Dose 
(mmol/kg) 
0.60 0.47 0.20 na 0.16 0.30 0.61 0.41 0.39 0.90 0.27 0.21 0.39 0.65 
Dose 
(mmol/kg/scan) 
0.20 0.16 0.20 na 0.16 0.30 0.20 0.41 0.39 0.45 0.27 0.21 0.19 0.13 
MRI-NSF time 
(days) 
76 83 477 na 2395 35 2 4 16 52 64 289 99 441 
MRI pre NSF 3 3 1 0 1 1 3 1 1 2 1 1 2 5 
MRI post NSF 1 2 0 0 1 1 1 1 0 3 0 0 1 0 
 
Table 7.4 - Pattern of MRI and gadodiamide dosage within NSF patients.  Y, yes; N, no.  Total median dose 
of gadodiamide administered prior to onset of NSF is given in ml and mmol/kg.  Median gadodiamide dose 
per scan is given in mmol/kg/scan.  MRI-NSF time is the time interval between gadolinium-enhanced MRI 
and NSF onset; MRI pre NSF is the total number of MRI scans prior to NSF diagnosis; MRI post NSF is the 
number of MRI scans performed after a diagnosis of NSF. 
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13/14 patients with NSF had undergone gadolinium-enhanced MRI, all having been dosed 
with gadodiamide (tables 7.3 and 7.4).  None of the NSF patients had been exposed to any 
of the other gadolinium-based contrast agents.  One patient (patient 4) in our study 
developed biopsy proven NSF without prior exposure to gadolinium.  This patient had been 
on renal replacement therapy for 32 years, had previous thrombotic vascular disease 
(diagnosed by conventional angiography) and was known to have chronic hepatitis C 
infection.  An extensive review of her past medical history was undertaken to ensure no 
gadolinium-enhanced MRI had been undertaken.  This patient died within 3 months of the 
diagnosis of NSF and thus direct questioning of the patient could not be performed.  
 
Analysis of the full cohort demonstrated a strongly significant association between 
undergoing gadolinium-enhanced MRI and the subsequent development of NSF (table 7.3, 
non-NSF 408/1812, 22.5% v NSF 13/14, 92.9%, p<0.001).  The relative risk of developing 
NSF following gadolinium–enhanced MRI was 43.38 ({13/421/{1/1405}).  13/421 (3.1%) 
of the ERF population exposed to gadodiamide developed NSF with 14/1826 (0.77%) of 
the RRT population having developed NSF.  When considering the 421 patients who had 
undergone gadolinium-enhanced MR, patients with a diagnosis of NSF were exposed to a 
significantly higher total dose of gadodiamide than their non-NSF counterparts (median 
45ml v 30ml, p<0.001).  This was supported by weight-adjusted data (median 0.39mmol/kg 
v 0.23mmol/kg, p=0.008).  Weight data was incomplete for 19 patients, all within the non-
NSF group, which were excluded.  Patients underwent a median of 1 scan per patient in 
both groups, however the distribution of scanning events demonstrated a greater proportion 
of gadolinium scans within the NSF group (p=0.009).  No difference was found in the 
average dose of gadodiamide per scan between the groups (median 0.20mmol/kg NSF v 
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0.21mmol/kg non-NSF, p=0.83) nor in the proportion of gadodiamide scans undertaken for 
angiography (16/25, 64% NSF v 323/455, 71% Non-NSF) (table 7.3). 
 
The time between gadolinium exposure and presentation with NSF ranged from 2 to 2395 
days (median time 76 days).  Five patients developed NSF greater than 90 days after 
receiving gadodiamide.  Of these, three had a time of onset greater than one year.  Six 
patients within the NSF group had undergone previous gadolinium-enhanced MRI without 
apparent complication and eight went on to receive further exposure after presentation with 
NSF. 
 
Outcome of NSF Patients 
 
Within the full cohort no significant difference between NSF and non-NSF groups was 
found with regard to mortality (p=0.77).  At the end of the study period 6/14 (42.9%) of 
patients with NSF had died however, the follow-up period for four of the remaining eight 
patients was less than three months.  The median time to death following diagnosis of NSF 
was 215 days.  In three patients the cause of death was recorded as sepsis-related occurring 
in hospital, two patients suffered an in-hospital cardiac arrest (one in the context of 
hyperkalaemia) and one patient died suddenly at home, all without subsequent post-mortem 
examinations.  Two patients demonstrated mild functional improvement determined by 
regular review at dialysis out patient clinics and patient self-reporting of symptoms: Patient 
2 started extracorporeal photophoresis in January 2005 and patient 6 had spontaneous 
improvement of renal function to an eGFR of 49ml/min.  Patient 5 started extracorporeal 
photophoresis in June 2006 and patient 12 received a functioning renal transplant in June 
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2006 but there was no detectable clinical improvement in their NSF at the end of the study 
period.  
 
 
7.4 Discussion  
 
A link between gadolinium-based contrast agents, in particular gadodiamide, and NSF was 
first postulated in January 2006, (77, 165) with further reports emerging thereafter (164, 
166-169).  At the time this study was completed there was no other case-control series 
examining this association or determining if there was a cumulative gadolinium dose-
related relationship with the subsequent development of NSF.  
 
These data align closely with those which have reported an association between 
gadolinium-enhanced MRI and the development of NSF in patients with ERF.  These data 
suggest the association to be dose-dependent.  No patient exposed to only a single standard 
dose of contrast agent (15 ml of 0.5 mol/l agent, approximately 0.1 mmol/kg) developed 
NSF.  1 in 130 (0.77%) of the overall ERF population developed NSF, however 1 in 32 
(3.1%) of the ERF population exposed to gadolinium-enhanced MRI developed the 
condition.  Mortality did not appear to differ significantly from that of the regular RRT 
population during this follow-up period. 
 
When considering the international NSF registry, more than 95% of reported cases are said 
to have evidence of gadolinium exposure (170).  Indeed, one patient in this study 
developed biopsy proven NSF without evidence of prior exposure to gadolinium.  A clear 
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explanation of this remains elusive but such cases suggest that exposure to gadolinium may 
not be the sole causative feature to developing NSF.  Similarly, in patients exposed to 
gadolinium, although the median time from gadolinium administration to the onset of NSF 
symptoms was 76 days, in four there was a period of months to years before clinical 
features developed.  This lag time is longer than that reported by some other groups (77, 
164-166, 171).  Such findings suggest that gadolinium, although causally implicated, is not 
the only factor involved in NSF.   
 
The combination of renal dysfunction and gadolinium exposure heighten the risk of 
developing NSF.  Why these conditions predispose to NSF is uncertain.  What we do know 
is that gadodiamide is distributed in the extracellular fluid and excreted unchanged by the 
kidneys with an elimination half-life in normal renal function of 80–100 minutes.  
Consequently 72 hours following gadolinium administration up to 95% has been excreted 
in individuals with normal renal function (176).  The pharmacokinetics of gadolinium 
handling in established renal failure is poorly understood however, in patients with a 
glomerular filtration rate of 2-10 ml/min, not on dialysis, the elimination half-life of 
gadodiamide intravenous injection has been found to be approximately 34 hours.  It follows 
that the lower excretion rate of gadolinium in established renal failure leads to a longer 
period of cumulative gadolinium exposure.   
 
The type of gadolinium chelate used in contrast studies may also impact on the degree of 
free gadolinium exposure. Different gadolinium chelates demonstrate varying properties in 
terms of their structure (linear versus macrocyclic), electrochemistry (ionic versus non-
ionic) and affinity towards binding proteins.  Gadolinium-based contrast agents differ 
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significantly with respect to their propensity to transmetallate (release toxic free 
gadolinium from the chelate) and in terms of their kinetic and thermodynamic stability. 
Gadodiamide has a lower conditional stability constant compared to other gadolinium 
chelates despite the addition of excess chelate (169, 170, 173-175).  This could be a 
plausible explanation for the especially pronounced association gadodiamide has with the 
development of NSF compared with other chelates.  This remains a theoretical concept and 
the transmetallation theory has yet to be observed in pharmacokinetic studies of ERF 
patients.  Indeed, it is not clear if alternative gadolinium-based agents are safer or if the 
preponderance of patients with NSF related to gadodiamide simply reflect its pattern of 
use. 
 
Acidosis, anaemia and hypoalbuminaemia at the time of MRI exposure have been cited as 
potential cofactors in the development of NSF (77, 165, 169, 171).  In this work no such 
associations were seen.  Such data are very difficult to interpret in a study of this 
methodology as patients may undergo MR imaging to investigate co-morbid conditions 
including vascular disease or sepsis, which may be responsible for these abnormalities and 
potentially confound any association demonstrated.  
 
How does gadolinium exposure relate to the development of NSF?  Several recent studies 
using spectroscopy have demonstrated the presence of gadolinium in the skin of some, but 
not all, patients with NSF (169, 176-179).  One autopsy study has demonstrated the 
deposition of gadolinium in the heart and vasculature of patients who died following a 
pathological diagnosis of NSF (180).  A pathological study of biopsy proven NSF has 
demonstrated deposition of gadolinium in irregular small aggregates that adhered to 
collagen fibres within connective tissue in the dermis (179).  Fibrocytes extracted from 
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these deposits in NSF patients have been demonstrated to synthesise excess levels of 
hyaluronan and collagen (181).  These findings have led researchers to speculate that 
gadolinium deposited within the dermis is phagocytosed by tissue macrophages, triggering 
a localised cytokine cascade that promotes the release of pro-fibrotic mediators.  These in-
vitro studies, along with in-vivo studies such as this, may strengthen the association 
between gadolinium-based contrast agents and development of NSF; however have yet to 
prove causation.  
 
Once NSF develops the clinical course appears varied.  Some reports suggest a proportion 
of patients undergo gradual improvement in symptoms over time.  This appears most 
pronounced in those who have subsequently undergone renal transplantation and thus 
gained a degree renal function.  Complete recovery of NSF symptoms with ongoing stage 
V kidney disease has yet to be described.  The majority appear to suffer heightened 
morbidity and impaired quality of life arising from musculoskeletal and other end-organ 
dysfunction.  Reports to date suggest that approximately 5% of NSF patients have 
especially aggressive disease that may progress and rapidly result in premature death (138).  
Within this study follow-up times were short although mortality was not increased in 
patients with NSF when compared to their non-NSF counterparts. 
 
No consistently successful treatment for NSF has emerged but extracorporeal 
photophoresis (ECP) has been advocated (151, 152, 182).  ECP involves extracorporeal 
exposure of blood cells to photoactivated 8-methoxypsoralen, which are subsequently 
reinfused.  How this exposure translates into a reduction in symptom burden is unknown.  
Some have postulated a role for ECP in modulating the activity of circulating fibrocytes 
however this has yet to be demonstrated in-vitro or in-vivo and thus remains a speculative 
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explanation (151).  One patient in this cohort had undergone ECP with some improvement 
and a second commenced treatment just prior to the end of the study period.  Randomised 
controlled trials of ECP treatment have yet to be performed in NSF patients.   
 
The restoration of renal function, whether by treatment of the underlying renal disease or 
by renal transplantation, anecdotally appears to confer a degree of symptomatic relief.  Up 
to 65% of injected gadodiamide may be eliminated during a single haemodialysis session 
whilst approximately 69% may be excreted over a 22-day period in patients on regular 
peritoneal dialysis (183).  A more aggressive regime of peritoneal dialysis involving 10 to 
15 exchanges per day has been shown to cause a 90% reduction in circulating gadolinium 
(182).  Whilst these data suggest that an aggressive dialysis strategy following gadolinium 
exposure may be beneficial, one study describes three patients in whom NSF developed 
despite daily haemodialysis on each of the three days immediately following gadodiamide 
exposure (164).  These data suggest such a strategy is therefore of limited benefit.   
 
This report has several limitations, predominately arising through its retrospective 
observational design.  Thorough patient review was conducted in an attempt to control for 
this although some issues could not be adequately addressed.  The duration of each MRI 
scan was not recorded and examinations were performed on separate scanners, hence no 
comment can be made on the relationship between scan duration, magnetic field strength or 
MRI system type and development of NSF.  The study population was restricted to those 
with CKD Stage V with no analysis of patients with acute renal failure or earlier stages of 
CKD.  These populations are considerably greater in size than the stage V CKD population 
and thus establishing the risk of developing NSF in these groups is of considerable 
importance.  As stipulated earlier, pathological confirmation of NSF is becoming 
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increasing important.  Two patients in this study did not undergo skin biopsy and thus 
histological confirmation of the diagnosis could not be made.  Conversely, the possibility 
that other patients with NSF were not diagnosed cannot be excluded, especially as 
awareness of the disease was limited 6 years ago.  In comparison with the RRT population 
studied the NSF caseload was small in number and this limited the use of more detailed 
statistical analyses that could examine independence of association alongside other clinical, 
laboratory and demographic variables.   
 
 
7.5 Conclusion 
 
This study confirms the association between gadodiamide-enhanced MRI and the 
development of NSF in patients with Stage V CKD and undergoing RRT.  These findings, 
together with those of other studies, suggest that gadodiamide should no longer be 
considered as without risk for use in patients with advanced renal failure (glomerular 
filtration rate < 15ml/min) and undergoing RRT.  
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Chapter 8 
 
Discussion and Conclusions 
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8.1 Independent Risk Factors for Adverse Clinical Outcomes 
  
The primary aim of this thesis was to perform a detailed evaluation of the risks to health 
conferred by aspects pertaining to the establishment and maintenance of haemodialysis 
vascular access in patients with renal failure.   
 
The work detailed in chapter 2 was a retrospective analysis of bacteraemia and mortality in 
a cohort of haemodialysis patients with established renal failure that was representative of a 
typical UK chronic haemodialysis population.  Despite a retrospective methodology in 
which a ‘snapshot’ of vascular access was related to outcomes over a subsequent 18-month 
period, use of a synthetic vascular access catheter was found to have an especially strong 
independent association with risk of bacteraemia and death compared with use of an 
arteriovenous fistula.  These effects were found to be independent of known adverse 
prognostic factors such as advanced age, sex, diabetes, anaemia, and the other clinical and 
laboratory variables that were studied.  The demonstration of such a relationship despite a 
methodology that was not sensitive to changes in vascular access type suggested that use of 
central venous catheters may have an especially strong association with adverse outcomes 
compared with other clinical and laboratory variables. 
 
Both the non-tunnelled and tunnelled central venous catheter groups in this study 
demonstrated poorer outcomes than their arteriovenous fistula counterparts.  Closer 
scrutiny of the two groups demonstrated those patients using tunnelled central venous 
catheters (TCVCs) to have been on renal replacement therapy (RRT) for a longer period of 
time compared to patients with non-tunnelled central venous catheters (NTCVCs).  
Analysis of the individual case-mix suggested this to be a product of patients whose 
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peripheral vasculature had been exhausted of attempts to create an arteriovenous fistula or 
graft.  Indeed, the demographics and co-morbidities of the TCVC group and arteriovenous 
fistula (AVF) group were found to be very similar and thus the conclusion that adverse 
outcomes are independently associated with TCVC use when compared to AVFs would 
appear to be valid.  When considering the NTCVC group, it was evident that this consisted 
of a higher proportion of patients who had commenced RRT for established renal failure 
within three months of study entry and in this setting the co-morbidities that often arise 
during this period may have contributed to the difference in clinical outcomes seen in this 
particular group when compared to the TCVC and AVF groups.   
 
Whilst this study suggested that central venous catheter use was associated with poorest 
outcomes, the different characteristics expressed by the TCVC and NTCVC groups made 
direct comparison limited.  What was not clear was the degree to which the different event 
rates expressed between groups was a function of the clinical characteristics of those 
undergoing a specific type of catheter insertion, or a function of the type of catheter 
insertion procedure itself.  The lack of detailed data on comorbidity, other than the data we 
included regarding age, duration on RRT and diabetes compounded this problem. 
 
To address these limitations, a prospective study of catheter insertion procedures was 
designed.  This methodology allowed real-time measurement of a broader number of 
comorbidity markers including Charlson score – a validated means of comorbidity scoring 
– and was sensitive to real-time changes in vascular access method.  The ensuing data, 
presented in chapter 3, demonstrate the significant differences between tunnelled and non-
tunnelled central venous haemodialysis catheter insertion procedures in terms of rates of 
catheter-related bacteraemia and another clinically significant outcome in catheter use, 
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catheter failure due to poor and unsustainable haemodialysis blood flow.  Patients with 
TCVCs demonstrated consistently better outcomes than those using NTCVCs, independent 
of the wide range of clinical and laboratory characteristics that were recorded.  Within the 
NTCVC groups a clear hierarchy of independent risk association was seen with de-novo 
internal jugular catheterisation being the best performing NTCVC procedure and guidewire 
catheter exchange in the femoral veins being the poorest performing NTCVC procedure.  
Again, these outcomes were independent of other important clinical and laboratory 
variables.   
 
These data bring greater clarity to the interesting debate of whether such adverse events 
develop as a function of the characteristics of the catheterisation procedure or the 
characteristics of the patient receiving the catheter.  It appears that the catheterisation 
procedure, in terms of tunnelling and site of insertion, contributes independently and most 
significantly to these important clinical outcomes.  The demonstrated hierarchy of risk 
association within NTCVC insertion procedures is of considerable clinical relevance; this 
should help guide clinical practice and could even be used as an evidence-based foundation 
on which clinical guidelines for central venous catheterisation for haemodialysis may be 
built. 
 
Whilst the study provided as detailed an account of independent risk association that most 
prospective observational studies could offer, the definitive answer to these questions can 
still only be achieved by randomised controlled trials.  Until such studies are conducted and 
designed to account for variables such as the number of previous vascular access 
procedures and standard baseline clinical and laboratory demographics, our understanding 
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of vascular access will remain limited to such observational work.  Furthermore, this study 
was limited to outcomes that relate to infection and thrombosis, other outcomes such as 
mortality, subsequent rates of conversion onto a functioning AVF or graft and subsequent 
sustainability of that AVF or graft remain of considerable interest.  Mapping the vascular 
access journey for a population of haemodialysis patients and relating this to these 
outcomes may identify the key junctures in which haemodialysis patients either follow a 
path of optimally safe, long-term, vascular access establishment, or may deviate down a 
route of repeated short lifespan vascular access methods, high complication rates and early 
death.  By identifying these points on a population level, interventions designed to prevent 
adverse outcome could be applied and outcomes improved.  It is these areas in which there 
remains a pressing need for further in-depth study. 
 
 
8.2 Optimising Catheter Performance with Lock Solutions 
 
Once established, the successful maintenance of patent central venous catheters for 
haemodialysis is of critical importance.  Historically the most common complication that 
limited catheter lifespan was catheter thrombosis.  Unfractionated heparin has become 
almost universal in its use across the world as a catheter-locking agent by preventing 
intraluminal catheter thrombosis due to its proven anticoagulant effect.  Catheter-locking 
practices have, however, evolved over recent years with an increase in the use of combined 
solutions that both limit thrombosis and lower risk of catheter-related bacteraemia by 
preventing and reducing bacterial biofilm.  Whilst the benefits of catheter-locking with 
combined anticoagulant and antimicrobial solutions are becoming increasingly well 
 175 
documented, the potential limitations or pitfalls of these techniques have not been fully 
explored.  The work described in chapters 4 and 5 examine the potential for catheter lock 
solutions to leak into the systemic circulation in patients, and examine how combinations 
of anti-coagulant and antimicrobial may alter their antimicrobial properties in vitro. 
 
The work described in chapter 4 successfully demonstrated that use of heparin as a 
catheter-locking agent in haemodialysis patients is associated with a significant degree of 
systemic heparinisation as demonstrated by prolongation of the activated partial 
thromboplastin time (APTT).  Systemic heparinisation occurred in both of the groups 
studied, either heparin 1000iu/mL or 5000iu/mL, despite only instilling a volume of 
heparin equal to the internal catheter luminal volume stated by the catheter manufacturer.  
Use of heparin 1000iu/mL conferred a significantly lower risk of systemic heparinisation 
than heparin 5000iu/mL.  There were, however, no instances of haemorrhage in either 
group over the course of the study, albeit within a relatively small cohort with a relatively 
short duration of follow-up.  The lack of any significant difference between groups with 
regard to the secondary outcome measures of catheter-related bacteraemia and catheter 
failure due to poor haemodialysis blood flow is of limited value due to the small sample 
size, the lack of power to examine these outcomes, the heterogeneity of non-tunnelled 
catheter insertion sites and the relatively short duration of follow-up.   
 
Whilst these findings are of particular clinical interest routine clinical practice cannot be 
greatly shaped by this study.  In specific instances however, such as when performing 
haemodialysis in patients with a significant bleeding risk, use of a lower concentration of 
heparin solution may be conducted knowing that this will lead to less systemic 
 176 
heparinisation between dialysis sessions and thus would be an appropriate additional 
measure to undertake. 
  
This study does raise other important clinical points, especially when considering the utility 
of combined anticoagulant-antimicrobial catheter lock solutions.  The concept of occult 
leakage of catheter lock solution into the systemic circulation may promote an environment 
in which antimicrobial resistance could be allowed to flourish.  Within the catheter lumen 
the concentration of antimicrobial is invariably very high and contained within a low 
volume of only a few millilitres – few, if any, susceptible microbes could survive in such 
an environment let alone develop antibiotic resistance.  If the solution leaks into the 
systemic circulation the volume of distribution for that antimicrobial increases 
considerably.  This dilution may produce systemic levels of antimicrobial that are of 
sufficiently low concentration to promote the preferential growth of antimicrobial-resistant 
microbes.  When considering a population of haemodialysis patients the emergence of 
antimicrobial resistance could lead to significant morbidity and mortality.  Through the 
same mechanism other adverse effects, such as ototoxicity with gentamicin, may become 
increasingly expressed by a dialysis population through continuous cumulative exposure to 
an antimicrobial.  It must be emphasised, however, that such limitations only realistically 
apply to those in whom concurrent systemic delivery of the antimicrobial is not taking 
place.  As such, these limitations would only appear relevant to those undergoing primary 
prevention of bacteraemia as opposed to those with a catheter-related bacteraemia who are 
reliant upon catheter salvage i.e. use of catheter locking as an adjunctive secondary 
prevention strategy.  Indeed, how the addition of catheter lock solutions to standard 
catheter salvage practice may affect outcome is another important question which remains 
to be fully evaluated. 
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This study highlights both the need for detailed outcome data when evaluating combined 
catheter lock solutions, and the need for long-term follow-up of the patient populations in 
which these techniques are trialled.  Whilst these uncertainties persist there remains a 
pressing need for a means of maintaining catheter patency and limiting bacteraemic events 
in haemodialysis patients with the minimum of adverse events.  Optimal catheter lock 
solution composition, technique of delivery and circumstances of use remain to be fully 
clarified and shall require continued study. 
 
It is also important to determine whether any interaction between constituent anticoagulant 
and antimicrobial solutions may exist and, if so, how this may affect overall performance.  
The work detailed in chapter 5 aimed to elicit whether any such interaction occurs between 
heparin and vancomycin on planktonic and biofilm embedded staphylococci.  
 
These in-vitro data demonstrated that heparin alone may independently heighten or 
suppress bacterial growth, depending upon the staphylococcus studied.  Across a range of 
vancomycin concentrations, the addition of heparin appeared to have the effect of lowering 
the MIC.  Similar patterns were seen when considering biofilm embedded staphylococci.  
This suggests that heparin could modulate bacterial growth when combined with the 
antimicrobial vancomycin.  Repeating these analyses with viability counts would be a way 
of testing this hypothesis by demonstrating the killing effect of the lock solution.  
 
Whilst of pharmacokinetic interest, these in-vitro findings were elicited in a small study of 
seven laboratory-grown staphylococcal isolates, albeit known biofilm producers and thus 
potential pathogens for catheter-related bacteraemia.  An evaluation of staphylococcal 
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isolates taken from cases of proven staphylococcal catheter-related bacteraemia would have 
greater clinical validity.  The relatively small number of duplicate experiments and sub-
optimal quality of the biofilm modelling are all aspects of the methodology that would 
require further refinement before these conclusions could be meaningfully advanced.   
 
These findings are, however, of significant clinical interest.  Standard catheter practice in 
many renal units involves catheter locking with heparin alone.  Whilst this may suppress 
growth of staphylococcal sub-species, others may experience heightened growth.  When 
considering combined antimicrobial-anticoagulant solutions excellent intraluminal 
suppression of biofilm may be achieved but, with occult leakage, may occur at the expense 
of poor suppression of planktonic bacterial grown in the bloodstream and biofilm 
production on the outside of the catheter containing increasingly resistant populations of 
organisms and perhaps accelerated by the presence of heparin.   
 
These theoretical limitations merit scrutiny.  This may be achieved by further laboratory 
study looking at intraluminal and extraluminal biofilm growth under differing 
antimicrobial-anticoagulant conditions.  On a clinical level, the role of extraluminal 
catheter biofilm versus intraluminal catheter biofilm with regard to risk of metastatic 
bacterial infection such as endocarditis and osteomyelitis remains unclarified and the 
presence of secondary metastatic infection would be a useful clinical endpoint when 
considering the clinical utility of combined antimicrobial-anticoagulant catheter lock 
solutions in vivo.  Randomised controlled evaluation of combined antimicrobial-
anticoagulant solutions using bacteraemia, resistance patterns, adverse events, catheter 
thrombosis and mortality as outcomes over both short and long-term periods of follow-up 
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could further tease out the relative advantages and disadvantages of these practices.  By 
performing such studies optimal catheter-locking practice with combined antimicrobial-
anticoagulant solutions may be determined.  
 
 
8.3 Vascular Imaging in Haemodialysis Patients 
 
Patients on RRT for many months or years are exposed to multiple vascular access 
procedures.  As time on RRT progresses vascular access complications may accumulate, 
impairing the function of existing access and limiting the availability of sites for future 
access.  It is under these circumstances that imaging of the central veins is used to 
determine appropriate access points to the vascular tree with the aim of linking suitable 
venous architecture with optimal access function.  Contrast enhanced magnetic resonance 
venography (CE-MRV) had become increased used over recent years due to its proven 
speed, accuracy and reproducibility in the detection and evaluation of central venous 
thrombus and stenosis (54).  Few had, however, formally quantified its clinical 
applicability and thus the work detailed in Chapter 6 was designed, studying all CE-MRV 
examinations undertaken in haemodialysis patients within Glasgow Royal Infirmary Renal 
Unit. 
 
This work described the abnormalities found on CE-MRV and the subsequent clinical 
course followed by the patients in whom CE-MRV imaging was undertaken.  The 
methodology used was observational, retrospective and in a select group of problematic 
patients and thus has to be taken carefully in this context.  Despite these limitations several 
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important themes were demonstrated.  CE-MRV gave a definitive assessment of venous 
patency that had proven difficult to quantify by clinical or other radiological means.  
Abnormalities were found in 74% of CE-MRVs with patients in whom an abnormality was 
found being significantly more likely to have successful vascular access establishment in 
the 6 months following scanning than those with a normal CE-MRV.  A positive 
association between the number of previous arteriovenous fistulae or synthetic graft 
procedures and the development of central venous stenosis was demonstrated.  Negative 
findings on CE-MRV also proved useful with several patients.  
 
These advantages however have had to be tempered with the emergent finding that four 
patients within the cohort developed nephrogenic systemic fibrosis (NSF) following CE-
MRV.  This coincided with the emergence of gadolinium contrast agents as a potential 
causative agent in the pathogenesis of NSF in published literature (77).  The serious nature 
of the condition effectively ended the mainstream usage of CE-MRV in RRT patients and 
highlighted the benefit of post-marketing surveillance when considering the use of 
medicines/contrast media extending into specific patient sub-groups.  Given the 
uncertainties surrounding the aetiology and pathogenesis of NSF, the work described in 
chapter 7 was designed.  On completion of this study there was no other case-control series 
examining this association or determining if there was a cumulative gadolinium dose-
related relationship with the subsequent development of NSF. 
 
The findings of this study supported the reported association between gadolinium-enhanced 
MRI and development of NSF in patients with ERF.  The relationship appeared dose 
related although mortality appeared to be unaffected when compared with the non-NSF 
cohort studied.  One patient in the study developed biopsy proven NSF without exposure to 
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gadolinium and in several instances the median time from gadolinium administration to the 
onset of NSF symptoms was relatively prolonged.  These findings suggest that gadolinium, 
although causally implicated, was not the only factor involved in the development of NSF.  
 
This study provided a significant step forward in our understanding of the association 
between gadolinium and NSF development.  Importantly, however, this study reported 
association, not causation and thus only provides a basis on which pathogenetic 
mechanisms can be hypothesised before being tested by in-vitro and in-vivo assessment.  
Several key areas require scrutiny. 
 
Firstly, the sequence of events linking gadolinium exposure, renal dysfunction and the 
development of a pro-fibrotic response requires elucidation.  A number of in-vitro studies 
have highlighted the prolonged excretion of gadolinium in renal failure, the deposition of 
gadolinium in the dermis and the pro-fibrotic responses that arise from local tissue injury in 
association with gadolinium deposition.  These in-vitro data need to be pursued further 
before a solid, tangible pathogenetic mechanism can be put forward.  Secondly, can 
modulation of these variables be undertaken that not-only reduces but obviates the risk of 
developing NSF?  The comparison of cyclic versus linear gadolinium chelates, effective 
renal replacement strategies that limit exposure/heighten excretion of the chelate and the 
generation of antifibrotic targets all merit detailed study.  Thirdly, what treatment strategies 
are effective in limiting the morbidity, progression and mortality associated with 
established NSF?  Few, if any of the therapeutic options reported have more than anecdotal 
support to their use.  Given the rarity of the condition and the assumption that the case 
incidence will decline following the withdrawal of CE-MRV in stage V CKD, this question 
may never be fully answered.  Whilst these issues remain unresolved the benefits that CE-
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MRV provided cannot go unrecognised and thus there remains a significant need to pursue 
other methods of imaging the vascular tree in which such reproducible image quality is 
obtained without any resultant adverse effect.  
 
 
8.4 Conclusions 
 
Successful vascular access provision is the bedrock on which successful haemodialysis is 
built.  The considerable expansion of haemodialysis worldwide has been built on a 
template of simple vascular access rules – fistula first, catheters when in crisis.  Within 
these rules it is clear that no method of vascular access remains risk free.  With the 
increasing provision of haemodialysis to aging, comorbid populations these rules require 
refinement and each facet of access provision requires close scrutiny. 
 
This thesis has provided a detailed evaluation of the risks to health conferred by some of 
the key elements of haemodialysis vascular access provision and maintenance.  The clear 
hierarchy of adverse risk across vascular access types, the spectrum of independent risk 
association expressed across the range of catheter insertion procedures, the varied 
considerations required when assessing catheter locking strategies and the advantages and 
disadvantages of imaging the vascular tree are important themes which have been explored, 
developed and clarified within this thesis.  Many questions have been answered and yet in 
many instances another set of important questions have arisen.  It is of considerable 
importance that many of the issues described in this thesis continue to be explored, 
solutions developed and outcomes improved in this especially large population of 
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vulnerable patients.  Small changes applied across a large, vulnerable, population can make 
a considerable change to outcome.  The safe and effective provision of haemodialysis 
vascular access therefore remains an area in which considerable improvements in the health 
of renal patients may be made in the future. 
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